keyword,recent_count,prior_count,growth
community advisory committee,30,0,999.0
new treatment approach,200,0,999.0
bases,135,0,999.0
overdose reduction,89,0,999.0
translational opportunities,62,0,999.0
antagonist,542,0,999.0
marijuana use and disorder,62,0,999.0
marginalized people,62,0,999.0
marginalized individual,62,0,999.0
ethnic individual,90,0,999.0
marginalized group,62,0,999.0
autism spectral disorder,43,0,999.0
asd,43,0,999.0
neurocognitive impairment in hiv-1,43,0,999.0
neurocognitive impairment in hiv,43,0,999.0
cocaine addicted,132,0,999.0
model developments,31,0,999.0
polymer,31,0,999.0
polymeric,31,0,999.0
resolutions,339,0,999.0
psychiatric comorbidity,91,0,999.0
psychiatric co-morbidity,91,0,999.0
hiv-1 associated neurocognitive impairment,43,0,999.0
addiction to psychostimulants,56,0,999.0
addiction to stimulants,56,0,999.0
research and methods,187,0,999.0
coping with stress,48,0,999.0
neural inflammation,135,0,999.0
reduce overdose,89,0,999.0
reduction in overdose,89,0,999.0
alcohol dependent,352,0,999.0
reducing risk,141,0,999.0
coronavirus disease 2019 consequence,35,0,999.0
low-resource area,61,0,999.0
reducing the risk,141,0,999.0
risk-reducing,141,0,999.0
biologics,61,0,999.0
coronavirus disease 2019 effect,35,0,999.0
coronavirus disease 2019 impact,35,0,999.0
structural determinants,41,0,999.0
structural factors,41,0,999.0
electronic health medical record,138,0,999.0
alcohol-related liver disease,48,0,999.0
snrna sequencing,41,0,999.0
electronic health plan record,138,0,999.0
electronic health registry,138,0,999.0
electronic medical health record,138,0,999.0
coronavirus disease-19 impact,35,0,999.0
pain measure,43,0,999.0
ethnic subgroup,62,0,999.0
economic assessment,41,0,999.0
customs,41,0,999.0
graduate school,41,0,999.0
single-nucleus sequencing,41,0,999.0
single nucleus seq,41,0,999.0
induced pluripotent cell,56,0,999.0
cell phone based app,56,0,999.0
mobile phone app,56,0,999.0
gene regulatory network,46,0,999.0
dissemination science,32,0,999.0
coronavirus disease-19,191,0,999.0
methamphetamine use disorder,78,0,999.0
abuse liability,319,0,999.0
abuse potential,319,0,999.0
meth use disorder,78,0,999.0
self-administer cocaine,318,0,999.0
cocaine use disorder,193,0,999.0
under served individual,78,0,999.0
underserved individual,78,0,999.0
hispanic group,35,0,999.0
medication for opioid use disorder,197,0,999.0
machine based learning,191,0,999.0
efficacy determination,198,0,999.0
self administered,600,0,999.0
determine efficacy,198,0,999.0
hispanic individual,35,0,999.0
hispanic people,35,0,999.0
barriers to implementation,92,0,999.0
operations,93,0,999.0
coronavirus infectious disease 2019,65,0,999.0
racial subgroup,65,0,999.0
ethanol dependent,65,0,999.0
rational design,77,0,999.0
coronavirus infectious disease-19,191,0,999.0
vulnerable people,327,0,999.0
smartphone based app,56,0,999.0
alcohol related liver disease,37,0,999.0
smartphone based application,56,0,999.0
inequity,56,0,999.0
cognitive treatment,56,0,999.0
hiv-1 associated neurocognitive deficit,43,0,999.0
hiv neurocognitive impairment,43,0,999.0
complementation,80,0,999.0
long term abstinence,37,0,999.0
atac sequencing,37,0,999.0
neural imaging,338,0,999.0
ethanol liver disease,37,0,999.0
alcohol-associated liver disease,37,0,999.0
hiv induced neurocognitive impairment,43,0,999.0
meeting,333,0,999.0
hiv induced neurocognitive deficit,43,0,999.0
transcriptomic profiling,37,0,999.0
transcriptome profiling,37,0,999.0
high schoolers,47,0,999.0
hiv associated neurocognitive impairment,43,0,999.0
hiv associated neurocognitive deficit,43,0,999.0
single cell expression profiling,129,0,999.0
single cell transcriptomic profiling,129,0,999.0
brain based,47,0,999.0
strokes,63,0,999.0
stroked,63,0,999.0
reduces the risk,141,0,999.0
reduces risk,141,0,999.0
reduce these risks,141,0,999.0
compare to control,87,0,999.0
rat transgene,36,0,999.0
data representations,36,0,999.0
neuropathologic,36,0,999.0
neuropathological,36,0,999.0
wearable tool,36,0,999.0
wearables,36,0,999.0
care as usual,173,0,999.0
addiction potential,173,0,999.0
process evaluation,36,0,999.0
cocaine-associated behaviors,32,0,999.0
comparison control,87,0,999.0
addiction liability,173,0,999.0
racial inequality,86,0,999.0
benchmark,59,0,999.0
engagement with communities,59,0,999.0
mortality rate,59,0,999.0
mortality ratio,59,0,999.0
novel pharmacological therapeutic,449,0,999.0
gene repair therapy,47,0,999.0
cocaine related behaviors,32,0,999.0
lived experiences,48,0,999.0
lived experience,48,0,999.0
effectiveness/implementation trial,48,0,999.0
effectiveness/implementation hybrid trial,48,0,999.0
prevent relapse,170,0,999.0
racial inequity,86,0,999.0
enzyme linked immunoassay,42,0,999.0
machine learning based method,60,0,999.0
ethnic minority group,59,0,999.0
ethnic minority individual,59,0,999.0
ethnic minority people,59,0,999.0
examine cost,60,0,999.0
evaluate cost,60,0,999.0
cost evaluation,60,0,999.0
inducible pluripotent stem cell,84,0,999.0
antinociception,84,0,999.0
antinociceptive,84,0,999.0
weights,42,0,999.0
rural individual,42,0,999.0
rural people,42,0,999.0
racially unequal,86,0,999.0
rural group,42,0,999.0
patient oriented outcomes,166,0,999.0
exposure to meth,36,0,999.0
exposure to methamphetamine,36,0,999.0
cocaine withdrawal,36,0,999.0
clustered regularly interspaced short palindromic repeats approach,169,0,999.0
crispr/cas approach,169,0,999.0
crispr tools,169,0,999.0
crispr based approach,169,0,999.0
cell cultures,85,0,999.0
crispr approach,169,0,999.0
cocaine motivated behaviors,32,0,999.0
asian,35,0,999.0
reduce the risk,141,0,999.0
resilient,145,0,999.0
resource-limited community,61,0,999.0
resource-limited area,61,0,999.0
resource-constrained setting,61,0,999.0
resource-constrained region,61,0,999.0
resource-constrained environment,61,0,999.0
resource-constrained community,61,0,999.0
social influence,57,0,999.0
medication-assisted therapy,146,0,999.0
resource-constrained area,61,0,999.0
covid-19 effect,35,0,999.0
low-resource setting,61,0,999.0
low-resource region,61,0,999.0
research associates,185,0,999.0
neurological imaging,508,0,999.0
covid-19 impact,35,0,999.0
cocaine seeking,143,0,999.0
antagonism,358,0,999.0
low-resource environment,61,0,999.0
covid-19 impacted,35,0,999.0
low-resource community,61,0,999.0
infusions,142,0,999.0
reduce risk,141,0,999.0
reduce risks,141,0,999.0
reduce that risk,141,0,999.0
post-doctoral trainee,185,0,999.0
examine effectiveness,185,0,999.0
cocaine behavior,32,0,999.0
resource-poor community,61,0,999.0
ingest,32,0,999.0
multi-modal neuro-imaging,41,0,999.0
effectiveness and implementation trial,48,0,999.0
suicides,82,0,999.0
multi-modal neuroimaging,41,0,999.0
health and care delivery,61,0,999.0
multimodal neuro-imaging,41,0,999.0
multimodal neuroimaging,41,0,999.0
resource-poor setting,61,0,999.0
resource-poor region,61,0,999.0
resource-poor environment,61,0,999.0
resource-poor area,61,0,999.0
caring for patients,58,0,999.0
data management center,88,0,999.0
data management and coordinating center,88,0,999.0
resource-limited setting,61,0,999.0
resource-limited region,61,0,999.0
covid-19 affected,35,0,999.0
covid-19 consequence,35,0,999.0
resource-limited environment,61,0,999.0
attenuate,364,0,999.0
attenuates,364,0,999.0
care for patients,58,0,999.0
care of patients,58,0,999.0
new treatment strategy,200,0,999.0
facilitators to implementation,76,0,999.0
homes,233,0,999.0
mental health care,76,0,999.0
subgroup disparity,45,0,999.0
community based organizations,38,0,999.0
disparate,38,0,999.0
primary care clinic,38,0,999.0
analyzing longitudinal,38,0,999.0
disparity among subgroups,45,0,999.0
disparity between groups,45,0,999.0
transcriptomic sequencing,255,0,999.0
disparity between subgroups,45,0,999.0
maladaptive behavior,109,0,999.0
group disparity,45,0,999.0
substance use and disorder,1009,0,999.0
infection by hepatitis c virus,39,0,999.0
population inequity,45,0,999.0
group inequality,45,0,999.0
group inequity,45,0,999.0
translational investigation,254,0,999.0
inequalities among populations,45,0,999.0
hands,39,0,999.0
predicting risk,39,0,999.0
predict risk,39,0,999.0
population inequality,45,0,999.0
psychostimulant use disorder,108,0,999.0
inequalities between populations,45,0,999.0
mechanic,108,0,999.0
unequal group,45,0,999.0
individuals from minority,38,0,999.0
individuals of minority,38,0,999.0
disparities across groups,45,0,999.0
disadvantaged people,45,0,999.0
health care inequity,37,0,999.0
health care inequality,37,0,999.0
disadvantaged subgroup,45,0,999.0
groups at risk,71,0,999.0
people at risk,71,0,999.0
persons at risk,71,0,999.0
preparations,239,0,999.0
brain impairment,50,0,999.0
reduction in disparity,45,0,999.0
abnormal brain function,50,0,999.0
biological engineering,37,0,999.0
unequal population,45,0,999.0
mitigate disparity,45,0,999.0
lower disparity,45,0,999.0
disparity across subgroups,45,0,999.0
coronavirus disease-19 global pandemic,259,0,999.0
coronavirus disease-19 pandemic,259,0,999.0
measurable outcome,113,0,999.0
disparity among groups,45,0,999.0
outcome measurement,113,0,999.0
decrease disparity,45,0,999.0
risk taking,52,0,999.0
genomic location,52,0,999.0
predict risks,39,0,999.0
predicted risk,39,0,999.0
community care,30,0,999.0
inequities between populations,45,0,999.0
naturally occurring product,39,0,999.0
inequity in groups,45,0,999.0
inequality between groups,45,0,999.0
cocaine-addicted,103,0,999.0
inequality in groups,45,0,999.0
african american population,104,0,999.0
african american people,104,0,999.0
african american individual,104,0,999.0
nonpharmacologic approach,30,0,999.0
inequities among populations,45,0,999.0
african american group,104,0,999.0
nonpharmacologic treatment,30,0,999.0
inequality among groups,45,0,999.0
inequity between groups,45,0,999.0
inequity across populations,45,0,999.0
overdose reversal,38,0,999.0
machine learning based model,51,0,999.0
machine learning model,51,0,999.0
reverse overdose,38,0,999.0
community advisory board,30,0,999.0
recovery support,106,0,999.0
inequities in populations,45,0,999.0
chipseq,51,0,999.0
inequity across groups,45,0,999.0
risk predictions,39,0,999.0
inequality across populations,45,0,999.0
pre ind fda meeting,30,0,999.0
primary care patient,30,0,999.0
pre-ind mtg,30,0,999.0
predicted risks,39,0,999.0
predicting risks,39,0,999.0
pre-ind consultation,30,0,999.0
predictive risk,39,0,999.0
pre-ind discussion,30,0,999.0
pre-ind meeting,30,0,999.0
pre-investigational new drug meeting,30,0,999.0
health disparity community,30,0,999.0
health disparity group,30,0,999.0
crystal methamphetamine,253,0,999.0
cannabis law,30,0,999.0
inequalities in populations,45,0,999.0
cannabis policy,30,0,999.0
cannabis regulation,30,0,999.0
cannabis use law,30,0,999.0
cannabis use policy,30,0,999.0
marijuana law,30,0,999.0
marijuana policy,30,0,999.0
older adulthood,30,0,999.0
nonpharmacologic intervention,30,0,999.0
predicts risk,39,0,999.0
hiv associated neurological disease,51,0,999.0
hiv associated neurological disorder,51,0,999.0
addiction to cocaine,235,0,999.0
meth,164,0,999.0
healthcare inequality,37,0,999.0
healthcare inequity,37,0,999.0
named,54,0,999.0
naming,54,0,999.0
manufacture,121,0,999.0
self-reported discrimination,37,0,999.0
immunosuppressive function,30,0,999.0
perception of discrimination,37,0,999.0
perceived discrimination,37,0,999.0
experienced discrimination,37,0,999.0
ethnic inequity,33,0,999.0
genetic predisposing factor,49,0,999.0
gene network,119,0,999.0
ethnic inequality,33,0,999.0
nicotine self-administration,49,0,999.0
ethnic based disparity,33,0,999.0
cryogenic electron microscopy,49,0,999.0
disparity in ethnic,33,0,999.0
marginalized background,33,0,999.0
shocks,33,0,999.0
statistic methods,75,0,999.0
controlled trials,296,0,999.0
validations,295,0,999.0
acute to chronic pain transition,53,0,999.0
incomes,75,0,999.0
clinical training,35,0,999.0
neuroprotective,35,0,999.0
name,54,0,999.0
health disparities research,48,0,999.0
intervention delivery,54,0,999.0
conformations,76,0,999.0
mental healthcare,76,0,999.0
stressful life experience,65,0,999.0
stressful life event,65,0,999.0
under represented people,123,0,999.0
future implementation,76,0,999.0
coping strategy,76,0,999.0
underrepresented people,123,0,999.0
conformational,76,0,999.0
translational potential,94,0,999.0
conformationally,76,0,999.0
pilot test,204,0,999.0
assess implementation,122,0,999.0
immunosuppressive activity,30,0,999.0
implementation assessment,122,0,999.0
evaluate implementation,122,0,999.0
community-based partners,33,0,999.0
community partners,33,0,999.0
use of stimulants,95,0,999.0
kids,298,0,999.0
psychostimulant use,95,0,999.0
immune suppressive activity,30,0,999.0
health disparities related research,48,0,999.0
cue-induced relapse,33,0,999.0
immune suppressive function,30,0,999.0
epigenetically,293,0,999.0
comparable efficacy,35,0,999.0
diagnostic criteria,53,0,999.0
race based inequality,72,0,999.0
diffuses,53,0,999.0
diffusing,53,0,999.0
diffusions,53,0,999.0
disparity due to race,72,0,999.0
identification of biomarkers,50,0,999.0
inequality due to race,72,0,999.0
inequity due to race,72,0,999.0
integrated care,40,0,999.0
integrated model of care,40,0,999.0
disadvantaged group,45,0,999.0
race based disparity,72,0,999.0
race based inequity,72,0,999.0
fentanyl use,35,0,999.0
race related disparity,72,0,999.0
race related inequality,72,0,999.0
race related inequity,72,0,999.0
treatment responsiveness,72,0,999.0
disadvantaged individual,45,0,999.0
covid-19 years,99,0,999.0
stimulant,232,0,999.0
covid-19 period,99,0,999.0
covid-19 era,99,0,999.0
high risk individual,115,0,999.0
high risk people,115,0,999.0
diffused,53,0,999.0
placebo controlled,116,0,999.0
snrna-seq,72,0,999.0
nociceptive neurons,97,0,999.0
chronic pain control,290,0,999.0
chronic pain intervention,290,0,999.0
chronic pain therapy,290,0,999.0
chronic pain treatment,290,0,999.0
treat chronic pain,290,0,999.0
therapy response,215,0,999.0
response to therapy,215,0,999.0
vulnerable individual,216,0,999.0
minority individual,117,0,999.0
fentanyl self-administration,44,0,999.0
syndemic,53,0,999.0
synergistic epidemic,53,0,999.0
alzheimer disease dementia,97,0,999.0
pharmacologic,768,0,999.0
cannabinoid type 1,74,0,999.0
consultation,74,0,999.0
snuc-seq,72,0,999.0
single nucleus rna-sequencing,72,0,999.0
single-nucleus rna-seq,72,0,999.0
pain-sensing somatosensory neurons,97,0,999.0
pain-sensing sensory neurons,97,0,999.0
pain-sensing neurons,97,0,999.0
panomics,35,0,999.0
racial population,67,1,826.33
black race,163,4,502.58
patient enrollment,60,2,370.0
participant enrollment,60,2,370.0
people of color,41,2,252.83
evaluation of implementation,122,6,250.78
implementation evaluation,122,6,250.78
clinically translatable,61,4,188.08
implementation facilitators,76,7,133.9
economic,167,17,121.16
sleep improvement,33,4,101.75
improvement on sleep,33,4,101.75
intervention refinement,41,5,101.13
marginalized population,62,8,95.58
remote delivery,43,6,88.39
delivered remotely,43,6,88.39
coronavirus disease 2019 global health crisis,259,42,76.06
covid-19 global pandemic,259,42,76.06
coronavirus disease 2019 health crisis,259,42,76.06
covid-19 global health crisis,259,42,76.06
severe acute respiratory syndrome coronavirus 2 pandemic,259,42,76.06
coronavirus disease 2019 global pandemic,259,42,76.06
coronavirus disease 2019 public health crisis,259,42,76.06
coronavirus disease 2019 crisis,259,42,76.06
severe acute respiratory syndrome cov 2 epidemic,259,42,76.06
severe acute respiratory syndrome coronavirus 2 epidemic,259,42,76.06
severe acute respiratory syndrome cov 2 pandemic,259,42,76.06
coronavirus disease epidemic,259,42,76.06
sars-coronavirus-2 pandemic,259,42,76.06
sars-coronavirus-2 epidemic,259,42,76.06
sars-cov-2 pandemic,259,42,76.06
sars-cov-2 global pandemic,259,42,76.06
sars-cov-2 global health crisis,259,42,76.06
covid-19 health crisis,259,42,76.06
coronavirus disease crisis,259,42,76.06
sars-cov-2 epidemic,259,42,76.06
coronavirus disease pandemic,259,42,76.06
covid-19 crisis,259,42,76.06
covid crisis,259,42,76.06
covid epidemic,259,42,76.06
covid-19 public health crisis,259,42,76.06
severe acute respiratory syndrome coronavirus 2 global health crisis,259,42,76.06
covid pandemic,259,42,76.06
severe acute respiratory syndrome coronavirus 2 global pandemic,259,42,76.06
health inequity,67,11,75.12
inequalities in health,67,11,75.12
inequities in health,67,11,75.12
health disparity populations,40,7,70.48
environmental hazards,68,12,69.89
old age,33,6,67.83
multidimensional datasets,53,10,65.37
transition to chronic pain,53,10,65.37
chronic pain transition,53,10,65.37
pain chronification,53,10,65.37
biologic,890,168,65.34
digital intervention,36,7,63.43
feasibility testing,125,25,61.67
implementation barriers,92,19,59.72
implementation challenges,92,19,59.72
recreation,87,18,59.61
implementation intervention,72,15,59.2
disadvantaged background,48,10,59.2
multiple substance use,129,27,58.93
multisubstance use,129,27,58.93
polysubstance use,129,27,58.93
poly substance use,129,27,58.93
forecasting risk,52,11,58.3
risk prediction,52,11,58.3
re-aim,94,20,57.97
community engagement,136,29,57.84
participant engagement,112,24,57.56
examine efficacy,279,60,57.35
efficacy analysis,279,60,57.35
efficacy assessment,279,60,57.35
evaluate efficacy,279,60,57.35
efficacy examination,279,60,57.35
helping end addiction longterm,595,130,56.45
helping to end addiction long-term,595,130,56.45
helping to end addiction longterm,595,130,56.45
heal initiative,595,130,56.45
helping end addiction long-term,595,130,56.45
multidimensional data,53,12,54.47
high dimensional data,53,12,54.47
effectiveness outcome,44,10,54.27
effectiveness-related outcomes,44,10,54.27
safety assessment,52,12,53.44
chronic pain management,290,67,53.38
cigarette craving,30,7,52.86
cv-19,191,45,52.35
under served community,55,13,52.18
underserved community,55,13,52.18
data infrastructure,37,9,50.7
transcriptional profile,142,35,50.04
noninvasive brain stimulation,44,11,49.33
non-invasive brain stimulation,44,11,49.33
xenograft transplant model,39,10,48.1
xenotransplant model,39,10,48.1
wearable biosensor,35,9,47.96
national center on minority health and health disparities,31,8,47.79
ncmhd,31,8,47.79
implementation outcomes,115,30,47.28
covid19 public health crisis,160,42,46.98
covid19 health crisis,160,42,46.98
covid19 global pandemic,160,42,46.98
covid19 global health crisis,160,42,46.98
covid19 crisis,160,42,46.98
sars-cov2 pandemic,160,42,46.98
sars-cov2 epidemic,160,42,46.98
nicotine treatment,38,10,46.87
consolidated framework for implementing change,98,26,46.49
consolidated framework for implementation research,98,26,46.49
consolidated framework for implementation science,98,26,46.49
dedications,180,48,46.25
health inequalities,67,18,45.91
overdose fatalities,528,143,45.54
acceleration,372,101,45.43
implementation science framework,77,21,45.22
acceptability and feasibility,242,66,45.22
implementation framework,77,21,45.22
implementation research framework,77,21,45.22
efficacy,73,20,45.02
reach,146,40,45.02
and maintenance,146,40,45.02
coronavirus disease 2019 epidemic,259,71,44.99
coronavirus disease 2019 pandemic,259,71,44.99
covid-19 epidemic,259,71,44.99
catalog,51,14,44.93
under representation of groups,123,34,44.62
under represented groups,123,34,44.62
under represented populations,123,34,44.62
underrepresentation of groups,123,34,44.62
ethnicity disparity,36,10,44.4
ethnic disparity,36,10,44.4
mφ,101,29,42.95
strategies for implementation,169,49,42.54
multiomics,79,23,42.36
pdx model,82,24,42.14
patient derived xenograft,82,24,42.14
patient derived xenograft model,82,24,42.14
implementation cost,34,10,41.93
implementation investment,34,10,41.93
community-based health,61,18,41.8
disparity in healthcare,37,11,41.48
healthcare disparity,37,11,41.48
health care disparity,37,11,41.48
disparity in care,37,11,41.48
veterans affairs,94,28,41.4
novel therapeutic strategies,304,91,41.2
assess effectiveness,270,81,41.11
quasi-experimental study,40,12,41.11
effectiveness assessment,270,81,41.11
quasi-experiment,40,12,41.11
quasi-experimental research,40,12,41.11
determine effectiveness,270,81,41.11
quasi-experimental methods,40,12,41.11
quasi-experimental analysis,40,12,41.11
quasi-experimental design,40,12,41.11
quasi-experimental approach,40,12,41.11
quasi-experimental technique,40,12,41.11
substance use treatment,386,116,41.04
military population,66,20,40.7
pain after surgery,132,40,40.7
combustible tobacco,46,14,40.52
prescription pain medication,36,11,40.36
prescription analgesic,36,11,40.36
community participatory research,88,27,40.2
community led research,88,27,40.2
community engaged research,39,12,40.08
irregular sleep,144,45,39.47
video conferencing,32,10,39.47
diets,67,21,39.35
newborn abstinence syndrome,114,36,39.06
veterans health administration,88,28,38.76
veterans health affairs,88,28,38.76
ethnicity population,90,29,38.28
ethnicity people,90,29,38.28
ethnic people,90,29,38.28
ethnic population,90,29,38.28
interindividual variability,34,11,38.12
sleep illness,79,26,37.47
immune system response,91,30,37.41
digital therapeutics,42,14,37.0
digital therapy,42,14,37.0
digital treatment,42,14,37.0
machine learning methodologies,60,20,37.0
health delivery systems,91,31,36.2
multiple omics,79,27,36.09
implementation process,58,20,35.77
non-opioid therapeutics,288,100,35.52
conventional cigarette,91,32,35.07
traditional cigarette,91,32,35.07
neurohiv,51,18,34.94
neuro-hiv,51,18,34.94
neuro-aids,51,18,34.94
wearable system,48,17,34.82
intervention for prevention,189,67,34.79
under served group,118,42,34.65
underserved group,118,42,34.65
under served people,118,42,34.65
cv19,126,45,34.53
minority population,117,42,34.36
minority people,117,42,34.36
findable,36,13,34.15
accessible,36,13,34.15
data standards,88,32,33.92
individualized therapeutic strategy,99,36,33.92
smoking initiation,33,12,33.92
2nd trimester,88,32,33.92
data standardization,88,32,33.92
health related behavior,89,33,33.26
non-drug therapy,35,13,33.21
non-drug treatment,35,13,33.21
nondrug therapy,35,13,33.21
nondrug treatment,35,13,33.21
cocaine self-administration,318,119,32.96
implementation efforts,32,12,32.89
prescribed medication,174,66,32.52
medication prescription,174,66,32.52
cancer-directed therapy,116,44,32.52
community research,71,27,32.43
tobacco product use,382,146,32.27
therapeutic opioid,34,13,32.26
repurposing agent,31,12,31.86
drug repurposing,31,12,31.86
repurposing medication,31,12,31.86
undergrad,126,49,31.71
impoverished,117,46,31.37
multi-modal datasets,38,15,31.24
multimodal datasets,38,15,31.24
dissemination and implementation,93,37,31.0
coronavirus disease 2019,191,76,31.0
biomarker identification,55,22,30.83
marker identification,55,22,30.83
implementation study,47,19,30.51
gender and sexual minorities,37,15,30.42
sexual and gender minorities,37,15,30.42
barcode,37,15,30.42
veteran population,118,48,30.32
military veteran,118,48,30.32
mobile device application,80,33,29.9
effectiveness study,43,18,29.46
candidate identification,50,21,29.37
rural location,138,58,29.34
efficacy evaluation,279,118,29.16
sociodeterminant,51,22,28.59
ten years of age,69,30,28.37
10 years of age,69,30,28.37
systemic inflammation,32,14,28.19
data harmonization,75,33,28.03
substance user,50,22,28.03
harmonized data,75,33,28.03
tobacco regulation,34,15,27.96
tobacco regulatory efforts,34,15,27.96
regulate tobacco,34,15,27.96
midtrimester,88,39,27.83
second pregnancy trimester,88,39,27.83
second trimester,88,39,27.83
corona virus disease 2019 epidemic,160,71,27.79
covid19 epidemic,160,71,27.79
corona virus disease 2019 pandemic,160,71,27.79
covid19 pandemic,160,71,27.79
stimulant use disorder,108,48,27.75
nicotine reward,40,18,27.41
effectiveness evaluation,270,122,27.3
evaluate effectiveness,270,122,27.3
urban location,44,20,27.13
urban region,44,20,27.13
single cell rnaseq,129,59,26.97
electroencephalogram,159,74,26.5
sociocultural,45,21,26.43
social culture,45,21,26.43
longterm prospective studies,30,14,26.43
socio-cultural,45,21,26.43
systemic inflammatory response,32,15,26.31
clinical pain,164,78,25.93
age 65 and greater,33,16,25.44
age 65 and older,33,16,25.44
aged 65 and greater,33,16,25.44
aged ≥65,33,16,25.44
wearable sensor technology,35,17,25.39
efficacious therapy,73,36,25.01
efficacious treatment,73,36,25.01
multimodal data,38,19,24.67
multi-modal data,38,19,24.67
marginalization,58,29,24.67
osteoarthritis associated pain,32,16,24.67
anxiety reduction,30,15,24.67
large datasets,81,41,24.37
large data sets,81,41,24.37
data integrity,59,30,24.26
wearable electronics,51,26,24.19
patient reported measures,92,47,24.14
electronic nicotine delivery product,90,46,24.13
electronic nicotine distribution system,90,46,24.13
cryo-em,70,36,23.98
opioid tapering,33,17,23.94
community health aides,33,17,23.94
community health worker,33,17,23.94
darkness,77,40,23.74
disparities in race,86,45,23.57
race disparity,86,45,23.57
national institute of children's health and human development,40,21,23.49
racism,53,28,23.35
supervised learning,34,18,23.3
supervised machine learning,34,18,23.3
genetically manipulate,147,78,23.24
genetically perturb,147,78,23.24
gene manipulation,147,78,23.24
economic analysis,58,31,23.08
social factors,86,46,23.06
three dimensional,224,120,23.02
treatment risk,39,21,22.9
synthetic opiate,172,93,22.81
synthetic opioid,172,93,22.81
traumatic stress,35,19,22.72
risk mitigation,46,25,22.69
stressed mothers,73,40,22.51
maternal stress,73,40,22.51
wearable technology,51,28,22.46
social health determinants,139,77,22.26
polygenic risk score,61,34,22.13
single cell sequencing,34,19,22.07
malleable risk,55,31,21.88
maternal health,112,64,21.58
socio-economically disadvantaged,40,23,21.45
socio-economic disadvantage,40,23,21.45
socio-economically underprivileged,40,23,21.45
stress reduction,38,22,21.3
racial disparity,86,50,21.21
malnourished,66,39,20.87
genetic strategy,213,126,20.85
atacseq,62,37,20.67
atac-seq,62,37,20.67
adverse childhood experiences,35,21,20.56
emergency hospital visit,128,77,20.5
lasting pain,88,53,20.48
constant pain,88,53,20.48
corona virus disease 2019,126,76,20.45
feasibility trial,38,23,20.38
machine learned algorithm,66,40,20.35
biopharmaceutical,61,37,20.33
biological agent,61,37,20.33
interactive atmosphere,31,19,20.12
interdisciplinary atmosphere,31,19,20.12
peer-group atmosphere,31,19,20.12
business-friendly atmosphere,31,19,20.12
collaborative atmosphere,31,19,20.12
conditional knock-out,70,43,20.08
conditional knockout,70,43,20.08
machine learning method,60,37,20.0
early life exposure,61,38,19.8
gene locus,77,48,19.78
genetic locus,77,48,19.78
genomic locus,77,48,19.78
clustered regularly interspaced short palindromic repeats methodology,169,106,19.66
clustered regularly interspaced short palindromic repeats technique,169,106,19.66
clustered regularly interspaced short palindromic repeats technology,169,106,19.66
clustered regularly interspaced short palindromic repeats method,169,106,19.66
adverse childhood events,35,22,19.62
deep learning,54,34,19.59
early adversity,47,30,19.32
early childhood adversity,47,30,19.32
differences between sexes,358,229,19.28
differs between sexes,358,229,19.28
sexual differences,358,229,19.28
cost estimation,64,41,19.25
cost estimate,64,41,19.25
non-pharmacologic therapy,45,29,19.14
nonpharmacologic therapy,45,29,19.14
long-term follow-up,31,20,19.12
longterm follow-up,31,20,19.12
longterm followup,31,20,19.12
long-term followup,31,20,19.12
co-occuring symptom,79,51,19.1
co-morbid symptom,79,51,19.1
drug epidemiology,34,22,19.06
pharmacoepidemiology,34,22,19.06
pharmacoepidemiologic,34,22,19.06
pharmaceutical epidemiology,34,22,19.06
pharmacoepidemiological,34,22,19.06
hpa axis,63,41,18.95
age 10 years,69,45,18.91
biological products,61,40,18.81
genetic signature,38,25,18.75
gene signatures,38,25,18.75
single cell rna-seq,129,85,18.72
scrna-seq,129,85,18.72
single-cell rna sequencing,129,85,18.72
prenatal visit,47,31,18.7
prenatal appointment,47,31,18.7
prenatal checkup,47,31,18.7
effectiveness testing,130,86,18.64
ad dementia,157,104,18.62
ten year old,69,46,18.5
10 year old,69,46,18.5
pharmacokinetics and pharmacodynamics,91,61,18.4
pk/pd,91,61,18.4
treatment research,88,59,18.4
depository,70,47,18.37
adaptive intervention,58,39,18.34
3d,224,152,18.18
ethnoracial,103,70,18.15
early life adversity,47,32,18.11
m mulatta,63,43,18.07
behavioral phenotyping,189,129,18.07
behavior phenotype,189,129,18.07
m. mulatta,63,43,18.07
model of human,130,89,18.01
fetal opioid exposure,42,29,17.86
fetal opiate exposures,42,29,17.86
prenatal opioid exposure,42,29,17.86
gestational opioid exposure,42,29,17.86
comparison intervention,55,38,17.85
compare intervention,55,38,17.85
actiq,363,251,17.84
duragesic,363,251,17.84
fentanest,363,251,17.84
newborn child,128,89,17.74
newborn children,128,89,17.74
patient engagement,112,78,17.71
pain catastrophizing,30,21,17.62
ecological systems,30,21,17.62
nano-sized particle,37,26,17.55
nanosized particle,37,26,17.55
injuries,270,190,17.53
maternal opioid use,51,36,17.47
maternal opiates use,51,36,17.47
central nervous system plasticity,237,168,17.4
implementation facilitation,31,22,17.38
pancreatic malignancy,31,22,17.38
wildtype mouse,100,71,17.37
emotional functioning,32,23,17.16
biotherapeutic agent,61,44,17.1
posttrauma stress disorder,316,228,17.09
post-trauma stress disorder,316,228,17.09
sleep diseases,79,57,17.09
stimulant use,95,69,16.98
transcriptomics,363,265,16.89
organoids,78,57,16.88
knee oa,41,30,16.86
knee joint oa,41,30,16.86
knee joint osteoarthritis,41,30,16.86
neurocircuitry,833,612,16.79
patient specific therapies,99,73,16.73
patient specific treatment,99,73,16.73
lead optimization,120,89,16.63
body worn sensor,35,26,16.6
body sensor,35,26,16.6
co-morbid,808,605,16.47
overdose risk,164,123,16.44
sleep dysregulation,144,108,16.44
conditioned place preference,283,214,16.31
place conditioning,283,214,16.31
multisite trial,38,29,16.16
intelligence quotient deficit,64,49,16.11
immune mediated therapy,43,33,16.07
patient subgroups,74,57,16.01
patient subpopulations,74,57,16.01
ion channel gatings,45,35,15.86
prematurely delivering,36,28,15.86
comparative effectiveness trial,36,28,15.86
rehab therapy,86,67,15.83
0-4 weeks old,128,100,15.79
osteoarthritis pain,32,25,15.79
tetrahydrocannabinol co-use,249,195,15.75
tetrahydrocannabinol use,249,195,15.75
underrepresented minority student,37,29,15.74
urm student,37,29,15.74
photometry,307,241,15.71
data science,93,73,15.71
mouse genetics,72,57,15.58
bipolar illness,58,46,15.55
single nucleotide variant,63,50,15.54
clinical center,73,58,15.52
sociodemographics,84,67,15.46
socio-demographics,84,67,15.46
opioid sparing,60,48,15.42
acute care,40,32,15.42
national institute of neurological diseases and stroke,65,52,15.42
bear children,83,67,15.28
bearing children,83,67,15.28
child bearing,83,67,15.28
sexually dimorphic,57,46,15.28
pregnancy care,47,38,15.25
comparator group,47,38,15.25
empowerment,80,65,15.18
65+ years old,33,27,15.07
childbearing,83,68,15.05
immune cell activation,46,38,14.93
ai system,52,43,14.91
surgery pain,35,29,14.89
surgical pain,35,29,14.89
knee osteoarthritis,41,34,14.87
precision-based medicine,153,127,14.86
brain health,30,25,14.8
racially diverse,74,62,14.72
racial diversity,74,62,14.72
mhealth application,31,26,14.71
residential building,31,26,14.71
m-health app,31,26,14.71
m-health application,31,26,14.71
pandemic disease,134,113,14.63
data coordinating center,136,115,14.59
data coordination center,136,115,14.59
implementation strategy,169,143,14.58
suicidal,65,55,14.58
nonhispanic,66,56,14.54
ph d. student,33,28,14.54
ph. d. student,33,28,14.54
ph.d student,33,28,14.54
ph.d. student,33,28,14.54
phd student,33,28,14.54
phd. student,33,28,14.54
ph d student,33,28,14.54
pain assay,106,90,14.53
nonneuronal cell,182,155,14.48
multi-modality,294,251,14.45
on-line education,35,30,14.39
on-line learning,35,30,14.39
functional magnetic resonance imaging scan,35,30,14.39
causative variant,37,32,14.26
causal mutation,37,32,14.26
biological sex,37,32,14.26
causal variant,37,32,14.26
causal gene,37,32,14.26
causal allele,37,32,14.26
causative mutation,37,32,14.26
opiate use disorder,1294,1120,14.25
ecologic systems,30,26,14.23
ecosystem,30,26,14.23
long-term prospective studies,30,26,14.23
barrier to health care,98,85,14.22
barrier to care,98,85,14.22
obstacle to healthcare,98,85,14.22
barrier to healthcare,98,85,14.22
barrier to treatment,98,85,14.22
obstacle to care,98,85,14.22
longitudinal outcome studies,217,189,14.16
opioid induced overdose,569,496,14.15
e-cig liquids,48,42,14.1
eliquid,48,42,14.1
ecigarette liquids,48,42,14.1
ejuice,48,42,14.1
e-cigarette liquids,48,42,14.1
electronic liquid,48,42,14.1
e-juice,48,42,14.1
e-liquid,48,42,14.1
ecig liquids,48,42,14.1
morphine administration,49,43,14.05
opiate exposure,241,212,14.02
opioid exposure,241,212,14.02
prenatal opiate exposure,42,37,14.0
biologic products,42,37,14.0
gestational opiate exposure,42,37,14.0
prenatally opiate exposed,42,37,14.0
multi-level analysis,71,63,13.9
multi-level model,71,63,13.9
protective factors,156,139,13.84
bio-engineered,37,33,13.83
bio-engineers,37,33,13.83
actigraph,38,34,13.78
predict therapy response,67,60,13.77
therapy prediction,67,60,13.77
treatment prediction,67,60,13.77
predict therapeutic response,67,60,13.77
clinical translation,77,69,13.76
treatment comparison,40,36,13.7
compare treatment,40,36,13.7
sleep debt,41,37,13.67
sleep deficiency,41,37,13.67
inadequate sleep,41,37,13.67
sleep loss,41,37,13.67
sleep deficit,41,37,13.67
sleep insufficiency,41,37,13.67
wearable device,51,46,13.67
insufficient sleep,41,37,13.67
deficient sleep,41,37,13.67
high dimensionality,72,65,13.66
bloodbrain barrier,84,76,13.63
wellbeing,254,230,13.62
pain score,33,30,13.57
chronic musculoskeletal pain,34,31,13.53
chronic msk pain,34,31,13.53
neonatal opioid withdrawal syndrome,114,104,13.52
healthcare availability,70,64,13.49
serious adverse reaction,35,32,13.49
serious adverse experience,35,32,13.49
health care access,70,64,13.49
healthcare accessibility,70,64,13.49
fish assay,59,54,13.48
non-steroidal anti-inflammatory drugs,72,66,13.45
computer based method,84,77,13.45
service availability,244,224,13.43
patient subsets,74,68,13.42
patient subtypes,74,68,13.42
waitlist,52,48,13.36
prediction of response to therapy,67,62,13.33
opioid use disorder,1294,1200,13.3
electron cryomicroscopy,70,65,13.28
cryoem,70,65,13.28
cryo-electron microscopy,70,65,13.28
pharmacobehavioral,131,122,13.24
pre-exposure prophylaxis,73,68,13.24
prep,73,68,13.24
minority communities,31,29,13.18
sleep disruption,144,135,13.16
impaired sleep,144,135,13.16
disturbed sleep,144,135,13.16
disrupted sleep,144,135,13.16
aberrant sleep,144,135,13.16
opioid detox,256,240,13.16
opioid detoxification,256,240,13.16
opiate withdrawal,256,240,13.16
vaping,147,138,13.14
early-career faculty,33,31,13.13
pragmatic effectiveness trial,50,47,13.12
druggable target,52,49,13.09
electronic communication,89,84,13.07
longitudinal dataset,36,34,13.06
longitudinal data set,36,34,13.06
electronic device,73,69,13.05
disadvantaged population,55,52,13.04
sex-related differences,358,339,13.02
sex-dependent differences,358,339,13.02
sex-specific differences,358,339,13.02
career transition,43,41,12.93
career mobility,43,41,12.93
career advancement,43,41,12.93
nutrition deficiency disorder,66,63,12.92
nutritional deficiency disorder,66,63,12.92
nutrition deficiency,66,63,12.92
electronic nicotine delivery device,90,86,12.91
precision medicine,153,148,12.75
tobacco smokers,31,30,12.74
mobile health app,31,30,12.74
mobile health application,31,30,12.74
mhealth app,31,30,12.74
preventing alcohol,40,39,12.65
prevent alcohol,42,41,12.63
on-going pain,88,86,12.62
ongoing pain,88,86,12.62
peer support,89,87,12.62
participatory action research,88,87,12.48
non-opioid,288,285,12.46
non-medical opioid use,511,506,12.46
nonmedical opioid use,511,506,12.46
opiate misuse,511,506,12.46
transcriptional signature,142,141,12.42
opioid crisis,972,966,12.41
opioid epidemic,972,966,12.41
opiate crisis,972,966,12.41
financial hardship,60,60,12.33
rural counties,36,36,12.33
hospital admission,210,210,12.33
socioenvironmental,86,86,12.33
financial burden,60,60,12.33
research contracts,36,36,12.33
health care delivery model,37,37,12.33
financial strain,60,60,12.33
financial stress,60,60,12.33
financial distress,60,60,12.33
skill development,117,118,12.23
exposed in utero,103,104,12.21
combustible cigarette,91,92,12.2
non-opioid analgesic,288,293,12.12
nonopiate analgesic,288,293,12.12
non-opiate analgesic,288,293,12.12
non-narcotic analgesic,288,293,12.12
osteoarthritic,50,51,12.09
underrepresented populations,123,126,12.04
bar codes,37,38,12.01
2-photon microscopy,37,38,12.01
two photon microscopy,37,38,12.01
two photon excitation microscopy,37,38,12.01
opiate related overdose,569,586,11.98
opioid toxicity,569,586,11.98
opioid related overdose,569,586,11.98
first in man,67,69,11.98
opioid drug overdose,569,586,11.98
first-in-human,67,69,11.98
opioid poisoning,569,586,11.98
opioid overdose,569,586,11.98
opiate overdose,569,586,11.98
opioid intoxication,569,586,11.98
opioid medication overdose,569,586,11.98
biocompatibility,30,31,11.94
death risk,58,60,11.92
mortality risk,58,60,11.92
pregnant mothers,222,230,11.9
imaging based approach,53,55,11.88
cryoelectron microscopy,70,73,11.83
treatment response prediction,67,70,11.8
parabrachial nucleus,41,43,11.76
pwuo,99,104,11.74
fluorescence in situ hybridization,59,62,11.74
people who use opioids,99,104,11.74
persons who use opioids,99,104,11.74
rehospitalization,38,40,11.72
re-admission,38,40,11.72
hospital re-admission,38,40,11.72
re-hospitalization,38,40,11.72
electronic nicotine delivery systems,90,95,11.68
wearable sensor,35,37,11.67
nonnarcotic analgesics,288,305,11.65
dietary deficiency,66,70,11.63
undernutrition,66,70,11.63
nutritional deficiency,66,70,11.63
pain perception,79,84,11.6
glial cell activation,47,50,11.59
glial activation,47,50,11.59
perioperative,77,82,11.58
tribal community,30,32,11.56
biomaterial compatibility,30,32,11.56
rehabilitative therapy,86,92,11.53
genomic dataset,71,76,11.52
genomic data-set,71,76,11.52
alaskan native american,69,74,11.5
nonopioid analgesics,288,310,11.46
nonopioid,288,310,11.46
fentyl,363,392,11.42
phentanyl,363,392,11.42
peer coaching,36,39,11.38
peer mentoring,36,39,11.38
peer led team learning,36,39,11.38
peer instruction,36,39,11.38
peer teaching,36,39,11.38
severe adverse event,35,38,11.36
medical costs,57,62,11.34
followup assessment,65,71,11.29
socio-economically,250,274,11.25
peripartum,83,91,11.25
faculty mentor,73,80,11.25
indigenous,61,67,11.23
hispanic-serving institution,30,33,11.21
structure of paraventricular nucleus of thalamus,60,66,11.21
paraventricular nucleus of thalamus,60,66,11.21
paraventricular thalamic nucleus,60,66,11.21
genomic therapy,47,52,11.15
3-dimensional,224,248,11.14
opiate mortality,264,293,11.11
opioid deaths,264,293,11.11
opioid mortality,264,293,11.11
opiate deaths,264,293,11.11
opioid overdose death,264,293,11.11
opioid related death,264,293,11.11
musculoskeletal,35,39,11.07
immune therapeutic approach,43,48,11.05
immune therapeutic strategy,43,48,11.05
immune therapeutic regimens,43,48,11.05
pain model,170,190,11.04
quality of sleep,68,76,11.04
degenerative arthritis,50,56,11.01
biobank,91,102,11.0
biorepository,91,102,11.0
reduce pain,201,226,10.97
pain reduction,201,226,10.97
rural place,40,45,10.96
rural locality,40,45,10.96
sleep dysfunction,79,89,10.95
epidemiological data,53,60,10.89
epidemiology data,53,60,10.89
post-partum,75,85,10.88
creativeness,37,42,10.87
creativity,37,42,10.87
natural language processing,59,67,10.86
natural language understanding,59,67,10.86
prescription pain reliever,36,41,10.83
global transcription profile,274,313,10.8
global gene expression,274,313,10.8
low ses,77,88,10.79
3-d,224,256,10.79
improve symptom,35,40,10.79
symptom improvement,35,40,10.79
symptomatic improvement,35,40,10.79
texting,67,77,10.73
short message service,67,77,10.73
personalized approach,67,77,10.73
tailored approach,67,77,10.73
individualized approach,67,77,10.73
precision approach,67,77,10.73
personalized medical approach,67,77,10.73
expecting mother,222,256,10.7
expectant mother,222,256,10.7
irb,91,105,10.69
developing fetus,32,37,10.67
drug use behavior,45,52,10.67
gestational ethanol exposure,32,37,10.67
opioid dependent,1157,1345,10.61
patient reported outcomes,92,107,10.6
patient outcomes assessments,92,107,10.6
efficacy study,115,134,10.58
clustered regularly interspaced short palindromic repeats,179,209,10.56
crispr,179,209,10.56
crispr/cas system,179,209,10.56
hiv seronegativities,35,41,10.53
hiv seronegativity,35,41,10.53
htlv-iii seronegativity,35,41,10.53
hiv negative,35,41,10.53
opiate consumption,1042,1220,10.53
opiate drug use,1042,1220,10.53
htlv-iii seronegativities,35,41,10.53
opiate use,1042,1220,10.53
opioid consumption,1042,1220,10.53
opioid drug use,1042,1220,10.53
opioid intake,1042,1220,10.53
opiate intake,1042,1220,10.53
active followup,650,763,10.51
followup,650,763,10.51
rural setting,40,47,10.5
socioeconomically disadvantaged,40,47,10.5
socioeconomically underprivileged,40,47,10.5
inter-individual variability,34,40,10.48
common data element,34,40,10.48
newborn infant,128,151,10.45
pain processing,61,72,10.45
data depository,33,39,10.44
malnutrition,66,78,10.44
biological sensor,99,117,10.44
people who use illicit drugs,131,155,10.42
pwud,131,155,10.42
people who use drugs,131,155,10.42
persons who use drugs,131,155,10.42
fish technique,59,70,10.4
fish analysis,59,70,10.4
fish technic,59,70,10.4
odor perception,43,51,10.4
olfactory perception,43,51,10.4
crispr-based tool,169,201,10.37
crispr/cas9 technology,169,201,10.37
crispr-based method,169,201,10.37
crispr methodology,169,201,10.37
crispr-based technique,169,201,10.37
crispr-based technology,169,201,10.37
longterm cohort study,42,50,10.36
self assessment,31,37,10.33
underrepresented groups,123,147,10.32
stigmatization,92,110,10.32
webinar,41,49,10.32
anti-cancer therapy,116,139,10.29
model the data,35,42,10.28
modeling of the data,35,42,10.28
human biology,35,42,10.28
noninsulin dependent diabetes,35,42,10.28
model of data,35,42,10.28
community health care,40,48,10.28
tenure track,60,72,10.28
flavorant,30,36,10.28
tenure process,60,72,10.28
translational researcher,38,46,10.19
translational investigator,38,46,10.19
translational scientist,38,46,10.19
post-partum women,33,40,10.17
overdose prevention,79,96,10.15
hypertrophic arthritis,50,61,10.11
degenerative joint disease,50,61,10.11
osteoarthrosis,50,61,10.11
degenerative polyarthritis,50,61,10.11
lmic,36,44,10.09
low and middle-income countries,36,44,10.09
cluster randomized trial,44,54,10.05
cluster randomization trial,44,54,10.05
therapeutic testing,34,42,9.98
pain outcome,59,73,9.97
injury to liver,38,47,9.97
healing,96,119,9.95
adolescent exposure to alcohol,33,41,9.93
adolescent exposure to ethanol,33,41,9.93
adolescent intermittent ethanol exposure,33,41,9.93
risk minimization,41,51,9.92
prevent suicide,41,51,9.92
suicidality prevention,41,51,9.92
prevent suicidality,41,51,9.92
infant and child development,134,167,9.9
child development,134,167,9.9
videoconferencing,32,40,9.87
brain reward regions,48,60,9.87
symptom comorbidity,79,99,9.84
symptom association,79,99,9.84
cooccuring symptom,79,99,9.84
comorbid symptom,79,99,9.84
concurrent symptom,79,99,9.84
associated symptom,79,99,9.84
illicit opiate,147,185,9.8
illicit opioid,147,185,9.8
transcriptional profiling,93,118,9.72
in vivo calcium imaging,92,117,9.7
fluorescent in situ hybridization,59,75,9.7
in vivo two-photon calcium imaging,92,117,9.7
intestinal biome,40,51,9.67
socioeconomic disadvantage,40,51,9.67
multimodality,294,375,9.67
enteric microbiome,40,51,9.67
prostate,40,51,9.67
gi microbiome,40,51,9.67
gut-associated microbiome,40,51,9.67
dissemination of results,46,59,9.62
unstably housed,35,45,9.59
pain signal,56,72,9.59
unstable housing,35,45,9.59
reduce disparity,56,72,9.59
death rate,105,135,9.59
housing instability,35,45,9.59
disparity reduction,56,72,9.59
instably housed,35,45,9.59
toxicant exposure,94,121,9.58
toxic exposure,94,121,9.58
medication misuse,59,76,9.57
public health emergency,76,98,9.56
suicide prevention,41,53,9.54
suicide precaution,41,53,9.54
suicide intervention,41,53,9.54
therapeutic evaluation,34,44,9.53
healthcare technology,64,83,9.51
medical care costs,57,74,9.5
painful sensation,30,39,9.49
pain sensation,30,39,9.49
ios app,83,108,9.48
opioid exposed,163,212,9.48
electronic health care record,213,277,9.48
smartphone application,83,108,9.48
android app,83,108,9.48
android application,83,108,9.48
cell phone application,83,108,9.48
cell phone app,83,108,9.48
cellular phone app,83,108,9.48
opiate exposed,163,212,9.48
smartphone app,83,108,9.48
ios application,83,108,9.48
cellular phone application,83,108,9.48
smart phone app,83,108,9.48
iphone application,83,108,9.48
iphone app,83,108,9.48
smart phone application,83,108,9.48
faculty development,36,47,9.45
instructor training,36,47,9.45
teacher development,36,47,9.45
faculty professional development,36,47,9.45
sleep quality,68,89,9.42
mobile phones,127,167,9.38
readmission,38,50,9.37
antiretroviral treatment,174,229,9.37
genetic architecture,41,54,9.36
optimal treatments,44,58,9.36
optimal therapies,44,58,9.36
rural region,138,182,9.35
primary endpoint,47,62,9.35
primary end point,47,62,9.35
overdose death,528,697,9.34
reduction in substance use,109,144,9.34
substance use reduction,109,144,9.34
translational model,34,45,9.32
multi-modal therapy,95,126,9.3
buprenorphine treatment,101,134,9.3
multi-modal treatment,95,126,9.3
economic evaluation,58,77,9.29
non-translated rna,73,97,9.28
μor,322,428,9.28
μ-or,322,428,9.28
fentanyl,363,483,9.27
survivors,45,60,9.25
assess cost,74,99,9.22
cost assessment,74,99,9.22
maternal and child health,38,51,9.19
(tnf)-α,73,98,9.19
arrestin b,64,86,9.18
pain treatment,785,1056,9.17
health data,49,66,9.16
retention rate,89,120,9.15
retention strategy,89,120,9.15
care delivery model,37,50,9.13
healthcare delivery model,37,50,9.13
service model,37,50,9.13
service delivery model,37,50,9.13
dashboard,51,69,9.12
emotional behavior,51,69,9.12
longterm potentiation,48,65,9.11
undergraduate,126,171,9.09
accessibility to health care,70,95,9.09
pain sensitivity,87,118,9.09
accessibility to healthcare,70,95,9.09
healthcare access,70,95,9.09
novel biomarker,39,53,9.08
machine intelligence,53,72,9.08
physiotherapy,39,53,9.08
physical medicine procedure,39,53,9.08
physical therapeutics,39,53,9.08
physiatric procedure,39,53,9.08
computer reasoning,53,72,9.08
longterm study,217,295,9.07
opioid use,1042,1419,9.06
multicenter clinical trial,58,79,9.05
multisite clinical trial,58,79,9.05
tobacco products,176,240,9.04
immuno therapy,43,59,8.99
immune-based treatments,43,59,8.99
immune-based therapies,43,59,8.99
immune therapeutic interventions,43,59,8.99
administrative supplement,82,113,8.95
relieve pain,264,364,8.95
pain relief,264,364,8.95
osteoarthritis,50,69,8.94
service delivery,84,116,8.93
promoting health,63,87,8.93
screening tools,47,65,8.92
data integration,94,130,8.92
outcome assessment,52,72,8.91
central sensitization,36,50,8.88
crispr/cas technology,169,235,8.87
crispr method,169,235,8.87
nicotine use,177,246,8.87
nicotine consumption,177,246,8.87
crispr technology,169,235,8.87
crispr technique,169,235,8.87
crispr/cas method,169,235,8.87
crispr-cas-9,169,235,8.87
crispr/cas9,169,235,8.87
individual response,33,46,8.85
center of biomedical research excellence,56,78,8.85
centers of research excellence,56,78,8.85
individualized response,33,46,8.85
cobre,56,78,8.85
rural population,66,92,8.85
community healthcare,40,56,8.81
community organizations,45,63,8.81
trauma exposure,50,70,8.81
exposure to trauma,50,70,8.81
opioid misuse,511,715,8.81
nurse,89,125,8.78
population diversity,163,229,8.78
conceptions,89,125,8.78
nicotine cessation,32,45,8.77
analgesia tests,106,149,8.77
pain measurement,106,149,8.77
pain assessment,106,149,8.77
nociception tests,106,149,8.77
individual variation,93,131,8.76
individual variability,93,131,8.76
individual heterogeneity,93,131,8.76
patient selection,31,44,8.69
new therapy approaches,304,432,8.68
new therapeutic strategies,304,432,8.68
novel therapy approach,304,432,8.68
computer analyses,78,111,8.67
computational analyses,78,111,8.67
post-surgical pain,132,188,8.66
postsurgical pain,132,188,8.66
human old age (65+),33,47,8.66
speed,406,579,8.65
newborns,128,183,8.63
hands on research,30,43,8.6
non-steroidal antiinflammatory drugs,46,66,8.6
hiv-1 test,39,56,8.59
hiv-2 test,39,56,8.59
pathogenicity,64,92,8.58
cas nuclease technology,169,243,8.58
postoperative pain,132,190,8.57
interindividual variation,34,49,8.56
inter-individual variation,34,49,8.56
full genome,86,124,8.55
user centered design,36,52,8.54
bioscience,45,65,8.54
endogenous opioids,101,146,8.53
endogenous opiate,101,146,8.53
post-operative pain,132,191,8.52
cells placenta-tissue,40,58,8.51
patient outcome,243,352,8.51
normal placentoma,40,58,8.51
placenta embryonic tissue,40,58,8.51
imaging in vivo,60,87,8.51
service providers,51,74,8.5
early life stress,42,61,8.49
lead candidate,35,51,8.46
machine learning,279,407,8.45
physical therapy,39,57,8.44
social media,95,139,8.43
pain interference,58,85,8.42
opioid treatment program,62,91,8.4
prenatal care,47,69,8.4
relieves symptoms,81,119,8.39
fewer symptoms,81,119,8.39
alleviate symptom,81,119,8.39
ameliorating symptom,81,119,8.39
symptom reduction,81,119,8.39
decrease symptom,81,119,8.39
reduce symptoms,81,119,8.39
symptom alleviation,81,119,8.39
symptom relief,81,119,8.39
extracellular vesicles,34,50,8.39
minority institution,36,53,8.38
intuition,40,59,8.36
18 years of age,44,65,8.35
eighteen years of age,44,65,8.35
cognitive development,73,108,8.34
underrepresented ethnic minority,100,148,8.33
under-representation of minorities,100,148,8.33
underrepresentation of minorities,100,148,8.33
contractor,77,114,8.33
harm reduction,218,323,8.32
digital,176,261,8.32
harm minimization,218,323,8.32
chronic pain disorder,99,147,8.31
chronic pain condition,99,147,8.31
professional society,31,46,8.31
professional membership,31,46,8.31
professional association,31,46,8.31
pre-clinical efficacy,35,52,8.3
resource allocation,41,61,8.29
technical skills,84,125,8.29
tobacco cessation intervention,51,76,8.28
tobacco cessation treatment,51,76,8.28
ecological momentary assessment,205,307,8.24
patient-centered outcomes,243,364,8.23
patient-focused outcomes,243,364,8.23
data representation,50,75,8.22
syringe exchange services,48,72,8.22
syringe service programs,48,72,8.22
syringe exchange,48,72,8.22
prediction model,157,236,8.2
disease outbreaks,55,83,8.17
mu opioid receptors,322,486,8.17
therapeutic agent development,208,314,8.17
neonatal substance withdrawal,114,172,8.17
outbreaks,55,83,8.17
medication therapy management,53,80,8.17
ethnicity group,90,136,8.16
depression of breathing,199,301,8.15
depressed breathing,199,301,8.15
modernization,160,242,8.15
opiate injection,60,91,8.13
opioid injection,60,91,8.13
opioid injector,60,91,8.13
intravenous opiate,60,91,8.13
intravenous opioid,60,91,8.13
neuroinflammatory,204,311,8.09
executive dysfunction,63,96,8.09
executive function deficit,63,96,8.09
placentome,40,61,8.09
executive impairment,63,96,8.09
clinical development,123,188,8.07
κ opiate,109,167,8.05
kappa opioid,109,167,8.05
κor,109,167,8.05
κ-or,109,167,8.05
kappa opiate,109,167,8.05
κ opioid,109,167,8.05
pain research,99,152,8.03
neuromodulatory,284,437,8.02
predict treatment response,39,60,8.02
pain behavior,67,103,8.02
health insurance plan,39,60,8.02
lenses,76,117,8.01
veterans administration,94,145,8.0
genome editing,48,74,8.0
genomic editing,48,74,8.0
united states department of veterans affairs,94,145,8.0
united states veterans administration,94,145,8.0
drug misuse,59,91,8.0
data base,261,403,7.99
human model,130,201,7.98
digestive tract microbiome,40,62,7.96
intestinal microbiome,40,62,7.96
gastrointestinal microbiome,40,62,7.96
product development,60,93,7.96
gut microbiome,40,62,7.96
training opportunity,130,202,7.94
anti-cancer drug,36,56,7.93
substance misuse,108,168,7.93
motor cortex,54,84,7.93
non-steroidal anti-inflammatory agents,72,112,7.93
predictive modeling,225,351,7.91
pain intensity,100,156,7.91
computer based prediction,225,351,7.91
early experience,89,139,7.9
antiinflammatory,85,133,7.88
vivitrol,236,370,7.87
peripheral nervous system diseases,30,47,7.87
peripheral nerve diseases,30,47,7.87
care facilities,30,47,7.87
pns diseases,30,47,7.87
peripheral neuropathy,30,47,7.87
evaluate cost-effectiveness,30,47,7.87
cost-effectiveness evaluation,30,47,7.87
time study,63,99,7.85
safety testing,56,88,7.85
tobacco regulatory science,54,85,7.84
in vivo evaluation,68,107,7.84
high risk group,173,272,7.84
high risk population,173,272,7.84
in vivo testing,68,107,7.84
predictive biomarkers,47,74,7.83
genomic strategy,47,74,7.83
genomic effort,47,74,7.83
predictive molecular biomarker,47,74,7.83
genomic approach,47,74,7.83
pre-clinical development,57,90,7.81
nonfatal attempt,38,60,7.81
preclinical development,57,90,7.81
geography,221,349,7.81
exclusion,83,131,7.81
neuroimmune,98,155,7.8
text messaging,67,106,7.8
mindfulness-based treatment,36,57,7.79
mindfulness-based approach,36,57,7.79
mindfulness-based training,36,57,7.79
mindfulness-based therapy,36,57,7.79
mindfulness training,36,57,7.79
mindfulness approach,36,57,7.79
mindfulness therapy,36,57,7.79
mindfulness treatment,36,57,7.79
safety study,111,176,7.78
thc use,249,396,7.76
thc co-use,249,396,7.76
health service access,244,388,7.76
accessibility to health services,244,388,7.76
treatment access,244,388,7.76
alaskan native,69,110,7.74
alaskan indian,69,110,7.74
qualitative reasoning,113,180,7.74
alaskan american,69,110,7.74
treatment optimization,54,86,7.74
therapy optimization,54,86,7.74
alaska indian,69,110,7.74
statistical analysis,127,203,7.72
opioid drug abuse,357,571,7.71
opiate drug abuse,357,571,7.71
electronic cigarette user,55,88,7.71
e-cig user,55,88,7.71
ecigarette user,55,88,7.71
ecig user,55,88,7.71
e-cigarette user,55,88,7.71
immunes,236,378,7.7
intervention arm,63,101,7.69
treatment arm,63,101,7.69
hospital readmission,38,61,7.68
immune system and related disorders,33,53,7.68
parent project,33,53,7.68
immunological system dysfunction,33,53,7.68
immune system dysfunction,33,53,7.68
immunological dysfunction,33,53,7.68
immunodeficiency and immunosuppression disorders,33,53,7.68
lens,76,122,7.68
lesson plans,130,209,7.67
education and training,74,119,7.67
clinical decision support,36,58,7.66
arkansas,31,50,7.65
histologic,75,121,7.64
histologically,75,121,7.64
fiber,411,664,7.63
participant recruitment,81,131,7.63
opioid receptor antagonist,131,212,7.62
opioid antagonist,131,212,7.62
opiate receptor antagonist,131,212,7.62
healthcare service organization,34,55,7.62
healthcare organization,34,55,7.62
pain centers,37,60,7.61
pain clinics,37,60,7.61
pain relief units,37,60,7.61
artificial intelligence,53,86,7.6
nsaids,72,117,7.59
cc motif,32,52,7.59
peripheral nerves,51,83,7.58
membrane protein gene,51,83,7.58
ecigarette,202,329,7.57
ecig,202,329,7.57
appalachian,38,62,7.56
substance using,1213,1980,7.56
peripheral nervous system disorders,30,49,7.55
ethnic diversity,85,139,7.54
teacher educator,36,59,7.53
predictive marker,47,77,7.53
faculty training,36,59,7.53
faculty education,36,59,7.53
teacher preparation,36,59,7.53
teacher training,36,59,7.53
teacher education,36,59,7.53
maltreatment,89,146,7.52
opioid withdrawal,256,420,7.52
mistreatment,89,146,7.52
skill acquisition,117,192,7.52
high reward,56,92,7.51
disparity in health,337,554,7.5
drug modulation,31,51,7.5
infant outcome,37,61,7.48
genomic data,71,117,7.48
sex dimorphism,57,94,7.48
musculoskeletal pain,37,61,7.48
sexual dimorphism,57,94,7.48
standardization,283,467,7.47
career track,49,81,7.46
career aspiration,49,81,7.46
career interest,49,81,7.46
career pathway,49,81,7.46
persons,1973,3268,7.45
computing method,84,139,7.45
neurobehavioral symptom,35,58,7.44
treatment resistance,67,111,7.44
youth alcohol co-use,80,133,7.42
youth alcohol use,80,133,7.42
adolescent alcohol intake,80,133,7.42
adolescent alcohol drinking,80,133,7.42
adolescent alcohol co-use,80,133,7.42
care services,95,158,7.42
drinking in adolescent,80,133,7.42
tumor microenvironment,39,65,7.4
cancer microenvironment,39,65,7.4
longitudinal cohort study,42,70,7.4
long-term cohort study,42,70,7.4
novel marker,39,65,7.4
new marker,39,65,7.4
epigenomics,122,204,7.38
longterm depression,46,77,7.37
longterm synaptic depression,46,77,7.37
bigdata,81,136,7.35
imaging approach,53,89,7.34
cell-extracellular matrix,50,84,7.34
ecm,50,84,7.34
digital learning,35,59,7.32
electronic learning,35,59,7.32
type two diabetes,35,59,7.32
hiv 1 associated neurocognitive disorder,67,113,7.31
hiv-1 associated neurocognitive disorder,67,113,7.31
effectiveness implementation study,32,54,7.31
hiv-associated neurocognitive disorder,67,113,7.31
effectiveness implementation hybrid,32,54,7.31
neurological degeneration,110,186,7.29
cyclic somatostatin,55,93,7.29
somatostatin-14,55,93,7.29
somatotropin release-inhibiting hormone,55,93,7.29
growth hormone release inhibiting factor,55,93,7.29
growth hormone inhibiting factors,55,93,7.29
somatotropin release inhibiting factors,55,93,7.29
growth hormone-inhibiting hormone,55,93,7.29
srih,55,93,7.29
srih-14,55,93,7.29
neonatal abstinence syndrome,114,193,7.28
privatization,114,193,7.28
neonatal withdrawal syndrome,114,193,7.28
individualized therapy,99,168,7.27
tailored therapy,99,168,7.27
connectome,53,90,7.26
anti-depressants,83,141,7.26
anti-depressant drugs,83,141,7.26
anti-depressive agents,83,141,7.26
anti-depressant agent,83,141,7.26
negative valence,40,68,7.25
atlases,74,126,7.24
health workforce,296,505,7.23
alzheimer's disease dementia,61,104,7.23
rnaseq,411,703,7.21
rna sequencing,411,703,7.21
rna seq,411,703,7.21
genetic approach,213,365,7.2
anatomic structures,414,711,7.18
anatomic sites,414,713,7.16
kappa opioid receptors,109,188,7.15
head ache,41,71,7.12
care delivery,72,125,7.1
big data,81,141,7.09
social isolation,77,134,7.09
individuals with disabilities,43,75,7.07
sensory input,43,75,7.07
disabled individual,43,75,7.07
implementation trial,52,91,7.05
low birth weight,36,63,7.05
low birth weight infant,36,63,7.05
low birthweight,36,63,7.05
physiological imaging,56,98,7.05
model of animal,999,1750,7.04
astrocytic glia,190,333,7.04
precision interventions,33,58,7.02
methadone maintenance therapy,71,125,7.01
methadone maintenance program,71,125,7.01
methadone treatment,71,125,7.01
methadone maintenance treatment,71,125,7.01
actigraphy,38,67,7.0
nociceptors,97,171,7.0
opiate pain reliever,226,399,6.99
opioid painkiller,226,399,6.99
opioid anesthetic,226,399,6.99
opioid pain reliever,226,399,6.99
negative affectivity,365,645,6.98
negative affect,365,645,6.98
prescribed opioid,540,955,6.97
prescribed opiate,540,955,6.97
social stigma,315,557,6.97
opioid medication,540,955,6.97
opiate medication,540,955,6.97
stigma,315,557,6.97
licit opioid,540,955,6.97
alcoholic liver injury,48,85,6.96
formative evaluation,31,55,6.95
formative assessment,31,55,6.95
summer research,40,71,6.95
individual patient,62,110,6.95
therapeutic resistance,67,119,6.94
caregiving,77,137,6.93
care giving,77,137,6.93
computer analysis,78,139,6.92
computational analysis,78,139,6.92
fetal development,32,57,6.92
person centered,42,75,6.91
machine learned,88,157,6.91
opiates,2130,3801,6.91
cooperative learning,33,59,6.9
longitudinal cohort,34,61,6.87
longterm cohort,34,61,6.87
overdose,811,1457,6.87
long-term cohort,34,61,6.87
positive valence,40,72,6.85
k12,35,63,6.85
fmri scan,35,63,6.85
functional mri scan,35,63,6.85
patient recruitments,81,146,6.84
δ(1)-tetrahydrocannabinol,82,148,6.83
δ(9)-thc,82,148,6.83
δ-9-tetrahydrocannabinol,82,148,6.83
δ(9)-tetrahydrocannabinol,82,148,6.83
teacher professional development,36,65,6.83
δ(1)-thc,82,148,6.83
δ9-tetrahydrocannabinol,82,148,6.83
encapsulated,36,65,6.83
care outcomes,58,105,6.81
temporal measurement,95,172,6.81
temporal resolution,95,172,6.81
time measurement,95,172,6.81
memory processing,53,96,6.81
healthcare outcomes,58,105,6.81
health care outcomes,58,105,6.81
transcriptome sequencing,411,744,6.81
treatment services,143,259,6.81
beneficiary,38,69,6.79
emergency medical care,44,80,6.78
prescription monitoring program,33,60,6.78
prescription drug monitoring program,33,60,6.78
er care,44,80,6.78
emergency department care,44,80,6.78
emergency room care,44,80,6.78
emergency health care,44,80,6.78
ed care,44,80,6.78
hazard,88,160,6.78
emergency healthcare,44,80,6.78
opioid agonist treatment,63,115,6.76
opioid agonist therapy,63,115,6.76
pain disorder,46,84,6.75
strategic planning,299,546,6.75
community based participatory research,88,161,6.74
non-medical prescription drug use,36,66,6.73
technical expertise,84,154,6.73
prescription medication misuse,36,66,6.73
nonmedical prescription drug use,36,66,6.73
opioid habituation,56,103,6.71
personalization of treatment,167,307,6.71
reward anticipation,37,68,6.71
immunoblotting,113,208,6.7
2-photon,126,232,6.7
autistic spectrum disorder,139,256,6.7
β-arrestin,64,118,6.69
statistical data analysis,127,234,6.69
statistical data interpretation,127,234,6.69
preventable death,106,196,6.67
patient with chronic pain,120,222,6.67
preventable mortality,106,196,6.67
electronic cigarette use,126,233,6.67
postpartum women,33,61,6.67
chronic pain patient,120,222,6.67
ecigarette use,126,233,6.67
e-cigarette use,126,233,6.67
e-cig use,126,233,6.67
ecig use,126,233,6.67
data interpretation,471,874,6.65
reproducibility,200,371,6.65
synergism,158,293,6.65
pain control,785,1456,6.65
pain therapy,785,1456,6.65
pain management,785,1456,6.65
novel druggable target,443,823,6.64
ages,836,1552,6.64
new druggable target,443,823,6.64
extracellular matrix,50,93,6.63
transcriptional differences,127,237,6.61
differentially expressed,127,237,6.61
differential expression,127,237,6.61
post-operative,99,185,6.6
painful symptom,53,99,6.6
pain symptom,53,99,6.6
postoperative period,99,185,6.6
κ opioid receptors,109,204,6.59
mobile application,80,150,6.58
mobile app,80,150,6.58
secondary analysis,96,180,6.58
epidemiology study,106,199,6.57
noncoding,73,137,6.57
postoperative,99,186,6.56
trust,109,205,6.56
psychoeducation,33,62,6.56
investigational drugs,100,188,6.56
in utero exposure,103,194,6.55
training module,111,209,6.55
fetal exposure,103,194,6.55
intra-uterine environmental exposure,103,194,6.55
intrauterine environmental exposure,103,194,6.55
small molecule inhibitor,81,153,6.53
ethanol-induced liver dysfunction,48,91,6.51
ethanol-mediated liver dysfunction,48,91,6.51
ethanol-induced liver disease,48,91,6.51
ethanol-induced hepatic dysfunction,48,91,6.51
ethanol-mediated liver injury,48,91,6.51
appalachia,38,72,6.51
ethanol induced liver injury,48,91,6.51
alcohol-induced liver disease,48,91,6.51
alcohol-mediated liver injury,48,91,6.51
alcohol-induced liver dysfunction,48,91,6.51
alcoholic liver diseases,48,91,6.51
alcohol induced hepatic injury,48,91,6.51
alcohol induced liver disorder,48,91,6.51
stress and coping,48,91,6.51
appalachian region,38,72,6.51
alcohol induced liver injury,48,91,6.51
alcohol-induced hepatic dysfunction,48,91,6.51
ethanol induced hepatic injury,48,91,6.51
ethanol induced liver disorder,48,91,6.51
alcohol-mediated liver dysfunction,48,91,6.51
etoh abuse,383,728,6.49
alcohol co-abuse,383,728,6.49
opiate agonist,209,398,6.48
opiate receptor agonist,209,398,6.48
opioid agonist,209,398,6.48
opioid receptor agonist,209,398,6.48
nicotine dependent,419,798,6.48
translational impact,42,80,6.48
emergency room visit,128,244,6.47
education research,74,141,6.47
ed visit,128,244,6.47
er visit,128,244,6.47
emergency care visit,128,244,6.47
emergency department visit,128,244,6.47
reduced substance use,109,208,6.46
murine model,598,1142,6.46
tobacco user,68,130,6.45
substance use among youth,81,155,6.45
preclinical efficacy,35,67,6.44
antianxiety drugs,62,119,6.43
therapeutic candidate,37,71,6.43
usability,176,338,6.42
antibiotic drugs,50,96,6.42
miscellaneous antibiotic,50,96,6.42
antibiotic agents,50,96,6.42
emotional dysregulation,39,75,6.41
transcranial magnetic stimulation,91,175,6.41
parvalbumins,65,125,6.41
drug modelings,92,177,6.41
emotion dysregulation,39,75,6.41
outpatient treatment,65,125,6.41
needs assessment,46,89,6.37
biotech,31,60,6.37
preservation,80,155,6.37
memory consolidation,31,60,6.37
brain dysfunction,50,97,6.36
doctoral student,33,64,6.36
pharmacological study,83,161,6.36
personalized intervention,33,64,6.36
pharmacology study,83,161,6.36
dysfunctional brain,50,97,6.36
hepatic disease,85,165,6.35
persistent pain,88,171,6.35
gene expression assay,93,181,6.34
autism spectrum disorder,139,271,6.33
smoking abstinence,78,152,6.33
perivascular glial cell,197,384,6.33
hortega cell,197,384,6.33
microgliocyte,197,384,6.33
microglial cell,197,384,6.33
mesoglia,197,384,6.33
gitter cell,197,384,6.33
potential biological marker,40,78,6.32
midbrain central gray substance,60,117,6.32
microbiome,40,78,6.32
investigational new drugs,100,195,6.32
potential biomarker,40,78,6.32
calcium indicator,85,166,6.32
exposure to nicotine,112,219,6.31
nicotine exposure,112,219,6.31
e-mail,89,175,6.27
biopsychosocial,89,175,6.27
email,89,175,6.27
statistical data analyses,127,250,6.27
electronic mail,89,175,6.27
quantitative rtpcr,35,69,6.26
quantitative reverse transcriptase pcr,35,69,6.26
work group,34,67,6.26
qrtpcr,35,69,6.26
weaning,39,77,6.25
microglia,197,389,6.25
data resource,43,85,6.24
antibiotics,50,99,6.23
metastatic lesion,70,139,6.21
metastatic mass,70,139,6.21
marijuana use disorder,95,189,6.2
cannabis use disorder,95,189,6.2
neuromodulation,284,565,6.2
chip-seq,87,173,6.2
chromatin immunoprecipitation-sequencing,87,173,6.2
nicotine seeking,36,72,6.17
psychedelics,47,94,6.17
psychedelic drug,47,94,6.17
psychedelic agents,47,94,6.17
hallucinogenic substances,47,94,6.17
hallucinogenic drugs,47,94,6.17
reduction in tobacco use,40,80,6.17
hallucinogenic agents,47,94,6.17
monocyte-derived tnf,73,146,6.17
macrophage-derived tnf,73,146,6.17
tobacco use reduction,40,80,6.17
psychotomimetic agents,47,94,6.17
memory dysfunction,70,140,6.17
somatostatin,55,110,6.17
opioid pain medication,226,452,6.17
placenta,40,80,6.17
opiate pain medication,226,452,6.17
traumatic event,51,102,6.17
nicotine seeking behavior,36,72,6.17
prescription opiate,540,1083,6.15
abused drug,550,1103,6.15
drug abused,550,1103,6.15
cigarette use,250,503,6.13
targeted therapeutic agents,386,778,6.12
scale up,210,423,6.12
targeted therapeutic,386,778,6.12
targeted drug treatments,386,778,6.12
targeted drug therapy,386,778,6.12
sleep disturbances,144,290,6.12
dogs mammals,69,139,6.12
novel drug treatments,686,1384,6.11
neuroinflammation,204,412,6.11
new drug treatments,686,1384,6.11
new drugs,686,1384,6.11
new therapy,686,1384,6.11
smoking dependence,51,103,6.11
smoking dependent,51,103,6.11
novel drugs,686,1384,6.11
novel therapy,686,1384,6.11
neural control,284,575,6.09
neural regulation,284,575,6.09
preterm birth,36,73,6.08
affinity purification,35,71,6.08
premature childbirth,36,73,6.08
premature birth,36,73,6.08
premature delivery,36,73,6.08
preterm delivery,36,73,6.08
dangerousness,90,183,6.07
symptomatic treatment,32,65,6.07
financial assistance,33,67,6.07
symptom treatment,32,65,6.07
molecular biomarker,32,65,6.07
treat symptom,32,65,6.07
smoking cessation treatment,156,318,6.05
anti-retroviral treatment,112,229,6.03
personalized therapy,167,342,6.02
personalized treatment,167,342,6.02
personalized medicine,167,342,6.02
phase i protocol,75,154,6.01
phase i clinical trials,75,154,6.01
proliferating,90,185,6.0
epidemiologic data,53,109,6.0
opioid therapy,102,210,5.99
opiate therapy,102,210,5.99
μ opioid receptors,322,663,5.99
career path,49,101,5.98
shared decision making,32,66,5.98
anxiety-like behavior,144,297,5.98
acute pain,227,469,5.97
annulus of the aqueduct,60,124,5.97
periaqueductal gray,60,124,5.97
midbrain central gray,60,124,5.97
mesencephalic central gray,60,124,5.97
hiv-hcv,83,172,5.95
ips,84,174,5.95
hiv and hepatitis c,83,172,5.95
induced pluripotent stem cell,84,174,5.95
hiv and hcv,83,172,5.95
exposed to ethanol,410,851,5.94
drug prescriptions,174,361,5.94
exposure to ethanol,410,851,5.94
c. elegans,40,83,5.94
tissue-specific gene expression,38,79,5.93
observation study,75,156,5.93
behavioral economics,113,235,5.93
tissue-specific differential gene expression,38,79,5.93
observational research,75,156,5.93
model-based simulation,51,106,5.93
mechanics,166,345,5.93
models and simulation,51,106,5.93
observation research,75,156,5.93
differential gene expression,38,79,5.93
metabonomics,62,129,5.93
assay development,38,79,5.93
knockin,48,100,5.92
waiver,48,100,5.92
minority-serving institution,36,75,5.92
personal care,34,71,5.91
bone,34,71,5.91
ecb signaling,55,115,5.9
preventative strategy,225,470,5.9
endocannabinoid signaling,55,115,5.9
nonmedical use of prescription opiates,105,220,5.89
opioid medication misuse,105,220,5.89
opioid analgesic misuse,105,220,5.89
nonmedical use of prescription opioids,105,220,5.89
non-medical use of prescription opioids,105,220,5.89
non-medical use of prescription opiates,105,220,5.89
opioid prescription medication misuse,105,220,5.89
neurodevelopment,200,419,5.89
anesthesia procedures,64,134,5.89
postpartum period,75,157,5.89
prescription opiate misuse,105,220,5.89
neural development,200,419,5.89
knockdown,292,611,5.89
cephalodynia,41,86,5.88
immune regulation,31,65,5.88
immunomodulatory,31,65,5.88
immunoregulatory,31,65,5.88
head pain,41,86,5.88
cranial pain,41,86,5.88
immunological response,91,191,5.88
cephalgia,41,86,5.88
mechanical allodynia,31,65,5.88
cephalalgia,41,86,5.88
bio-markers,501,1051,5.88
mechanical,166,349,5.87
life expectancy,87,183,5.86
tobacco dependent,160,337,5.86
resistance to therapy,67,141,5.86
resistant to therapy,67,141,5.86
therapy resistant,67,141,5.86
drug adherence,101,213,5.85
drug compliance,101,213,5.85
cell body,1629,3437,5.85
improved outcome,264,558,5.84
basal transcription factor genes,223,471,5.84
opioid maintenance therapy,36,76,5.84
opioid substitution therapy,36,76,5.84
opiate substitution therapy,36,76,5.84
opioid maintenance treatment,36,76,5.84
opiate replacement therapy,36,76,5.84
opioid replacement therapy,36,76,5.84
opioid replacement treatment,36,76,5.84
opioid substitution treatment,36,76,5.84
opiate substitution treatment,36,76,5.84
designer receptors exclusively activated by designer drugs,237,501,5.83
canis familiaris,69,146,5.83
dreadds,237,501,5.83
canine species,69,146,5.83
domestic dog,69,146,5.83
canine,69,146,5.83
smoking addiction,51,108,5.82
smoke addiction,51,108,5.82
cost analysis,74,157,5.81
dna injury,38,81,5.79
sensor,247,527,5.78
antidepressant effect,30,64,5.78
statistical linear mixed models,74,158,5.78
new pharmacotherapy target,443,946,5.78
probability models,74,158,5.78
novel pharmacotherapy target,443,946,5.78
novel therapy target,443,946,5.78
statistical linear models,74,158,5.78
novel drug target,443,946,5.78
new drug target,443,946,5.78
new therapy target,443,946,5.78
anti-depressant effect,30,64,5.78
basal transcription factor,223,477,5.77
general transcription factors,223,477,5.77
sodium chloride,43,92,5.76
heroin use,99,212,5.76
salt,43,92,5.76
heroin intake,99,212,5.76
tnf alpha,73,157,5.73
whole genome,86,185,5.73
pathologic,337,725,5.73
entire genome,86,185,5.73
secondary school student,66,142,5.73
secondary student,66,142,5.73
tnfa,73,157,5.73
proteome,73,157,5.73
national institute of neurological disorders and stroke,65,140,5.73
biosensor,99,214,5.71
tnf-α,73,158,5.7
tnfα,73,158,5.7
titrations,37,80,5.7
symposia,317,687,5.69
legalized marijuana,54,117,5.69
back ache,30,65,5.69
cirrhotic,48,104,5.69
il1-β,36,78,5.69
incentive salience,84,182,5.69
summit,317,687,5.69
il-1β,36,78,5.69
marijuana legalization,54,117,5.69
backache,30,65,5.69
back pain,30,65,5.69
data analytics,78,169,5.69
convention,317,687,5.69
alcohol risk,149,323,5.69
il-1 β,36,78,5.69
legalized cannabis,54,117,5.69
cannabis legalization,54,117,5.69
legal marijuana,54,117,5.69
interleukin-1β,36,78,5.69
targeted therapy,386,838,5.68
opioid drug user,99,215,5.68
opiate user,99,215,5.68
ablation,134,291,5.68
targeted treatment,386,838,5.68
opioid user,99,215,5.68
dsm-5,75,163,5.67
dsm5,75,163,5.67
cannabinoid receptor type 2,51,111,5.67
healthcare settings,101,220,5.66
translation strategy,61,133,5.66
translational strategy,61,133,5.66
health care settings,101,220,5.66
university medical centers,71,155,5.65
academic medical centers,71,155,5.65
short interfering rna,60,131,5.65
dna damage,38,83,5.65
evidence based intervention,236,515,5.65
repetitive transcranial magnetic stimulation,33,72,5.65
hybrids,202,442,5.64
medication-assisted treatment,146,320,5.63
business-friendly environment,31,68,5.62
collaborative environment,31,68,5.62
emotional regulation,103,226,5.62
interactive environment,31,68,5.62
peer-group environment,31,68,5.62
interdisciplinary environment,31,68,5.62
resilience,228,500,5.62
anti-inflammatories,120,264,5.61
immune suppression,30,66,5.61
undergraduate student,126,277,5.61
anxious symptom,60,132,5.61
general transcription factor gene,223,491,5.6
transcription factor proto-oncogene,223,491,5.6
electrostimulation,71,157,5.58
ventilatory depression,199,440,5.58
frequencies,516,1140,5.58
respiratory depression,199,440,5.58
neuropsychiatric disorder,287,636,5.57
spinal ganglia,88,195,5.57
neuropsychiatric disease,287,636,5.57
drug prescribing,174,387,5.55
il1β,36,80,5.55
excretory function,47,105,5.52
societal costs,64,143,5.52
beta-arrestin,64,143,5.52
incubated,59,132,5.51
anatomy,414,927,5.51
opiate analgesia,226,507,5.5
ion channel gating,45,101,5.5
anti-inflammatory agents,120,269,5.5
transcription factor genes,223,500,5.5
opioid analgesia,226,507,5.5
opiate analgesic,226,507,5.5
mhealth,130,292,5.49
low socioeconomic position,77,173,5.49
low socio-economic status,77,173,5.49
low socio-economic position,77,173,5.49
mobile health,130,292,5.49
care seeking,49,110,5.49
m-health,130,292,5.49
nerve cell loss,36,81,5.48
neuron cell loss,36,81,5.48
neuron death,36,81,5.48
oncology cancer,40,90,5.48
psychiatric symptom,52,117,5.48
neuronal cell loss,36,81,5.48
nerve cell death,36,81,5.48
electrophysiological,836,1880,5.48
neuronal death,36,81,5.48
neuronal circuit,148,334,5.47
alcohol co-morbidity,51,115,5.47
reproductive,83,187,5.47
environmental exposure,106,239,5.47
community outreach,39,88,5.47
alcohol comorbidity,51,115,5.47
predictive factor,47,106,5.47
excretion,47,106,5.47
chronic low back pain,55,124,5.47
mobile device,54,122,5.46
handheld mobile device,54,122,5.46
interruption,101,228,5.46
image-based method,73,165,5.46
privacy,46,104,5.46
talents,76,172,5.45
major depression disorder,131,297,5.44
alcohol consequences,94,213,5.44
virtual,272,617,5.44
therapeutic response,215,488,5.43
response to treatment,215,488,5.43
alcohol prevention,40,91,5.42
capital,43,98,5.41
monetary incentive,50,114,5.41
parent grant,90,205,5.41
anesthesia,64,146,5.41
financial reward,50,114,5.41
spottings,32,73,5.41
pbmc,42,96,5.4
care givers,123,281,5.4
peripheral blood mononuclear cell,42,96,5.4
resistance mechanism,46,105,5.4
support tools,49,112,5.4
serious adverse event,35,80,5.4
dorsal root ganglia,88,201,5.4
hiv antibody positive,42,96,5.4
dorsal root ganglion,88,201,5.4
resistant mechanism,46,105,5.4
cost analyses,74,169,5.4
pregnant,132,302,5.39
caregivers,123,282,5.38
migraine headache,37,85,5.37
chronic neuropathic pain,54,124,5.37
health care service use,90,207,5.36
healthcare service use,90,207,5.36
young woman,30,69,5.36
outcome prediction,58,134,5.34
stressful event,65,150,5.34
support network,38,88,5.33
neuropathic pain,202,468,5.32
disease of the lung,41,95,5.32
painful neuropathy,202,468,5.32
disorder of the lung,41,95,5.32
daytrana,31,72,5.31
managed care,34,79,5.31
neuropathic,99,230,5.31
opiate addiction,1157,2687,5.31
opiate dependence,1157,2687,5.31
concerta,31,72,5.31
metadate,31,72,5.31
cognitive performance,56,130,5.31
neuronal injury,34,79,5.31
neuron injury,34,79,5.31
e-cigarette,202,470,5.3
e-cig,202,470,5.3
electronic cigarette,202,470,5.3
pain patient,54,126,5.29
preinterleukin 1 beta,36,84,5.29
interleukin-1 beta,36,84,5.29
beta proprotein interleukin 1,36,84,5.29
interleukin 1beta,36,84,5.29
il-1 beta,36,84,5.29
il-1-b,36,84,5.29
health insurance for aged and disabled,45,105,5.29
health insurance for disabled title 18,45,105,5.29
il1-beta,36,84,5.29
medicare,45,105,5.29
il1b protein,36,84,5.29
health insurance for disabled,45,105,5.29
il1f2,36,84,5.29
neuranatomies,79,185,5.27
positive allosteric modulator,44,103,5.27
epigenome,85,199,5.27
neuroanatomies,79,185,5.27
neuranatomy,79,185,5.27
e-learning,35,82,5.26
web-based training,35,82,5.26
technology-enhanced learning,35,82,5.26
virtual learning,35,82,5.26
computer-based instruction,35,82,5.26
online learning,35,82,5.26
online education,35,82,5.26
multimedia learning,35,82,5.26
internet-based training,35,82,5.26
computer-based training,35,82,5.26
computer-based learning,35,82,5.26
digital education,35,82,5.26
elearning,35,82,5.26
cognitive process,104,244,5.26
authorization,60,141,5.25
permission,60,141,5.25
authorization documentation,60,141,5.25
neuropathy,99,233,5.24
cocaine dependence,235,554,5.23
physical function,39,92,5.23
novel therapeutic intervention,304,718,5.22
novel therapeutic approach,304,718,5.22
attentional control,33,78,5.22
smart phone,163,385,5.22
iphone,163,385,5.22
smartphone,163,385,5.22
new therapeutic intervention,304,718,5.22
new therapeutic approach,304,718,5.22
meth effect,55,130,5.22
methamphetamine effect,55,130,5.22
b cell,30,71,5.21
spatiotemporal,126,298,5.21
headache,41,97,5.21
b cells,30,71,5.21
cannabidiol,49,116,5.21
routine care,30,71,5.21
prenatal,189,448,5.2
unborn,189,448,5.2
training achievement,53,126,5.19
educational level,53,126,5.19
educational status,53,126,5.19
tribes,48,114,5.19
cannabis use,249,592,5.19
training status,53,126,5.19
educational achievement,53,126,5.19
nociceptive,219,521,5.18
nociception,219,521,5.18
anti-retroviral therapy,112,267,5.17
psychiatric illness,801,1912,5.17
gwa study,227,541,5.17
g protein-coupled receptor genes,249,595,5.16
prescription misuse,36,86,5.16
computerized tools,54,129,5.16
computational tools,54,129,5.16
gpcr,249,595,5.16
assessment instrument,36,86,5.16
assessment tool,36,86,5.16
gene expression pattern,142,340,5.15
certification,43,103,5.15
recommendation,397,951,5.15
prenatally exposed,103,247,5.14
ethanol during adolescence,80,192,5.14
prenatal exposure,103,247,5.14
clinical care,207,497,5.14
anesthestic drugs,55,132,5.14
perinatal,83,199,5.14
relapse risk,188,451,5.14
fibrosis,30,72,5.14
alcohol use in adolescents,80,192,5.14
alcohol use in adolescence,80,192,5.14
painful,1259,3019,5.14
anesthetic drugs,55,132,5.14
scientific advances and accomplishments,93,223,5.14
anesthetic agents,55,132,5.14
rural community,85,204,5.14
scientific accomplishments,93,223,5.14
scientific advances,93,223,5.14
chip sequencing,87,209,5.13
health communication,37,89,5.13
population heterogeneity,163,392,5.13
cognitive testing,59,142,5.12
standard of care,179,431,5.12
electronic health record,213,513,5.12
cognitive assessment,59,142,5.12
early-stage clinical trials,75,181,5.11
phase 1 clinical trials,75,181,5.11
cell type,795,1924,5.1
devices,329,796,5.1
cocaine relapse,76,184,5.09
kinase family gene,33,80,5.09
sleep monitoring,33,80,5.09
primary care provider,90,218,5.09
relapse against cocaine,76,184,5.09
career choice,49,119,5.08
pregnant women,222,539,5.08
neuroaids,51,124,5.07
non steroidal antiinflammatory agents,46,112,5.07
hcv/hiv,83,202,5.07
biopsy,37,90,5.07
nonsteroidal antiinflammatory agents,46,112,5.07
syringe-exchange programs,48,117,5.06
two-photon,126,307,5.06
needle exchange,48,117,5.06
modifiable risk,55,134,5.06
needle-exchange programs,48,117,5.06
length of stay,77,188,5.05
number of days in hospital,77,188,5.05
hospital days,77,188,5.05
hospital stay,77,188,5.05
rdoc,45,110,5.05
title 18,90,220,5.05
data warehouse,36,88,5.05
transportation,69,169,5.04
habenula,126,309,5.03
homolog of drosophila toll,31,76,5.03
toll homologue,31,76,5.03
γ-aminobutyric acid,286,703,5.02
neuroplastic,237,582,5.02
health service utilization,41,101,5.01
enzyme gene,315,775,5.01
health service use,41,101,5.01
anxiety symptoms,60,148,5.0
hallucinogens,47,116,5.0
medicaid,134,331,4.99
virtual reality,50,124,4.97
qualitative research,99,246,4.96
memory retrieval,39,97,4.96
inflammatory pain,76,189,4.96
mentorship,646,1605,4.96
ko mice,242,603,4.95
professional positions,59,147,4.95
study population,36,90,4.93
socioeconomically,250,625,4.93
opioid tolerance,56,140,4.93
ecb system,62,155,4.93
neuro-imaging,508,1272,4.93
alabama,30,75,4.93
fracture,32,80,4.93
bone fracture,32,80,4.93
signaling factor proto-oncogene,97,243,4.92
individualized patient treatment,99,248,4.92
biomedical engineering,37,93,4.91
investigational new drug application,53,133,4.91
bioengineering,37,93,4.91
neurocognitive impairment,64,161,4.9
neurocognitive decline,64,161,4.9
emergency care,44,111,4.89
vulnerable group,327,824,4.89
stress reactivity,61,154,4.89
care access,244,615,4.89
substance use disorder,1514,3816,4.89
signaling pathway gene,97,245,4.88
dissociation,105,266,4.87
national institutes of health,1355,3435,4.87
nih,1355,3435,4.87
united states national institutes of health,1355,3435,4.87
drug discovery,234,594,4.86
inflammatory,326,827,4.86
small business technology transfer research,41,104,4.86
sttr,41,104,4.86
west virginia,37,94,4.85
nonsteroidal anti-inflammatory drugs,46,117,4.85
sleep polysomnography,33,84,4.85
interventional trial,57,145,4.85
nonsteroidal anti-inflammatory agents,46,117,4.85
ifn,33,84,4.85
advanced development,59,150,4.85
somnography,33,84,4.85
walking,48,122,4.85
sleep measurement,33,84,4.85
polysomnographic,33,84,4.85
nonsteroidal antiinflammatory drug,46,117,4.85
tobacco smoking behavior,69,176,4.84
training level,53,135,4.84
visualization,149,380,4.84
deep brain stimulation,56,143,4.83
research domain criteria,45,115,4.83
pwid,90,230,4.83
people who inject drugs,90,230,4.83
people who inject illicit drugs,90,230,4.83
persons who inject drugs,90,230,4.83
cannabinoid receptor type 1,116,296,4.83
improve access,120,307,4.82
transcriptome,274,701,4.82
polymers,39,100,4.81
behavioral response,297,761,4.81
behavior response,297,761,4.81
bypass,64,164,4.81
opioid addiction,1157,2970,4.8
opioid dependence,1157,2970,4.8
pain,1259,3242,4.79
experiential learning,33,85,4.79
alcohol intervention,98,253,4.78
low back ache,43,111,4.78
low back pain,43,111,4.78
lumbago,43,111,4.78
low backache,43,111,4.78
rural area,138,356,4.78
molecular profile,102,264,4.77
cnr2 gene,51,132,4.77
cannabinoid receptor cb2,51,132,4.77
cnr2,51,132,4.77
missouri,48,124,4.77
cb2r,51,132,4.77
cannabinoid receptor 2,51,132,4.77
anti-inflammatory,120,311,4.76
explosion,32,83,4.76
biophysical sciences,59,153,4.76
biophysical principles,59,153,4.76
biophysical foundation,59,153,4.76
rod-opsin,54,140,4.76
opsin,54,140,4.76
dogs,69,179,4.75
waiting lists,52,135,4.75
drug treatment,685,1777,4.75
ethnic minority,126,328,4.74
receptor bound,53,138,4.74
pediatric hospitals,46,120,4.73
genetically engineered,33,86,4.73
protocol screening,108,282,4.72
eligibility determination,108,282,4.72
eligibility,108,282,4.72
behavioral outcome,126,330,4.71
behavior outcome,126,330,4.71
advisory team,115,301,4.71
biometrics,219,574,4.71
biometry,219,574,4.71
biostatistics,219,574,4.71
health system,258,675,4.71
institutional review boards,91,239,4.7
irbs,91,239,4.7
phosphotransferase gene,136,357,4.7
neurological development disorder,38,100,4.69
prescription opioid,540,1421,4.69
neurodevelopmental disorder,38,100,4.69
under-represented minority,100,263,4.69
sodium ion channels,30,79,4.68
us state,30,79,4.68
guanosine cyclic monophosphate,44,116,4.68
cgmp,44,116,4.68
vulnerable populations,327,864,4.67
commercialization,111,293,4.67
oxycodone sr,185,490,4.66
dihydrohydroxycodeinone,185,490,4.66
calibration,45,119,4.66
tumor necrosis factor-alpha,73,193,4.66
oxycodeinon,185,490,4.66
oxycodone,185,490,4.66
oxycontin,185,490,4.66
roxicodone,185,490,4.66
cachectin,73,193,4.66
health care organization,34,90,4.66
chronic pain,701,1854,4.66
hyperalgia,138,366,4.65
validation studies,52,138,4.65
hyperalgesic sensations,138,366,4.65
transcript expression analysis,93,247,4.64
transcript expression analyses,93,247,4.64
gene expression pattern analysis,93,247,4.64
gene expression monitoring,93,247,4.64
health care technology,64,170,4.64
health technology,64,170,4.64
phenotypic data,41,109,4.64
inflammatory marker,52,139,4.61
gestation,270,722,4.61
qualitative methods,113,302,4.61
long-term depression,46,123,4.61
inflammation marker,52,139,4.61
advocacy,52,139,4.61
repression,59,158,4.61
computational methods,84,225,4.6
data reporting,50,134,4.6
periaqueductal gray matter,60,161,4.6
computer methods,84,225,4.6
methamphetamine use,120,322,4.6
meth use,120,322,4.6
computing methodologies,84,225,4.6
computational methodology,84,225,4.6
hepatic damage,38,102,4.59
liver damage,38,102,4.59
hepatic injury,38,102,4.59
liver injury,38,102,4.59
ultrasound,38,102,4.59
human imaging,30,81,4.57
pain medication,560,1512,4.57
painkiller,560,1512,4.57
pain killer,560,1512,4.57
pain reliever,560,1512,4.57
open source,40,108,4.57
inflammatory mediator,44,119,4.56
xeno-transplantation,54,146,4.56
xeno-transplant,54,146,4.56
automobile driving,519,1403,4.56
driving,519,1403,4.56
quinine,31,84,4.55
tnf gene,73,198,4.55
tnf a,73,198,4.55
tnf,73,198,4.55
beds,39,106,4.54
sensory neurons,107,291,4.53
afferent neurons,107,291,4.53
neuroregulation,284,774,4.53
punishment,148,403,4.53
nichd,40,109,4.53
national institute of child health and human development,40,109,4.53
inflammation mediators,44,120,4.52
pre-clinical model,275,751,4.52
tumor necrosis factor,73,199,4.52
axonal signaling,377,1029,4.52
preclinical models,275,751,4.52
glial signaling,377,1029,4.52
axon-glial signaling,377,1029,4.52
heterogeneous population,163,445,4.52
axon signaling,377,1029,4.52
neural signaling,377,1029,4.52
neuronal signaling,377,1029,4.52
associative conditioning,134,366,4.52
diverse populations,163,445,4.52
therapeutic development,208,567,4.52
clinical decision-making,44,120,4.52
adverse experience,207,565,4.52
glia signaling,377,1029,4.52
adverse event,207,565,4.52
nerve signaling,377,1029,4.52
prescription opioid misuse,105,287,4.51
prediction of response,34,93,4.51
enterobacteria phage p1 cre recombinase,64,175,4.51
alcohol related consequences,38,104,4.51
multilevel modeling,71,194,4.51
multilevel model,71,194,4.51
multilevel analysis,71,194,4.51
methods to study multiple-level influences,71,194,4.51
hepatic disorder,85,233,4.5
high school student,66,181,4.5
liver diseases,85,233,4.5
hepatopathy,85,233,4.5
residential site,31,85,4.5
symptomatology,47,129,4.49
cost-effective analysis,55,151,4.49
emergency medicine,36,99,4.48
association learning,89,245,4.48
arthritic,32,88,4.48
in vivo imaging,60,165,4.48
optogenetics,669,1841,4.48
mathematic model,49,135,4.48
access to treatment,244,673,4.47
access to services,244,673,4.47
access to health services,244,673,4.47
health services accessibility,244,673,4.47
dsm-v,75,207,4.47
5th edition,75,207,4.47
diagnostic and statistical manual of mental disorders-v,75,207,4.47
availability of services,244,673,4.47
non-hispanic,66,182,4.47
cyclicity,125,345,4.47
health services availability,244,673,4.47
rhythmicity,125,345,4.47
periodicity,125,345,4.47
not hispanic or latino,66,182,4.47
transplant,42,116,4.47
respiratory mechanism,55,152,4.46
alcohol use among adolescents,80,221,4.46
field learning,44,122,4.45
field test,44,122,4.45
astroglia,190,528,4.44
astrocytus,190,528,4.44
neural correlate,104,289,4.44
hiv/hcv,83,231,4.43
behavioral assessment,119,331,4.43
epigenetic regulation,64,178,4.43
predicting response,46,128,4.43
rural,226,629,4.43
hiv/hepatitis c,83,231,4.43
behavior assessment,119,331,4.43
treatment group,64,179,4.41
inflammation,359,1003,4.41
child health,44,123,4.41
coping behavior,34,95,4.41
screenings,295,827,4.4
specialist,135,378,4.4
low socioeconomic status,77,216,4.4
access to care,240,673,4.4
clinical effect,46,129,4.4
astrocytes,190,532,4.4
healthcare service,35,98,4.4
professional organizations,31,87,4.39
evidence base,841,2365,4.39
metabolism measurement,62,174,4.39
bacteriophage p1 recombinase cre,64,180,4.39
respiration,55,155,4.38
population health,91,256,4.38
attentional bias,34,96,4.37
health care service organization,34,96,4.37
care providers,77,218,4.36
immunologically,36,102,4.35
cellular telephone,163,462,4.35
practice setting,30,85,4.35
endocannabinoid system,62,176,4.34
active learning,33,94,4.33
interferons,33,94,4.33
populations at risk,94,268,4.33
microscope,42,120,4.32
opiate tolerance,56,160,4.32
metabolomics,62,177,4.32
tolerance to opiates,56,160,4.32
hospital length of stay,77,220,4.32
cell phone,163,466,4.31
migraine,37,106,4.31
meteorological climate,37,106,4.31
climate,37,106,4.31
immune therapy,43,123,4.31
cellular phone,163,466,4.31
climatic,37,106,4.31
microbial,51,146,4.31
immunologically directed therapy,43,123,4.31
absorption,85,244,4.3
learning strategy,30,86,4.3
knock-down,292,838,4.3
learning activity,30,86,4.3
learning method,30,86,4.3
prenatally exposed to alcohol,32,92,4.29
surgical interventions,333,958,4.29
gestation ethanol exposure,32,92,4.29
surgical procedure,333,958,4.29
prenatally alcohol exposed,32,92,4.29
pregnancy ethanol exposure,32,92,4.29
pregnancy alcohol exposure,32,92,4.29
pregnancy etoh exposure,32,92,4.29
surgical,333,958,4.29
clinical protocols,32,92,4.29
prenatal alcohol exposure,32,92,4.29
in utero etoh exposure,32,92,4.29
fetal etoh exposure,32,92,4.29
genome scale,195,560,4.29
prenatal etoh exposure,32,92,4.29
imaging study,112,322,4.29
operative surgical procedures,333,958,4.29
gestation alcohol exposure,32,92,4.29
prenatal ethanol exposure,32,92,4.29
fetal alcohol exposure,32,92,4.29
operative procedures,333,958,4.29
alcohol-exposed pregnancy,32,92,4.29
in utero alcohol exposure,32,92,4.29
exposed to alcohol prenatally,32,92,4.29
in utero ethanol exposure,32,92,4.29
gestation etoh exposure,32,92,4.29
fetal ethanol exposure,32,92,4.29
genetic engineering molecular biology,33,95,4.28
glutamate signaling,86,248,4.28
surgery,333,959,4.28
liver disorder,85,245,4.28
marrow monocyte,58,167,4.28
blood monocyte,58,167,4.28
glutamatergic signaling,86,248,4.28
glutamatergic dendrodendritic synapses,86,248,4.28
genetic engineering biotechnology,33,95,4.28
suicidal thoughts,55,159,4.27
feeling suicidal,55,159,4.27
suicidal ideation,55,159,4.27
suicidal thinking,55,159,4.27
suicide ideation,55,159,4.27
internet-assisted education,35,101,4.27
hyperalgesia,138,399,4.27
computer-based education,35,101,4.27
computer-assisted instruction,35,101,4.27
web-based instruction,35,101,4.27
thoughts about suicide,55,159,4.27
adoption,475,1376,4.26
economic burden,150,434,4.26
cirrhosis,48,139,4.26
specimen collection,37,107,4.26
collaborative care,38,110,4.26
neural injury,62,180,4.25
tamoxifen,30,87,4.25
freezing,50,145,4.25
somatosensory,31,90,4.25
macrophage,101,294,4.24
cre recombinase,64,186,4.24
b-cell differentiation factor,54,157,4.24
socioeconomics,250,727,4.24
qol,437,1271,4.24
children's hospital,46,134,4.23
genetic manipulation,147,429,4.23
behavioral study,154,449,4.23
segregation,48,140,4.23
shapes,419,1222,4.23
adverse outcome,232,676,4.23
behavior study,154,449,4.23
adverse consequence,232,676,4.23
behavior mechanism,115,336,4.22
regulatory element,51,149,4.22
cancer patient,99,289,4.22
epidemiologist,51,149,4.22
chromatin,187,547,4.22
hypersensitivity,117,342,4.22
tailored medical treatment,99,290,4.21
customized therapy,99,290,4.21
individualized medicine,99,290,4.21
risk reduction,163,477,4.21
individualized treatment,99,290,4.21
customized treatment,99,290,4.21
implant,149,436,4.21
molecular dynamics simulation,44,129,4.21
locus ceruleus structure,59,173,4.21
unique treatment,99,290,4.21
cannabis user,70,205,4.21
cyclic gmp,44,129,4.21
tailored treatment,99,290,4.21
tumor growth,66,194,4.2
cognitive defects,125,367,4.2
immunosuppressive effect,30,88,4.2
critical developmental period,30,88,4.2
pup,30,88,4.2
immunosuppression effect,30,88,4.2
allodynia,48,141,4.2
analytical method,81,238,4.2
b-cell differentiation factor-2,54,159,4.19
secure,185,544,4.19
hybridoma growth factor,54,159,4.19
bcdf,54,159,4.19
b cell stimulating factor 2,54,159,4.19
bsf-2,54,159,4.19
b cell differentiation factor,54,159,4.19
bsf2,54,159,4.19
hepatocyte-stimulating factor,54,159,4.19
allergy,117,344,4.19
ifn-beta 2,54,159,4.19
b-cell stimulatory factor-2,54,159,4.19
ifnb2,54,159,4.19
il-6,54,159,4.19
il6 protein,54,159,4.19
interleukin-6,54,159,4.19
mgi-2,54,159,4.19
myeloid differentiation-inducing protein,54,159,4.19
plasmacytoma growth factor,54,159,4.19
interferon beta 2,54,159,4.19
hpgf,54,159,4.19
sensory,397,1169,4.19
mental hygiene services,76,224,4.18
antinociceptive drugs,560,1653,4.18
analgesic preparation,560,1653,4.18
antinociceptive agents,560,1653,4.18
anodynes,560,1653,4.18
analgesic drugs,560,1653,4.18
harvest,43,127,4.18
analgesic agents,560,1653,4.18
human whole genome,75,222,4.17
protein activation,45,133,4.17
neuronal circuitry,148,438,4.17
in vivo model,103,305,4.17
resource sharing,50,148,4.17
relapse prediction,71,210,4.17
heart rate variability,44,130,4.17
human genome,75,222,4.17
productivity,361,1070,4.16
pharmaceutical chemistry,159,471,4.16
desire for food,134,397,4.16
safety net,53,157,4.16
patents,90,267,4.16
legal patent,90,267,4.16
epigenetic change,443,1316,4.15
epigenetic,443,1316,4.15
underserved population,118,351,4.15
under served population,118,351,4.15
underserved people,118,351,4.15
epigenetic mechanism,443,1316,4.15
epigenetic process,443,1316,4.15
flexible,383,1142,4.14
anesthetics,55,164,4.14
genetic biomarker,45,134,4.14
rna expression,523,1557,4.14
gene transcription,523,1557,4.14
self management,60,179,4.13
brain trauma,80,239,4.13
longitudinal analysis,64,191,4.13
bound protein,68,203,4.13
thymus derived lymphocyte,59,176,4.13
t-lymphocyte,59,176,4.13
chemotherapy,106,317,4.12
taste response,52,156,4.11
immune system disorder,33,99,4.11
immune dysfunction,33,99,4.11
immune system diseases,33,99,4.11
gustatory response,52,156,4.11
taste processing,52,156,4.11
pharmacies,126,378,4.11
immunologic diseases,33,99,4.11
genetic transcription,523,1568,4.11
optic imaging,40,120,4.11
optical imaging,40,120,4.11
catalyst,37,111,4.11
cannabinoid receptor cb1,116,348,4.11
cnr1 gene,116,348,4.11
cb1r,116,348,4.11
immunological diseases,33,99,4.11
gustatory processing,52,156,4.11
cannabinoid receptor 1,116,348,4.11
pharmacy facility,126,378,4.11
deposition,88,264,4.11
immune diseases,33,99,4.11
deposit,88,264,4.11
gene expression profiling,93,279,4.11
immune disorders,33,99,4.11
gustatory perception,52,156,4.11
brain circuitry,103,310,4.1
brain cell,126,379,4.1
hazardous drinking,61,184,4.09
application context,118,356,4.09
contextual factors,118,356,4.09
nerve injury,62,187,4.09
stem,247,744,4.09
mental health services,76,230,4.08
in vitro model,48,145,4.08
expression signature,142,429,4.08
substance use among adolescents,81,245,4.08
cancer center,42,127,4.08
field based data,44,133,4.08
network models,37,112,4.07
sample collection,37,112,4.07
poor sleep,33,100,4.07
t-cells,59,179,4.07
recombinant dna technology,33,100,4.07
gender-associated difference,59,179,4.07
mobile technology,50,152,4.06
mobile platform,50,152,4.06
tablets,52,158,4.06
mobile computing,50,152,4.06
american indians,83,252,4.06
next generation,349,1060,4.06
minority groups,117,355,4.06
quality of life,437,1330,4.05
narcan,150,457,4.05
narcanti,150,457,4.05
systematic review,42,128,4.05
predictive outcomes,44,134,4.05
closure by ligation,42,128,4.05
ligation,42,128,4.05
life sciences,45,137,4.05
predictors of outcomes,44,134,4.05
distant,45,137,4.05
biological sciences,45,137,4.05
biologic sciences,45,137,4.05
point of care,44,134,4.05
temperature,54,165,4.04
gene expression profile,142,434,4.04
brain-injured,60,183,4.04
regulatory pathway,57,174,4.04
gene expression signature,142,434,4.04
dropout,109,333,4.04
floxed,54,165,4.04
peripheral nervous system,58,177,4.04
interpeduncular nucleus,36,110,4.04
public policy,120,366,4.04
multidisciplinary,593,1811,4.04
modality,377,1151,4.04
toxicant,50,153,4.03
self care,34,104,4.03
polysomnography,33,101,4.03
prevent drug addiction,83,254,4.03
cancermodel,31,95,4.02
cancer model,31,95,4.02
healthcare facility,30,92,4.02
community health,61,187,4.02
behavioral plasticity,31,95,4.02
health facilities,30,92,4.02
clinical research site,76,234,4.01
clinical site,76,234,4.01
development plans,209,643,4.01
genetic recombination,53,163,4.01
epidemic,649,1998,4.01
calcium,389,1197,4.01
data systems,64,197,4.01
test result,43,133,3.99
preventative intervention,189,584,3.99
new therapeutic target,443,1369,3.99
arthritis,32,99,3.99
loxp-flanked allele,54,167,3.99
floxed allele,54,167,3.99
novel therapeutic target,443,1369,3.99
community services,32,99,3.99
clinical management,65,201,3.99
investments,169,522,3.99
studies of populations,31,96,3.98
research methodology,269,833,3.98
outreach,171,530,3.98
ethanol use disorder,969,3002,3.98
population-level study,31,96,3.98
alcohol use disorder,969,3002,3.98
traumatic brain injury,80,248,3.98
traumatic brain damage,80,248,3.98
lack of energy,40,124,3.98
population-based study,31,96,3.98
study of the population,31,96,3.98
opiate abuse,357,1109,3.97
calcium ion signaling,58,180,3.97
opioid abuse,357,1109,3.97
clinical depression,131,407,3.97
antiinflammatories,85,264,3.97
calcium signaling,58,180,3.97
ambulatory care,65,202,3.97
opioid,2130,6634,3.96
sleeplessness,90,280,3.96
cancer pain,51,159,3.96
insomnia disorder,90,280,3.96
sleep deprivation,41,128,3.95
insurers,42,131,3.95
genetic study,158,493,3.95
insurance carriers,42,131,3.95
suicide risk,50,156,3.95
suicidal risk,50,156,3.95
pathogen,38,119,3.94
monocyte,58,182,3.93
critical period,116,364,3.93
leadership,445,1395,3.93
underrepresented minority,100,315,3.92
brain tissue,187,588,3.92
observational study,77,242,3.92
patient satisfaction,47,148,3.92
client satisfaction,47,148,3.92
insomnia,90,284,3.91
science,1001,3155,3.91
cancer type,50,158,3.9
interventional study,134,424,3.9
interventional research,134,424,3.9
parturition,199,630,3.9
race differences,36,114,3.89
constipation,78,247,3.89
lc/ms,41,130,3.89
pharmaceutic chemistry,159,504,3.89
racial difference,36,114,3.89
institution,487,1545,3.89
medicinal chemistry,159,504,3.89
flexibility,383,1214,3.89
unhealthy alcohol use,168,532,3.89
psychosocial stress,33,105,3.88
discipline of obstetrics,51,162,3.88
proxy,55,175,3.88
risk-associated variant,57,181,3.88
drug development,284,906,3.87
illicit drug use,131,417,3.87
disease risk,169,539,3.87
co-morbidity,808,2577,3.87
cytoplasm,43,137,3.87
disorder risk,169,539,3.87
best practice analysis,79,252,3.87
benchmarking,79,252,3.87
chemokine,83,265,3.86
sleep,280,894,3.86
obstetrics,51,163,3.86
formulation,253,810,3.85
cost effectiveness analysis,55,176,3.85
cost efficient analysis,55,176,3.85
pre-clinical research,105,336,3.85
excitatory neuron,35,112,3.85
social sciences,34,109,3.85
birth,199,638,3.85
preclinical research,105,336,3.85
disability,294,942,3.85
animal behavior,75,240,3.85
disabled population,43,138,3.84
people with disabilities,43,138,3.84
disabled persons,43,138,3.84
persons with disabilities,43,138,3.84
tumor cell metastasis,70,225,3.84
handicapped,43,138,3.84
disabled people,43,138,3.84
transplantation,42,135,3.84
cofactor,38,122,3.84
skin,83,267,3.83
antiinflammatory agents,85,274,3.83
user-friendly,60,193,3.83
confocal microscopy,64,206,3.83
alcohol access,67,216,3.83
access to alcohol,67,216,3.83
fda approved,471,1516,3.83
cardiovascular diseases,192,619,3.83
smell perception,43,139,3.82
dna recombination,53,171,3.82
multifaceted intervention,31,100,3.82
olfaction,43,139,3.82
pancreatic cancer,31,100,3.82
multicomponent intervention,31,100,3.82
multi-modal intervention,31,100,3.82
multimodal intervention,31,100,3.82
malignant neoplasm of pancreas,31,100,3.82
muscular,65,210,3.82
multi-faceted intervention,31,100,3.82
pancreas cancer,31,100,3.82
multi-component intervention,31,100,3.82
smell,43,139,3.82
respiratory,138,445,3.82
malignant pancreatic neoplasm,31,100,3.82
documentation,75,243,3.81
necropsy,173,560,3.81
autopsy,173,560,3.81
county,202,654,3.81
absence of sensibility to pain,266,862,3.81
no sensitivity to pain,266,862,3.81
feels no pain,266,862,3.81
risk assessment,62,201,3.8
oncology,40,130,3.79
xenograft model,39,127,3.79
dna therapy,47,153,3.79
newly diagnosed,32,104,3.79
gene-based therapy,47,153,3.79
cardiac chronotropism,101,329,3.79
compensation,50,163,3.78
health care facility,30,98,3.78
absence of pain sensation,264,862,3.78
noncoding rna,73,238,3.78
enhancers,95,310,3.78
nontranslated rna,73,238,3.78
untranslated rna,73,238,3.78
alcohol misuse,168,549,3.77
ethanol misuse,168,549,3.77
follow up assessment,65,213,3.76
psychotomimetic drug,47,154,3.76
immune,236,777,3.75
nausea,38,125,3.75
cardiovascular disorder,192,632,3.75
natural experiment,37,122,3.74
connector neuron,213,703,3.74
patient care delivery,186,613,3.74
genetically predisposed,71,234,3.74
opioid analgesics,226,746,3.74
intercalary neuron,213,703,3.74
fatigue,40,132,3.74
orthologous gene,34,112,3.74
high throughput screening,106,350,3.74
internuncial neuron,213,703,3.74
ortholog,34,112,3.74
internuncial cell,213,703,3.74
intercalated neurons,213,703,3.74
receptor inhibition,30,99,3.74
high throughput assay,106,350,3.74
biologic marker,501,1658,3.73
alcohol exposure during adolescence,33,109,3.73
ethanol exposure during adolescence,33,109,3.73
transdisciplinary collaboration,36,119,3.73
biological markers,501,1658,3.73
genomic variant,170,562,3.73
allele variant,170,562,3.73
adolescent ethanol exposure,33,109,3.73
adolescent alcohol exposure,33,109,3.73
neoplasm metastasis,70,232,3.72
metastatic tumor,70,232,3.72
injectable,97,322,3.72
head,159,527,3.72
cancer metastasis,70,232,3.72
career development,532,1766,3.72
secondary tumor,70,232,3.72
metastasize,70,232,3.72
randomization trial,176,583,3.72
reward circuitry,196,649,3.72
metastatic neoplasm,70,232,3.72
secondary neoplasm,70,232,3.72
vapor,165,548,3.71
substance use prevention,64,213,3.71
prevent substance use,64,213,3.71
continuity of patient care,84,280,3.7
neurophysiology / electrophysiology,836,2789,3.7
immunological,36,120,3.7
post intervention,98,327,3.7
negative reinforcements,127,423,3.7
medicine,566,1888,3.7
functional genomics,69,230,3.7
genetic engineering,33,110,3.7
electrophysiology (science),836,2789,3.7
continuity of care,84,280,3.7
economic impact,48,160,3.7
continuum of care,84,280,3.7
validation,454,1518,3.69
open label study,64,214,3.69
open label,64,214,3.69
therapeutic target,499,1666,3.69
ethanol accessibility,67,224,3.69
alcohol accessibility,67,224,3.69
alcohol availability,67,224,3.69
ethanol availability,67,224,3.69
emotional distress,31,104,3.68
immune activation,46,154,3.68
medulla spinalis,133,446,3.68
feeling upset,31,104,3.68
pregnancy,270,906,3.68
neuronal excitability,118,395,3.68
program evaluation,48,161,3.68
feeling distress,31,104,3.68
survival rate,42,141,3.67
heterogeneity,301,1012,3.67
funding opportunities,42,141,3.67
color,91,307,3.66
care systems,95,320,3.66
clinical data,167,565,3.65
hippocampal pyramidal neuron,126,426,3.65
ethnic origin,303,1024,3.65
pyramidal neuron,126,426,3.65
toxicology,243,822,3.65
salutogenesis,63,213,3.65
health promotion,63,213,3.65
chromatin structure,37,125,3.65
inhibitory neuron,32,108,3.65
secondary outcome,292,988,3.65
ms contin,455,1538,3.65
bipolar disease,58,196,3.65
infancy,66,223,3.65
ki mice,41,139,3.64
knockin mice,41,139,3.64
novel therapeutics,686,2324,3.64
biomedical research,150,508,3.64
next generation therapeutics,686,2324,3.64
new therapeutics,686,2324,3.64
behavioral health,229,776,3.64
recurrent,160,544,3.63
recurrence,160,544,3.63
cigar,33,112,3.63
academy,65,221,3.63
feasibility studies,125,425,3.63
marijuana use,249,845,3.63
data acquisition,35,119,3.63
research priority,149,508,3.62
hospitalization,210,715,3.62
ohio,47,160,3.62
appetite,134,457,3.62
socio-economic position,103,352,3.61
socioeconomic status,103,352,3.61
socioeconomic position,103,352,3.61
interneurons,213,728,3.61
early detection,74,253,3.61
coping skills,76,260,3.61
postnatal,135,462,3.6
patient care,186,637,3.6
adolescent and young adult,75,258,3.59
financial incentive,50,172,3.59
cytokine,216,745,3.58
metastasis,70,241,3.58
responsible research conduct,104,358,3.58
community setting,77,266,3.57
engineering / architecture,165,570,3.57
ligand binding protein gene,68,235,3.57
biobehavioral,111,383,3.57
caring,1002,3466,3.57
biobehavior,111,383,3.57
provider,622,2149,3.57
architecture,165,570,3.57
ribosomes,40,138,3.57
regulator genes,66,228,3.57
gene transfer clinical,47,163,3.56
veterans,335,1159,3.56
genetic intervention,47,163,3.56
genetic therapy,47,163,3.56
social work,105,364,3.56
analytical tool,38,132,3.55
nucleus pigmentosus pontis,59,205,3.55
blue nucleus,59,205,3.55
statistical models,74,257,3.55
policies,675,2347,3.55
opioid medication abuse,48,167,3.54
prescription opiate abuse,48,167,3.54
opioid prescription drug abuse,48,167,3.54
alcohol seeking,198,690,3.54
alcohol seeking behavior,198,690,3.54
ethanol seeking,198,690,3.54
ethanol-seeking behavior,198,690,3.54
ethics,194,676,3.54
hepatic body system,148,515,3.54
hepatic organ system,148,515,3.54
fatal suicide,131,458,3.53
fatal attempt,131,458,3.53
health care systems,319,1113,3.53
intent to die,131,458,3.53
viral vector,186,650,3.53
uptake,427,1492,3.53
cellular targeting,53,185,3.53
selectively expressed,71,249,3.52
oral drug administration,44,154,3.52
bioavailability,118,413,3.52
biological availability,118,413,3.52
physiologic availability,118,413,3.52
public health priorities,69,242,3.52
tumor suppressor proteins,36,126,3.52
tumor suppressor,36,126,3.52
motor control,44,154,3.52
selective expression,71,249,3.52
it systems,64,225,3.51
information technology systems,64,225,3.51
drinking initiation,39,137,3.51
syringes,39,137,3.51
neural degenerative disorders,97,341,3.51
degenerative diseases of motor and sensory neurons,97,341,3.51
degenerative neurological diseases,97,341,3.51
endogenous cannabinoid system,62,218,3.51
obsessive-compulsive neurosis,112,394,3.51
liquid chromatography mass spectrometry,41,144,3.51
career,1086,3814,3.51
msm,33,116,3.51
obsessive-compulsive disorder,112,394,3.51
neural degenerative diseases,97,341,3.51
reduce tobacco use,40,141,3.5
repair,71,250,3.5
repaired,71,250,3.5
substance use,1213,4282,3.49
enroll,685,2418,3.49
food and drug administration,180,637,3.49
usfda,180,637,3.49
united states food and drug administration,180,637,3.49
treatment adherence,85,300,3.49
flow cytofluorometry,44,156,3.48
trauma,238,844,3.48
solubility,50,177,3.48
relapsed disease,44,156,3.48
recurrent disease,44,156,3.48
flow microfluorometry,44,156,3.48
data modeling,35,124,3.48
spinal,82,291,3.48
neurobehavioral signs and symptoms,35,124,3.48
reduced alcohol use,93,330,3.48
fitness,40,142,3.47
disease progression,128,455,3.47
competence,116,412,3.47
early diagnosis,74,263,3.47
research methods,269,955,3.47
cigarette smoke,96,341,3.47
electroencephalography,189,671,3.47
emotion regulation,103,366,3.47
nanoparticle,37,132,3.46
combinatorial,83,296,3.46
quality control,66,235,3.46
recombination,53,189,3.46
marketing,248,883,3.46
wakefulness,32,114,3.46
peripheral,336,1198,3.46
nano particle,37,132,3.46
immunosuppression,30,107,3.46
mitochondria,95,339,3.46
synaptic circuit,833,2980,3.45
suicidal attempt,38,136,3.45
ensure,752,2689,3.45
synaptic circuitry,833,2980,3.45
neural circuit,833,2980,3.45
information systems,64,229,3.45
pharmacogenomics,33,118,3.45
cancer treatment,116,415,3.45
malignant neoplasm therapy,116,415,3.45
neural circuitry,833,2980,3.45
cancer therapy,116,415,3.45
malignant neoplasm treatment,116,415,3.45
single molecule,40,143,3.45
non fatal attempt,38,136,3.45
suicide attempt,38,136,3.45
cancer cell,158,565,3.45
malignant cell,158,565,3.45
defined contribution,31,111,3.44
data set,646,2313,3.44
public health schools,31,111,3.44
axon,167,598,3.44
immunomodulation,31,111,3.44
immunologic reactivity control,31,111,3.44
oncogene addiction,61,219,3.44
immune modulation,31,111,3.44
program development,114,409,3.44
epithelial cells,41,147,3.44
motivated behavior,286,1028,3.43
positioning attribute,772,2779,3.43
position,772,2779,3.43
mindfulness,82,295,3.43
antiretroviral therapy,174,625,3.43
neuron loss,36,130,3.42
infrastructure,482,1739,3.42
retinal s-antigen,56,202,3.42
timeline,117,422,3.42
neuron cell death,36,130,3.42
policy maker,165,595,3.42
neuronal loss,36,130,3.42
neuronal cell death,36,130,3.42
maps,646,2330,3.42
catalogs,51,184,3.42
qoc,100,362,3.41
transcriptional regulatory elements,66,239,3.41
mitochondrial,95,344,3.41
post-traumatic neuroses,316,1142,3.41
post-traumatic stress disorders,316,1142,3.41
posttraumatic neuroses,316,1142,3.41
feedback,591,2139,3.41
quality of care,100,362,3.41
trans acting element,66,239,3.41
risk gene,57,207,3.4
cognitive discrimination,159,576,3.4
licensing,75,272,3.4
disorder model,87,316,3.4
risk loci,57,207,3.4
risk locus,57,207,3.4
sodium channel,32,116,3.4
postmortem,173,627,3.4
risk genotype,57,207,3.4
risk allele,57,207,3.4
financial support,33,120,3.39
needles,41,149,3.39
deterioration,30,109,3.39
medical rehabilitation,86,313,3.39
healthcare systems,319,1162,3.39
marijuana user,70,255,3.39
pathway analysis,107,391,3.38
network analysis,107,391,3.38
discrimination,159,581,3.38
biophysics,59,215,3.38
cessation of life,911,3322,3.38
scientist,859,3146,3.37
muscle tissue,65,238,3.37
contracting opportunities,178,652,3.37
cause of death,251,919,3.37
fighting,44,161,3.37
neuroglia,182,666,3.37
neuroglial cells,182,666,3.37
kolliker's reticulum,182,666,3.37
glial cells,182,666,3.37
technology,1125,4113,3.37
non-neuronal cell,182,666,3.37
nerve cement,182,666,3.37
contracts,178,652,3.37
2-arachidonoyl-sn-glycerol,30,110,3.36
2-ag,30,110,3.36
misuse of prescription only drugs,36,132,3.36
prescription drug misuse,36,132,3.36
death,911,3343,3.36
rodent model,359,1316,3.36
home,347,1273,3.36
mortality,830,3043,3.36
fetal,90,330,3.36
endothelial cells,33,121,3.36
mouse model,598,2203,3.35
recruit,1401,5152,3.35
therapy adherence,47,173,3.35
focus groups,206,758,3.35
compare effectiveness,68,251,3.34
engineering,275,1015,3.34
electronic healthcare record,75,277,3.34
sprague-dawley rats,32,118,3.34
foundations,894,3309,3.33
immunohistochemistry cell/tissue,219,812,3.33
analgesics,560,2076,3.33
genome sequencing,50,185,3.33
tlr4,31,115,3.32
malignant breast tumor,63,234,3.32
breast cancer,63,234,3.32
malignant breast neoplasm,63,234,3.32
tlr4 gene,31,115,3.32
small molecule,353,1312,3.32
hepatocyte,38,141,3.32
viral,644,2394,3.32
familiarity,39,145,3.32
body tissues,679,2521,3.32
tissues,679,2525,3.32
cross-over designs,37,138,3.31
translations,391,1458,3.31
data management,102,380,3.31
native americans,72,268,3.31
accidents,62,232,3.3
iq deficit,64,239,3.3
neurocognitive deficit,64,239,3.3
childrearing,65,243,3.3
optical,178,665,3.3
oncogenic,121,452,3.3
data sources,79,295,3.3
output,433,1619,3.3
resources,1303,4876,3.3
research resources,1303,4873,3.3
inflammatory response,61,229,3.29
phase 1 study,55,206,3.29
phase i study,55,206,3.29
scaffolding,164,615,3.29
pilot trial,112,420,3.29
scaffold,164,615,3.29
organ,132,495,3.29
optics,178,668,3.29
translation research,390,1460,3.29
alcohol measurement,81,304,3.29
united states,1312,4911,3.29
treatment as usual,268,1004,3.29
usual care,268,1004,3.29
ethyl alcohol measurements,81,304,3.29
ethanol measurement,81,304,3.29
risk variant,57,214,3.29
sound,117,438,3.29
alcohol level,81,304,3.29
etoh level,81,304,3.29
case report,48,180,3.29
case study,48,180,3.29
research support,219,822,3.29
nasal passages nose,37,139,3.28
health services delivery,91,342,3.28
enzyme-linked immunosorbent assay,42,158,3.28
mothers,194,730,3.28
predictor of response,34,128,3.28
mutagenesis molecular biology,72,271,3.28
predictive response,34,128,3.28
elisa,42,158,3.28
pharmacists,37,139,3.28
response prediction,34,128,3.28
adolescent boy,33,124,3.28
male adolescents,33,124,3.28
health care delivery,91,342,3.28
socio-economic status,103,389,3.27
glia,182,687,3.27
cholinergic neuron,39,147,3.27
nursing profession,48,181,3.27
nursing field,48,181,3.27
discipline of nursing,48,181,3.27
study models,90,339,3.27
permeability,104,392,3.27
ketamine,54,204,3.26
loss of function,95,359,3.26
impaired behavior,42,159,3.26
behavioral impairment,42,159,3.26
gene therapy,47,178,3.26
hyperactivity,132,499,3.26
suicide,131,496,3.26
reversal learning,45,171,3.25
logistics,68,258,3.25
healthy volunteer,50,190,3.25
protocols documentation,836,3177,3.25
learned behavior,57,216,3.25
learning behavior,57,216,3.25
academia,40,152,3.25
pragmatic trial,50,190,3.25
surgeon,74,281,3.25
glean,34,129,3.25
research activity,152,577,3.25
molecular dynamics,44,167,3.25
diaries,53,202,3.24
informant,53,202,3.24
infectious disorder,140,533,3.24
problematic alcohol use,383,1458,3.24
infectious disease pathway,140,533,3.24
educational aspects,498,1895,3.24
infectious diseases,140,533,3.24
problematic alcohol consumption,383,1458,3.24
female health,53,202,3.24
arm,305,1163,3.23
flow cytophotometry,44,168,3.23
chemistry,173,661,3.23
thalamic,187,715,3.23
thalamic structure,187,715,3.23
psychological distress,43,164,3.23
inhibitory synapse,34,130,3.23
clinic,613,2341,3.23
flow cytofluorometries,44,168,3.23
flow microfluorimetry,44,168,3.23
recombinant oxytocin,48,184,3.22
ocytocin,48,184,3.22
healthcare delivery,91,349,3.22
pre-clinical study,314,1206,3.21
alcohol initiation,39,150,3.21
demographics,101,388,3.21
preclinical study,314,1206,3.21
neoplasm/cancer,602,2310,3.21
alcohol use initiation,39,150,3.21
malignancy,602,2310,3.21
malignant tumor,602,2310,3.21
malignant neoplasms,602,2310,3.21
cancers,602,2310,3.21
signaling protein,97,374,3.2
hair,40,154,3.2
communicable diseases,140,539,3.2
gpcr signaling,60,231,3.2
g protein-coupled receptor signaling,60,231,3.2
effective intervention,218,841,3.2
alkaloids,46,178,3.19
resolution,525,2029,3.19
police,37,143,3.19
gastrointestinal,36,139,3.19
implantation,31,120,3.19
pancreas,30,116,3.19
pancreatic,30,116,3.19
mentors,1034,3997,3.19
dimensions,252,974,3.19
9-ene-tetrahydrocannabinol,82,317,3.19
delta-9-tetrahydrocannabinol,82,317,3.19
metabolic,305,1180,3.19
tetrahydrocannabinol,82,317,3.19
delta(1)-thc,82,317,3.19
delta(1)-tetrahydrocannabinol,82,317,3.19
delta(9)-thc,82,317,3.19
delta(9)-tetrahydrocannabinol,82,317,3.19
structural biology,49,190,3.18
cell count,32,124,3.18
update,198,769,3.18
dependoparvovirus,34,132,3.18
minor tranquilizing agents,94,365,3.18
cell number,32,124,3.18
msir,455,1766,3.18
oramorph,455,1766,3.18
kadian,455,1766,3.18
infumorph,455,1766,3.18
statex sr,455,1766,3.18
oramorph sr,455,1766,3.18
roxanol,455,1766,3.18
morphia,455,1766,3.18
drug candidate,89,346,3.17
hep c,70,272,3.17
social service,105,408,3.17
discover genes,44,171,3.17
fright,211,820,3.17
custom,91,354,3.17
evidence based treatment,246,958,3.17
cannabis,252,980,3.17
psychological health,716,2790,3.17
mental hygiene,716,2790,3.17
chemotactic cytokines,46,179,3.17
bacteria,32,125,3.16
critical pathways,32,125,3.16
in situ hybridization genetics,102,398,3.16
critical paths,32,125,3.16
tool development,31,121,3.16
personal satisfaction,254,992,3.16
well-being,254,992,3.16
arrestins,56,219,3.15
computer models,186,729,3.15
clinical effectiveness,35,137,3.15
non-polyadenylated rna,201,786,3.15
rna gene products,201,786,3.15
collection,303,1185,3.15
patient centered,160,626,3.15
patient oriented,160,626,3.15
pain tolerance,35,137,3.15
pain tolerance level,35,137,3.15
war,30,118,3.14
anhedonia,83,326,3.14
safety,621,2438,3.14
intraoral drug delivery,44,173,3.14
cognitive manifestations,35,138,3.13
histology,52,205,3.13
traumatic neurosis,316,1247,3.13
clinical assessments,64,252,3.13
ptsd,316,1247,3.13
cognitive symptoms,35,138,3.13
education,498,1964,3.13
hepatic cells,34,134,3.13
mental health,716,2819,3.13
neurobehavioral manifestations,35,138,3.13
clinical practice,282,1110,3.13
hepatic parenchymal cell,34,134,3.13
lung,153,602,3.13
phase ii study,46,182,3.12
lipids,145,574,3.12
gxe interaction,38,150,3.12
cancer etiology,80,316,3.12
gene x environment interaction,38,150,3.12
reporter,177,700,3.12
in situ,66,261,3.12
cancer cause,80,316,3.12
particle,49,194,3.12
translational science,390,1549,3.11
primary outcome,398,1577,3.11
medical specialties,228,904,3.11
gene regulation,133,528,3.11
adanon,339,1343,3.11
gene expression regulation,133,528,3.11
gene regulation process,133,528,3.11
dolophine,339,1343,3.11
methadose,339,1343,3.11
efficacy testing,228,904,3.11
rodents mammals,739,2935,3.11
althose,339,1343,3.11
gene action regulation,133,528,3.11
life span,162,644,3.1
sedation procedure,105,418,3.1
manuscripts,179,712,3.1
lifespan,162,644,3.1
menthol,48,191,3.1
crossover design,37,147,3.1
health care,532,2116,3.1
sedation,105,418,3.1
muscle,65,259,3.1
lung respiratory system,114,453,3.1
nutrition,49,195,3.1
brainstem,83,330,3.1
probabilistic models,74,294,3.1
research specimen,97,387,3.09
interdisciplinary study,200,797,3.09
in utero,71,283,3.09
protective effect,72,287,3.09
specimen,97,387,3.09
skills,999,3987,3.09
consumption,541,2156,3.09
ritalin,31,124,3.08
causation,488,1953,3.08
poverty,117,469,3.08
training activity,111,445,3.08
kentucky,38,152,3.08
neonate,43,172,3.08
justice,98,392,3.08
sociobehavior,71,285,3.07
sociobehavioral,71,285,3.07
motion,53,213,3.07
postdoctoral fellow,249,1000,3.07
postdoc,249,1000,3.07
protocol development,55,221,3.07
acute stress,59,237,3.07
negative emotional state,60,241,3.07
child rearing,65,261,3.07
adaptive behaviors,54,217,3.07
k-series research career programs,179,720,3.07
post-doctoral,249,1000,3.07
translational approach,61,245,3.07
stains,58,233,3.07
research associate,249,1000,3.07
post-doc,249,1000,3.07
analgesia,266,1068,3.07
satisfaction,200,807,3.06
memory deficit,70,282,3.06
michigan,65,262,3.06
e-health,31,125,3.06
ehealth,31,125,3.06
research clinical testing,77,310,3.06
combat,214,862,3.06
memory impairment,70,282,3.06
clinical test,77,310,3.06
clinical testing,77,310,3.06
clinical evaluation,77,310,3.06
cns nervous system,301,1212,3.06
evolution,103,415,3.06
immunohistochemistry staining method,219,883,3.06
social interaction,91,368,3.05
g-protein-coupled receptors,249,1008,3.05
rhode island,44,178,3.05
clinical relevance,372,1505,3.05
neurophysiological,249,1008,3.05
pregnenedione,41,166,3.05
delta4-pregnene-3,41,166,3.05
clinically relevant,372,1505,3.05
injury,270,1093,3.05
corpus luteum hormone,41,166,3.05
conduct clinical trials,92,372,3.05
fear,211,853,3.05
therapeutic progesterone,41,166,3.05
electrophysiology,836,3377,3.05
behavioral paradigm,107,432,3.05
site-directed mutagenesis,43,174,3.05
route,198,800,3.05
g protein-complex receptor,249,1008,3.05
medical center,155,628,3.04
bio-informatics,230,937,3.03
metabolic disorder,40,163,3.03
statistics,201,817,3.03
neuroprotection,43,175,3.03
metabolic diseases,40,163,3.03
liver,148,602,3.03
docking,58,236,3.03
adulthood,1391,5669,3.03
thesaurismosis,40,163,3.03
metabolism disorder,40,163,3.03
oral,387,1573,3.03
addictive disorder,4553,18553,3.03
drug combinations,49,200,3.02
trial design,103,421,3.02
buprenorphine,445,1815,3.02
cancer risk,46,188,3.02
cohesion,32,131,3.01
drug kinetics,336,1378,3.01
intergenerational,39,160,3.01
b-cell,30,123,3.01
immunotherapy,43,176,3.01
age 18 years,44,180,3.01
immunology,52,213,3.01
qualifying,143,586,3.01
thalamus,187,768,3.0
tissue sample,38,156,3.0
neoplastic disease chemotherapeutic agents,36,148,3.0
neonatal,79,325,3.0
predict relapse,51,210,3.0
intervention effect,133,549,2.99
spinal cord,133,548,2.99
neuromodulator,109,449,2.99
penetration,105,433,2.99
bioinformatics,230,949,2.99
buffers,69,285,2.99
intervention trial,57,235,2.99
virus,199,822,2.99
relaxation,36,149,2.98
toxicities,311,1285,2.98
toxic effect,311,1285,2.98
molecular analysis,30,124,2.98
staining method,58,240,2.98
cellular model,73,303,2.97
algorithms,199,825,2.97
small molecule libraries,32,133,2.97
glucocorticoid receptor,38,158,2.97
pro-drugs,39,162,2.97
chemical library,32,133,2.97
economic income,107,445,2.97
drug precursors,39,162,2.97
economical income,107,445,2.97
physical health,141,586,2.97
chemoattractant cytokine,46,191,2.97
behavioral assay,128,532,2.97
cholesterol,32,133,2.97
drug design,82,341,2.97
physical conditioning,141,586,2.97
sis cytokines,46,191,2.97
cell model,73,303,2.97
intercrines,46,191,2.97
homologous chemotactic cytokines,46,191,2.97
disease model,87,361,2.97
experimental designs,153,637,2.96
national institute on drug abuse,1041,4342,2.96
neural mechanism,446,1857,2.96
neuromechanism,446,1857,2.96
disabled,33,138,2.95
pallidum,103,430,2.95
globus pallidus,103,430,2.95
sbir,109,456,2.95
positron emission tomographic (pet) imaging,99,414,2.95
positron emission tomographic imaging,99,414,2.95
migration,50,209,2.95
neurosciences,649,2714,2.95
positron emitting tomography,99,414,2.95
coupled,455,1902,2.95
fellowship,175,731,2.95
model development,47,197,2.94
alcohol testing,36,151,2.94
ethanol testing,36,151,2.94
treatment effectiveness,87,365,2.94
registries,85,356,2.94
injection drug use,71,298,2.94
older adult,129,541,2.94
experimental models,47,197,2.94
alcohol behavior,101,425,2.93
healthcare,532,2243,2.93
cb2 receptor,51,215,2.93
intervention therapy,294,1239,2.93
ethanol related behavior,101,425,2.93
publishing,763,3212,2.93
ethanol induced behavior,101,425,2.93
ethanol behavior,101,425,2.93
therapeutic intervention,294,1239,2.93
alcohol related behavior,101,425,2.93
alcohol induced behavior,101,425,2.93
cb2,51,215,2.93
rest,304,1280,2.93
mass spectrum analyses,113,476,2.93
pressure,74,311,2.93
mass spectrum analysis,113,476,2.93
mass spectroscopy,113,476,2.93
mass photometry/spectrum analysis,113,476,2.93
pre-clinical,651,2744,2.93
survey instrument,616,2595,2.93
positive reinforcements,54,227,2.93
epinephrine receptors,47,198,2.93
chronic alcohol use,135,570,2.92
chronic alcohol drinking,135,570,2.92
chronic alcohol ingestion,135,570,2.92
chronic ethanol consumption,135,570,2.92
small business innovation research grant,109,460,2.92
chronic etoh drinking,135,570,2.92
chronic ethanol drinking,135,570,2.92
chronic ethanol ingestion,135,570,2.92
chronic alcohol consumption,135,570,2.92
appointment,81,342,2.92
small business innovation research,109,460,2.92
tumor,210,888,2.92
approach behavior,35,148,2.92
rodent,739,3126,2.92
gene discovery,44,186,2.92
meth abuse,31,131,2.92
health benefit,91,384,2.92
awareness,200,849,2.91
logic,38,161,2.91
patient population,202,857,2.91
alternative treatment,47,199,2.91
medial,463,1963,2.91
face,312,1323,2.91
collaborations,1070,4539,2.91
faces,312,1322,2.91
facial,312,1322,2.91
overexpression,270,1144,2.91
overexpress,270,1144,2.91
nasal,37,157,2.91
rodentia,739,3141,2.9
canada,43,183,2.9
r-series research projects,564,2400,2.9
genomics,406,1728,2.9
severities,707,3021,2.89
wireless,33,141,2.89
department of health and human services,34,145,2.89
preclinical,651,2779,2.89
intracellular skeleton,45,192,2.89
united states dept. of health and human services,34,145,2.89
united states department of health and human services,34,145,2.89
cytoskeletal system,45,192,2.89
cellular matrix,45,192,2.89
nucleus,451,1923,2.89
predictive value,49,210,2.88
functional impairment,60,257,2.88
libraries,167,716,2.88
pharmacologic management,53,227,2.88
writing,285,1222,2.88
analgesic management,53,227,2.88
cell nucleus,451,1930,2.88
mental depression,942,4034,2.88
opiate receptors,326,1395,2.88
medication management,53,227,2.88
genome wide association scan,227,975,2.87
ovocylin,46,198,2.87
therapeutic estradiol,46,198,2.87
gwas,227,975,2.87
dimenformon,46,198,2.87
ovocyclin,46,198,2.87
estraldine,46,198,2.87
progynon,46,198,2.87
diogyn,46,198,2.87
diogynets,46,198,2.87
genome wide association,227,975,2.87
whole genome association study,227,975,2.87
genome wide association studies,227,975,2.87
translating,597,2564,2.87
o element,30,129,2.87
whole genome association studies,227,975,2.87
estradiol-17beta,46,198,2.87
estradiol-17 beta,46,198,2.87
treatment compliance,61,262,2.87
o2 element,30,129,2.87
estrace,46,198,2.87
genome wide association study,227,975,2.87
aquadiol,46,198,2.87
whole genome association analysis,227,975,2.87
advocate,74,318,2.87
reconstruction,37,159,2.87
genomewide association study,227,975,2.87
genomewide association studies,227,975,2.87
genomewide association scan,227,975,2.87
cancer drug,36,155,2.86
antineoplastic agents,36,155,2.86
intravenous,263,1135,2.86
antineoplastic drugs,36,155,2.86
tumor-specific treatment agents,36,155,2.86
fostering,381,1644,2.86
extramural activities,67,289,2.86
morbidity,579,2494,2.86
anti-cancer agents,36,155,2.86
extmr,67,289,2.86
extramural,67,289,2.86
molecular stereochemistry,107,461,2.86
conformational state,107,461,2.86
specialty,228,982,2.86
molecular conformation,107,461,2.86
healthcare policy,95,409,2.86
oxytocin,48,207,2.86
molecular configuration,107,461,2.86
data analyses,471,2030,2.86
morbidity - disease rate,579,2494,2.86
proteomics,161,695,2.86
coculture techniques,34,147,2.85
administrator,99,429,2.85
coculture,34,147,2.85
success,900,3895,2.85
math models,49,212,2.85
avoidance behavior,53,229,2.85
malignant - descriptor,43,186,2.85
mathematical modeling,49,212,2.85
co-culture,34,147,2.85
phase 2 study,46,199,2.85
computational modeling,186,804,2.85
computer based models,186,804,2.85
computerized modeling,186,804,2.85
computerized models,186,804,2.85
computational models,186,804,2.85
cocultivation,34,147,2.85
disease remission,83,361,2.84
ribonucleic acid,201,873,2.84
phase ii protocol,53,230,2.84
benefits and risks,35,152,2.84
remission,83,361,2.84
phase ii clinical trials,53,230,2.84
collegiate,204,888,2.83
american,687,2997,2.83
liver cells,34,148,2.83
systematics,185,806,2.83
classification,185,806,2.83
aversive stimulus,67,292,2.83
immunohistochemistry,219,954,2.83
prevent,1450,6309,2.83
clinical study,780,3401,2.83
preventing,1450,6309,2.83
risk factors,749,3267,2.83
kidney urinary system,39,170,2.83
social workers,38,166,2.82
child youth,450,1967,2.82
youngster,450,1967,2.82
visit,348,1520,2.82
data quality,30,131,2.82
0-11 years old,450,1967,2.82
equipment,86,376,2.82
children (0-21),450,1967,2.82
simulation,111,487,2.81
manpower,155,681,2.81
human resources,155,681,2.81
multi-site trial,38,167,2.81
meth exposure,36,158,2.81
methamphetamine exposure,36,158,2.81
hypothalamic-pituitary-adrenal axis,63,277,2.81
hypothalamic-pituitary-adrenal (hpa) axis,63,277,2.81
methodology,738,3240,2.81
postdoctoral training,63,277,2.81
hypothalmus-pituitary-adrenal axis,63,277,2.81
post-doctoral training,63,277,2.81
homelessness,80,351,2.81
unhoused,80,351,2.81
adaptive behavior,54,237,2.81
adaptation behavior,54,237,2.81
injured,39,172,2.8
income,107,472,2.8
biology,363,1600,2.8
genetic models,89,392,2.8
health related quality of life,39,172,2.8
neurologic disorders,314,1384,2.8
nervous system diseases,314,1384,2.8
joints,156,688,2.8
cancer cell line,35,154,2.8
high risk,725,3188,2.8
hospitals,300,1323,2.8
neurological disorders,314,1384,2.8
tobacco control,96,423,2.8
cognitive control,160,706,2.8
refractory,71,313,2.8
chronic stress,91,401,2.8
clinical sciences,88,387,2.8
neurological disease,314,1384,2.8
sleep problem,79,348,2.8
training and education,74,327,2.79
immunochemical immunologic,36,159,2.79
physiological homeostasis,208,919,2.79
mirnas,68,301,2.79
peer,328,1450,2.79
running,212,936,2.79
benzodiazepine compounds,88,389,2.79
ligand binding,87,385,2.79
disease causation,488,2157,2.79
autoregulation,208,919,2.79
monitor,921,4065,2.79
causality,488,2157,2.79
cue reactivity,133,588,2.79
resistant,403,1788,2.78
homeostasis,208,923,2.78
tm domain,37,164,2.78
alcohol abuse therapy,359,1590,2.78
pulmonary,114,506,2.78
alcohol abuse treatment,359,1590,2.78
alcohol treatment,359,1590,2.78
transmembrane region,37,164,2.78
young adulthood,353,1567,2.78
strains cell lines,216,958,2.78
transmembrane domain,37,164,2.78
drug abstinence,100,445,2.77
neural network,110,490,2.77
anxiolytics,94,418,2.77
anxiolytic agents,94,418,2.77
blood reticuloendothelial system,264,1174,2.77
research ethics,31,138,2.77
regulatory gene product,37,165,2.77
genetic regulatory protein,37,165,2.77
regulatory protein,37,165,2.77
service utilization,47,209,2.77
therapeutic effect,113,503,2.77
electric stimulation,71,316,2.77
anti-anxiety agents,94,418,2.77
receptor signaling,298,1325,2.77
anti-anxiety drugs,94,418,2.77
social support system,50,223,2.77
support system,50,223,2.77
novel approaches,579,2588,2.76
oxygen,30,134,2.76
novel strategies,579,2588,2.76
novel strategy,579,2588,2.76
ontogeny,381,1700,2.76
tissue growth,381,1700,2.76
behavioral model,165,738,2.76
new approaches,579,2588,2.76
antineoplastics,36,161,2.76
multidisciplinary collaboration,200,895,2.76
generalized growth,381,1700,2.76
scientific publication,433,1932,2.76
resistance,403,1798,2.76
lateral,273,1221,2.76
multidisciplinary research,200,895,2.76
interdisciplinary research,200,895,2.76
behavioral sciences,78,349,2.76
youth alcohol consumption,80,359,2.75
innovative technologies,45,202,2.75
nose,74,332,2.75
alcohol during adolescence,80,359,2.75
suicidality,102,458,2.75
relapse prevention,224,1005,2.75
prodrugs,39,175,2.75
growth,381,1711,2.75
drinking during adolescence,80,359,2.75
guidelines,290,1299,2.75
health services,187,840,2.75
feeling,100,450,2.74
nurses,89,401,2.74
feelings,100,450,2.74
biological process,111,500,2.74
implementation research,97,436,2.74
biological function,111,500,2.74
award,696,3132,2.74
satiety,53,239,2.74
nervous system disorder,314,1412,2.74
functional rna,73,328,2.74
non-coding rna,73,328,2.74
non-coding,73,328,2.74
treatment response,215,971,2.73
adrenoceptors,47,212,2.73
adenoreceptor,47,212,2.73
career development awards,179,808,2.73
genome-wide,195,880,2.73
career development awards and programs,179,808,2.73
physiology,339,1532,2.73
genomewide,195,880,2.73
therapeutic uses,49,221,2.73
career development programs k-series,179,808,2.73
clinical efficacy,72,325,2.73
research career program,179,808,2.73
k-awards,179,808,2.73
tumor cell,78,352,2.73
woman,683,3093,2.72
severe mental disorder,30,136,2.72
chronic mental illness,30,136,2.72
serious mental disorder,30,136,2.72
opiate antagonist,131,593,2.72
brain vascular accident,95,431,2.72
develop therapy,405,1835,2.72
anxiety,770,3493,2.72
persistent mental illness,30,136,2.72
palate,30,136,2.72
heritability,147,666,2.72
emergency room,164,745,2.71
legal,218,993,2.71
cardiovascular organ system,139,632,2.71
withdrawal symptom,296,1346,2.71
emergency department,164,745,2.71
accident and emergency department,164,745,2.71
heart vascular,139,632,2.71
general public,346,1576,2.71
effective therapy,686,3117,2.71
adherence,338,1541,2.71
general population,346,1576,2.71
effective treatment,686,3117,2.71
nerve supply,93,424,2.71
back,256,1169,2.7
dorsum,256,1169,2.7
neural pathways,67,306,2.7
discipline,214,976,2.7
label,403,1838,2.7
awake,119,544,2.7
wellbutrin,30,137,2.7
early childhood,42,192,2.7
transgenic mice,193,883,2.7
histone acetylation,53,242,2.7
millisecond,34,156,2.69
educational workshop,241,1107,2.69
distress,130,595,2.69
binge drinking,199,914,2.69
child maltreatment,41,188,2.69
childhood maltreatment,41,188,2.69
information dissemination,46,211,2.69
child abuse and neglect,41,188,2.69
neuraxis,301,1380,2.69
episodic drinking,199,914,2.69
msec,34,156,2.69
cellular motility,31,142,2.69
genetics-mutagenesis,72,330,2.69
binge alcohol consumption,199,914,2.69
cohort studies,109,501,2.68
image,749,3448,2.68
psychologist,83,382,2.68
dissection,83,382,2.68
concurrent studies,109,501,2.68
prevention strategy,225,1034,2.68
preventive strategy,225,1034,2.68
translational study,81,373,2.68
emotional,456,2102,2.68
satiation,53,245,2.67
18 year old,44,203,2.67
eighteen year old,44,203,2.67
national institute of drug abuse,1041,4815,2.67
cytochrome p450,67,309,2.67
heterologous transplantation,54,249,2.67
toll-like receptor 4,31,143,2.67
fly,56,259,2.67
flies,56,259,2.67
cell growth,43,199,2.66
circulatory shock,62,287,2.66
circulatory collapse,62,287,2.66
immunologics,36,167,2.66
cellular growth,43,199,2.66
cellular expansion,43,199,2.66
pilot projects,483,2236,2.66
cytoskeleton,45,209,2.66
plasma serum,221,1024,2.66
pilot study,483,2236,2.66
shock,62,288,2.66
neoplastic cell,78,362,2.66
neglect,73,339,2.66
rehabilitation therapy,86,399,2.66
rehabilitative,86,399,2.66
authority,86,398,2.66
phase 2 clinical trials,53,247,2.65
standard treatment,125,582,2.65
cell growth in number,58,270,2.65
epidemiologic investigation,106,494,2.65
standard care,125,582,2.65
cell multiplication,58,270,2.65
cellular proliferation,58,270,2.65
clinical trials design,80,372,2.65
self-help groups,37,172,2.65
brain stem,83,386,2.65
support groups,37,172,2.65
health economics,83,387,2.65
clinical application,84,392,2.64
approaches to prevention,55,257,2.64
xenograft,54,252,2.64
xenograft procedure,54,252,2.64
agreement,95,443,2.64
xenotransplantation,54,252,2.64
inherited factor,68,318,2.64
clinical applicability,84,392,2.64
secondary to,43,201,2.64
advanced age,116,541,2.64
behavioral mechanisms,115,537,2.64
senior citizen,116,541,2.64
geriatric,116,541,2.64
down-regulation,142,664,2.64
elements,463,2162,2.64
genetic risk factor,68,318,2.64
faculty,400,1866,2.64
heterograft,54,252,2.64
mechanisms of behavior and behavior change,115,537,2.64
insurance coverage,30,140,2.64
prototype,149,696,2.64
global health,43,201,2.64
sleep disorders,79,369,2.64
depression symptom,186,870,2.64
neurologic,200,935,2.64
prevention approach,55,257,2.64
dorsal raphe nucleus,33,154,2.64
insurance status,30,140,2.64
pathway interactions,1721,8072,2.63
infection,264,1239,2.63
consult,69,323,2.63
tetraethylthiuram disulfide,46,216,2.63
antabuse,46,216,2.63
phone,190,892,2.63
biosynthesis,44,206,2.63
massachusetts,69,324,2.63
anabolism,44,206,2.63
basal forebrain,32,150,2.63
neurological,200,940,2.62
psychosocial variables,58,273,2.62
fetus,35,165,2.62
combined treatment,95,447,2.62
combined modality treatment,95,447,2.62
telephone,190,896,2.62
psychosocial factor,58,273,2.62
biologic factor,59,278,2.62
multimodal treatment,95,447,2.62
combined modality therapy,95,447,2.62
mass spectrum,113,531,2.62
multimodal therapy,95,447,2.62
immersion,30,141,2.62
computer software,167,786,2.62
interdisciplinary collaboration,36,170,2.61
consultations,107,506,2.61
fire,37,175,2.61
excision,121,572,2.61
thoughts,117,553,2.61
abscission,121,572,2.61
transcript,139,657,2.61
cancer biology,43,203,2.61
withdrawal from alcohol,180,852,2.61
laboratory research,52,246,2.61
neurobiological mechanism,288,1362,2.61
ethanol withdrawal,180,852,2.61
extirpation,121,572,2.61
removal,121,572,2.61
alcohol withdrawal,180,852,2.61
alcohol withdrawal syndrome,180,852,2.61
resection,121,572,2.61
surgical removal,121,572,2.61
nasal passages,37,175,2.61
medical college,209,992,2.6
organismal process,76,361,2.6
behavior change,202,960,2.6
presynaptic nerve endings,84,398,2.6
exposure to,1167,5533,2.6
organism-level process,76,361,2.6
physiological processes,76,361,2.6
physiologic processes,76,361,2.6
effectiveness research,39,185,2.6
medical schools,209,992,2.6
decision making,532,2526,2.6
biologic models,208,992,2.59
in situ hybridization staining method,102,485,2.59
research scientist development award,102,486,2.59
dwi-mri,37,176,2.59
dmri,37,176,2.59
diffusion-weighted magnetic resonance imaging,37,176,2.59
mentored research scientist development award,102,486,2.59
mentored training award,102,486,2.59
motivation,1001,4761,2.59
k01 program,102,486,2.59
health insurance,39,186,2.59
k01 mechanism,102,486,2.59
k01 award,102,486,2.59
interdisciplinary approach,142,676,2.59
multidisciplinary approach,142,676,2.59
esthesia,111,529,2.59
health policy,95,452,2.59
bilateral,63,300,2.59
residence,31,148,2.58
g-proteins,194,926,2.58
categories,159,761,2.58
side effect,612,2920,2.58
liquid,99,474,2.58
alcohol exposed,410,1960,2.58
consensus,96,459,2.58
life experience,38,182,2.58
incarcerated,137,655,2.58
services,800,3818,2.58
alcohol exposure,410,1960,2.58
exposure to alcohol,410,1960,2.58
exposed to alcohol,410,1960,2.58
ethanol exposure,410,1960,2.58
racial and ethnic,100,478,2.58
virus-induced disease,52,249,2.58
guanine nucleotide regulatory proteins,194,926,2.58
guanine nucleotide coupling protein,194,926,2.58
ethanol exposed,410,1960,2.58
gtp-regulatory proteins,194,926,2.58
gtp-binding proteins,194,926,2.58
liquid substance,99,474,2.58
fluid,99,475,2.57
cognitive function abnormal,244,1171,2.57
nutrient,41,197,2.57
renal,39,187,2.57
cognitive decline,244,1171,2.57
cognitive impairment,244,1171,2.57
sensation,111,533,2.57
disturbance in cognition,244,1171,2.57
sight,110,528,2.57
impaired cognition,244,1171,2.57
drug action,94,451,2.57
visual function,110,528,2.57
emergency situation,53,254,2.57
emergencies,53,254,2.57
retrieval,51,245,2.57
cognitive disturbance,244,1171,2.57
cognitive dysfunction,244,1171,2.57
cognitive loss,244,1171,2.57
phenotype,906,4352,2.57
molecular fingerprinting,102,491,2.56
intoxication,141,680,2.56
peer review,130,627,2.56
solid,115,555,2.56
molecular profiling,102,491,2.56
abstinence from alcohol,83,400,2.56
molecular signature,102,491,2.56
outcome study,95,458,2.56
research grants,564,2714,2.56
research and development,175,842,2.56
r&d,175,842,2.56
r & d,175,842,2.56
development and research,175,842,2.56
ethanol abstinence,83,400,2.56
r01 program,564,2714,2.56
r01 mechanism,564,2714,2.56
abstinence from ethanol,83,400,2.56
alcohol abstinence,83,400,2.56
health professional,92,443,2.56
task forces,115,554,2.56
healthcare professional,92,443,2.56
health care professional,92,443,2.56
resistant to drug,68,328,2.56
resistance to drug,68,328,2.56
advisory committees,115,554,2.56
research project grants,564,2714,2.56
abstaining from alcohol,83,400,2.56
abstaining from ethanol,83,400,2.56
systems biology,48,232,2.55
oxygen radicals,38,184,2.55
under age alcohol use,80,387,2.55
alcohol intake among adolescents,80,387,2.55
adolescent alcohol consumption,80,387,2.55
underage alcohol consumption,80,387,2.55
reactive oxygen species,38,184,2.55
teenage alcohol use,80,387,2.55
teenager alcohol use,80,387,2.55
underage alcohol use,80,387,2.55
pro-oxidants,38,184,2.55
under age alcohol consumption,80,387,2.55
gain of function,49,237,2.55
alcohol use during adolescence,80,387,2.55
geographic region,56,271,2.55
geographic locations,56,271,2.55
perceptual stimulus,35,169,2.55
measurable,51,247,2.55
sensory stimulus,35,169,2.55
physicochemical phenomena related to the senses,35,169,2.55
malignant,43,208,2.55
geographic area,56,271,2.55
geographical location,56,271,2.55
active oxygen,38,184,2.55
clinical significance,110,535,2.54
businesses,50,243,2.54
wild type mouse,100,486,2.54
assay,844,4103,2.54
behavioral test,168,816,2.54
drug targeting,243,1181,2.54
clinically significant,110,535,2.54
ethanol metabolism,38,185,2.53
payment,39,190,2.53
health status,72,351,2.53
novel technologies,152,742,2.53
new technology,152,742,2.53
eyeball,38,185,2.53
v-fos fbj murine osteosarcoma viral oncogene homolog,86,419,2.53
c-fos proto-oncogenes,86,419,2.53
level of health,72,351,2.53
pyramidal cells,43,210,2.53
c-fos gene,86,419,2.53
alcohol metabolism,38,185,2.53
c fos,86,419,2.53
protooncogene fos,86,419,2.53
behavioral pharmacology,131,639,2.53
geographic site,56,273,2.53
statistical methods,121,590,2.53
g0s7,86,419,2.53
fos gene,86,419,2.53
brain control,33,161,2.53
social behavior,71,346,2.53
affinity chromatography,35,171,2.52
glutamate translocase,37,181,2.52
glutamate transport glycoprotein,37,181,2.52
emerging adulthood,35,171,2.52
addiction,4553,22270,2.52
bioassay,844,4132,2.52
dna methylation,83,406,2.52
graduate student,96,470,2.52
aging,144,705,2.52
depression,942,4605,2.52
interventions research,134,656,2.52
alcohol related research,186,909,2.52
environment,1057,5164,2.52
diabetes,174,853,2.52
effectiveness,841,4122,2.52
vision,110,538,2.52
diffusion weighted imaging,37,182,2.51
men who have sex with men,33,162,2.51
dwi (diffusion weighted imaging),37,182,2.51
eye,38,187,2.51
industry,105,516,2.51
executive control,221,1086,2.51
age group,93,457,2.51
men who have sex with other men,33,162,2.51
protein family,39,192,2.51
sales,73,359,2.51
neuropsychologic,64,314,2.51
neurobehavioral,183,899,2.51
neuropsychologies,64,314,2.51
brachydanio rerio,35,172,2.51
danio rerio,35,172,2.51
zebra danio,35,172,2.51
zebra fish,35,172,2.51
thickness,34,167,2.51
thick,34,167,2.51
neoplasm progression,52,257,2.5
cost effective,232,1143,2.5
ethanol relapse,100,493,2.5
alcohol relapse,100,493,2.5
tumor progression,52,257,2.5
neoplastic progression,52,257,2.5
workshop,241,1189,2.5
cancer progression,52,257,2.5
cognitive behavioral treatment,171,843,2.5
patch clamp,189,931,2.5
inpatients,189,934,2.5
specific qualifier value,175,863,2.5
specified,175,863,2.5
locus coeruleus,59,291,2.5
congresses,30,148,2.5
genetic risk,100,494,2.5
executive function,221,1092,2.5
cell culture,85,420,2.5
site-specific mutagenesis,43,212,2.5
targeted dna modification,43,212,2.5
targeted modification,43,212,2.5
homeless,80,394,2.5
morphine addiction,31,153,2.5
cell culture techniques,85,420,2.5
morphine dependence,31,153,2.5
metabolism,297,1471,2.49
salivary,43,213,2.49
clinical investigator,57,282,2.49
cell proliferation,58,287,2.49
synapse function,118,585,2.49
synaptic function,118,585,2.49
4-amino-butanoic acid,286,1419,2.49
member,586,2900,2.49
cellline,216,1070,2.49
cultured cell line,216,1070,2.49
host response,91,450,2.49
prefrontal cortex,714,3531,2.49
prematurity,105,521,2.49
immunoresponse,91,450,2.49
south carolina,44,219,2.48
centers for disease control,158,786,2.48
centers for disease control and prevention (u.s.),158,786,2.48
immunoregulation,31,154,2.48
united states centers for disease control,158,786,2.48
research design,456,2265,2.48
drug resistant,68,338,2.48
reward processing,202,1004,2.48
study type,456,2265,2.48
study design,456,2265,2.48
sedative,60,298,2.48
united states centers for disease control and prevention,158,786,2.48
centers for disease control and prevention,158,786,2.48
diacetylmorphine,368,1831,2.48
multi-site clinical trial,58,289,2.48
structure-activity relationship,93,463,2.48
multi-center clinical trial,58,289,2.48
multi-institutional clinical trial,58,289,2.48
structure function relationship,93,463,2.48
late life,109,541,2.48
diamorphine,368,1831,2.48
cellular immune function,45,225,2.47
mrna expression,90,450,2.47
actins,45,225,2.47
disease prevention,65,324,2.47
disorder prevention,65,324,2.47
premature,105,525,2.47
immune response,91,455,2.47
heart rate,101,504,2.47
innervation,93,464,2.47
human disease,109,544,2.47
emerging adult,84,420,2.47
glucocorticoids,44,220,2.47
savings,44,220,2.47
tail,74,369,2.47
early adulthood,84,420,2.47
neurontin,37,185,2.47
immunologic,36,180,2.47
oncogenesis,64,319,2.47
healthcare service availability,70,349,2.47
tumorigenesis,64,319,2.47
rewards,1719,8580,2.47
symposium,317,1586,2.47
central nervous system,301,1504,2.47
ngs system,48,241,2.46
next gen sequencing,48,241,2.46
addiction to methamphetamine,48,241,2.46
generations,442,2217,2.46
universities,970,4869,2.46
longitudinal design,63,316,2.46
ngs method,48,241,2.46
human immunodeficiency virus type 1,67,336,2.46
willingness,76,381,2.46
nextgen sequencing,48,241,2.46
inhibitor,487,2444,2.46
regulatory gene,66,331,2.46
evidence based practice,120,602,2.46
cancer genes,76,382,2.45
mr imaging,250,1260,2.45
natural products,60,302,2.45
non-drug,108,543,2.45
amentia,57,287,2.45
mr tomography,250,1260,2.45
conference,317,1594,2.45
nondrug,108,543,2.45
magnetic resonance / nuclear magnetic resonance,250,1260,2.45
cancer-promoting gene,76,382,2.45
neural patterning,33,166,2.45
measurement,578,2909,2.45
source,535,2692,2.45
nmr imaging,250,1260,2.45
nmr tomography,250,1260,2.45
nuclear magnetic resonance imaging,250,1260,2.45
transforming genes,76,382,2.45
zeugmatography,250,1260,2.45
intervention efficacy,290,1463,2.44
treatment efficacy,290,1463,2.44
surface proteins,51,258,2.44
membrane-associated proteins,51,258,2.44
training programs,265,1341,2.44
self efficacy,209,1056,2.44
steroid compound,35,177,2.44
therapeutic efficacy,290,1463,2.44
training support,55,278,2.44
genetic technics,41,207,2.44
national institute on alcohol abuse and alcoholism,339,1713,2.44
slice,435,2197,2.44
therapy efficacy,290,1463,2.44
ethnic group,90,456,2.43
laws,86,436,2.43
central lobe,111,563,2.43
insula,111,563,2.43
insula of reil,111,563,2.43
island of reil,111,563,2.43
drug seeking behavior,297,1510,2.43
logistic regressions,38,193,2.43
brain attack,95,483,2.43
cerebral vascular accident,95,483,2.43
mission,420,2133,2.43
instrumental learning,52,264,2.43
instrumental conditioning,52,264,2.43
flow cytometry,44,223,2.43
apoplexy,95,483,2.43
cerebral stroke,95,483,2.43
cerebrovascular accident,95,483,2.43
cerebrovascular stroke,95,483,2.43
cerebrovascular apoplexy,95,483,2.43
human t-lymphotropic virus type iii infections,223,1133,2.43
type ii diabetes mellitus,35,178,2.43
slow-onset diabetes mellitus,35,178,2.43
type ii dm,35,178,2.43
type 2 dm,35,178,2.43
ketosis-resistant diabetes mellitus,35,178,2.43
non-insulin-dependent diabetes mellitus,35,178,2.43
adult-onset diabetes mellitus,35,178,2.43
stable diabetes mellitus,35,178,2.43
t2 dm,35,178,2.43
type 2 diabetes mellitus,35,178,2.43
metabolic processes,281,1435,2.42
withdrawal,809,4123,2.42
influentials,59,301,2.42
medical records,33,168,2.42
pill,49,250,2.42
efficacy trial,89,453,2.42
records,119,607,2.42
household,62,316,2.42
chromatin remodeling,31,158,2.42
treatment development,405,2065,2.42
therapy development,405,2065,2.42
intervention development,405,2065,2.42
estradiol,46,234,2.42
classical conditioning,134,683,2.42
intermediary metabolism,281,1435,2.42
progesterone,41,210,2.41
anticancer therapy,81,415,2.41
drug resistance,68,348,2.41
informatics,66,338,2.41
inhaling,97,497,2.41
life course,56,287,2.41
life cycle stages,56,287,2.41
outpatient care,65,332,2.41
international,299,1530,2.41
nucleotides,40,205,2.41
smoking cessation intervention,156,798,2.41
saccharose,131,671,2.41
stressor,229,1177,2.4
north carolina,45,231,2.4
hypothalamic structure,212,1088,2.4
psychologic,374,1920,2.4
pharmacodynamics,90,462,2.4
healthcare personnel,296,1523,2.4
inhalation,97,498,2.4
health care worker,296,1523,2.4
treatment provider,296,1523,2.4
parents,325,1669,2.4
medical personnel,296,1523,2.4
animal model,999,5134,2.4
hypothalamic,212,1088,2.4
healthcare providers,296,1523,2.4
stroke,95,489,2.4
healthcare worker,296,1523,2.4
animal models and related studies,999,5134,2.4
treatment protocols,107,550,2.4
health provider,296,1523,2.4
health personnel,296,1523,2.4
health care providers,296,1523,2.4
social support,154,792,2.4
working group,34,175,2.4
elderly,116,598,2.39
college,204,1054,2.39
falls,133,687,2.39
theories,549,2830,2.39
review literature,33,170,2.39
gabapentin,37,191,2.39
older person,105,541,2.39
complement proteins,373,1933,2.38
proteins growth factors,32,166,2.38
admission activity,122,633,2.38
hour,355,1842,2.38
exercise,120,622,2.38
immune system,70,362,2.38
complement,373,1936,2.38
pharmaceutical agent,186,962,2.38
brain region,1048,5441,2.38
stress,1110,5751,2.38
pharmaceuticals,186,962,2.38
pharmacological substance,186,962,2.38
cancer prevention,33,171,2.38
seizures,72,373,2.38
alcohol related cue,79,409,2.38
production,298,1547,2.38
admission,122,633,2.38
pharmacologic substance,186,962,2.38
clinical psychology,32,166,2.38
health care personnel,296,1533,2.38
kinase inhibitor,34,176,2.38
cell movement,31,161,2.37
major depressive disorder,131,682,2.37
half-life,75,390,2.37
cellular migration,31,161,2.37
california,131,681,2.37
length of life,124,644,2.37
longevity,124,646,2.37
maryland,41,213,2.37
necrocytosis,80,417,2.37
cell motility,31,161,2.37
kidney,39,203,2.37
heterosexuals,36,187,2.37
healthcare utilization,90,469,2.37
healthcare service utilization,90,469,2.37
health care utilization,90,469,2.37
zebrafish,35,182,2.37
cell locomotion,31,161,2.37
metabolic pathway,37,193,2.36
post-translational protein processing,53,277,2.36
drug testing,72,376,2.36
post-translational modification protein/amino acid biochemistry,53,277,2.36
posttranslational protein processing,53,277,2.36
sugar,32,167,2.36
l-serine,32,167,2.36
membrane,253,1324,2.36
chronic disease,193,1008,2.36
neighborhoods,96,501,2.36
chronic disorder,193,1008,2.36
chronic illness,193,1008,2.36
post-translational protein modification,53,277,2.36
hcrts/orxs,65,341,2.35
psychiatry,234,1228,2.35
hcrt protein,65,341,2.35
hypocretin,65,341,2.35
hcrt/orx,65,341,2.35
hypocretin/orexin,65,341,2.35
hypocretins/orexins,65,341,2.35
imprisonment,137,719,2.35
informal social control,71,372,2.35
viral infection,52,273,2.35
new england,36,189,2.35
northeastern united states,36,189,2.35
web site,106,557,2.35
physiologic,880,4620,2.35
dorsal,313,1640,2.35
physicians,314,1645,2.35
oncogenes,76,399,2.35
reagent,94,493,2.35
virus diseases,52,273,2.35
viral diseases,52,273,2.35
website,106,557,2.35
incarceration,137,719,2.35
odors,48,252,2.35
virus infection,52,273,2.35
affective disorders,192,1006,2.35
nursing,48,252,2.35
treatment strategy,411,2154,2.35
preparation,391,2060,2.34
followed up,650,3429,2.34
spinal column,119,626,2.34
spine,119,626,2.34
vertebral column,119,626,2.34
backbone,119,626,2.34
blood specimen,67,353,2.34
serine,32,169,2.34
statutes and laws,45,237,2.34
pediatrics,42,221,2.34
neurobiological,905,4776,2.34
affective,300,1579,2.34
epidemiologic,251,1325,2.34
blood sample,67,353,2.34
physiological,880,4640,2.34
follow up,650,3429,2.34
posters,61,322,2.34
adrenergic receptor,47,248,2.34
plants,49,258,2.34
regimen,185,981,2.33
mass spectrometry,113,598,2.33
distal,79,419,2.33
blood plasma,221,1172,2.33
cns disorder,54,286,2.33
early identification,43,228,2.33
stress response,171,906,2.33
central nervous system diseases,54,286,2.33
neurotransmitter release,98,519,2.33
cns diseases,54,286,2.33
model system,208,1102,2.33
pre-doc,77,408,2.33
life cycle,56,296,2.33
pre-doctoral,77,408,2.33
psychological,374,1976,2.33
predoctoral,77,408,2.33
biological adaptation to stress,171,906,2.33
youth 10-21,367,1943,2.33
youth,367,1943,2.33
crisis,171,906,2.33
disulfiram,46,243,2.33
perception,260,1375,2.33
cross-sectional survey,50,266,2.32
alcohol drinking,1149,6109,2.32
noninsulin dependent diabetes mellitus,35,186,2.32
cross-sectional analyses,50,266,2.32
blood vessels,49,260,2.32
disease frequency surveys,50,266,2.32
legislation,45,239,2.32
urban area,44,234,2.32
alcohol ingestion,1149,6109,2.32
noradrenergic,68,361,2.32
cross-sectional studies,50,266,2.32
cross sectional analysis,50,266,2.32
microscopy,110,585,2.32
ethanol use,1149,6109,2.32
alcoholic drink intake,1149,6109,2.32
ethanol drinking,1149,6109,2.32
alcohol consumption,1149,6110,2.32
ethanol product use,1149,6109,2.32
field study,44,234,2.32
ethanol consumption,1149,6109,2.32
abnormal psychology,225,1194,2.32
alcohol use,1149,6109,2.32
alcohol product use,1149,6109,2.32
cb1 receptor,116,616,2.32
cb1,116,616,2.32
government,78,414,2.32
ethanol ingestion,1149,6109,2.32
dysphoria,52,277,2.32
etoh drinking,1149,6109,2.32
ethanol intake,1149,6109,2.32
alcohol intake,1149,6109,2.32
etoh use,1149,6109,2.32
chemicals,403,2148,2.31
presynaptic terminals,84,448,2.31
nerve impulse transmission,377,2013,2.31
characteristics,835,4460,2.31
t2d,35,187,2.31
t2dm,35,187,2.31
randomisation,930,4959,2.31
failure,241,1285,2.31
maturity onset diabetes,35,187,2.31
ketosis resistant diabetes,35,187,2.31
adult onset diabetes,35,187,2.31
synaptic boutons,84,448,2.31
type 2 diabetes,35,187,2.31
synaptic terminals,84,448,2.31
orexin,65,347,2.31
type ii diabetes,35,187,2.31
nerve transmission,377,2013,2.31
axon terminals,84,448,2.31
niddm,35,187,2.31
neurotransmission,377,2013,2.31
youth drinking,80,428,2.31
adolescent alcohol use,80,428,2.31
maturity-onset diabetes mellitus,35,187,2.31
designer drugs,30,160,2.31
adolescent drinking,80,428,2.31
teen drinking,80,428,2.31
randomly assigned,930,4959,2.31
non-insulin dependent diabetes,35,187,2.31
randomization,930,4959,2.31
teenage drinking,80,428,2.31
underage drinking,80,428,2.31
customized drugs,30,160,2.31
neuronal transmission,377,2013,2.31
inbreeding,32,171,2.31
excessive alcohol intake,415,2222,2.3
extreme drinking,415,2222,2.3
neurophysiology,249,1336,2.3
excessive ethanol ingestion,415,2222,2.3
stria terminalis nucleus,79,423,2.3
excessive drinking,415,2222,2.3
nalorex,236,1267,2.3
heavy alcohol use,415,2222,2.3
heavy drinking,415,2222,2.3
high prevalence,187,1004,2.3
nemexin,236,1267,2.3
drink heavily,415,2222,2.3
bed nucleus of stria terminalis,79,423,2.3
depressive symptoms,186,996,2.3
excessive alcohol ingestion,415,2222,2.3
excessive alcohol consumption,415,2222,2.3
central nervous system disorders,54,290,2.3
recording of previous events,707,3798,2.3
fats,44,236,2.3
fatty acid glycerol esters,44,236,2.3
emotional depression,186,996,2.3
structure of terminal stria nuclei of preoptic region,79,423,2.3
placebo effect,30,161,2.3
membrane structure,253,1359,2.3
mammalia,88,471,2.3
nocebo,30,161,2.3
expectation effect,30,161,2.3
expectancy effect,30,161,2.3
emotions,224,1199,2.3
research projects,564,3028,2.3
biological systems,37,198,2.3
placebo response,30,161,2.3
revia,236,1267,2.3
epidemiological studies,106,572,2.29
health care costs,170,916,2.29
circulatory system,139,749,2.29
language,71,382,2.29
cardiovascular system,139,749,2.29
healthcare costs,170,916,2.29
applications grants,207,1117,2.29
health costs,170,916,2.29
epidemiology research,106,572,2.29
epidemiologic research,106,572,2.29
genetic techniques,41,221,2.29
epidemiologic studies,106,572,2.29
diabetes mellitus,174,936,2.29
cardiovascular body system,139,749,2.29
blood serum,97,523,2.29
respiratory system,45,242,2.29
adult youth,353,1903,2.29
cognitive psychotherapy,171,925,2.28
educational curriculum,130,702,2.28
camp,103,556,2.28
adenosine cyclic monophosphate,103,556,2.28
disinhibition,81,439,2.28
genetic variant,170,918,2.28
adenosine cyclic 3',103,556,2.28
depressive,186,1008,2.28
cognition therapy,171,925,2.28
methadone maintenance,71,384,2.28
qtl,74,400,2.28
equipment and supply inventories,52,281,2.28
3'5'-cyclic ester of amp,103,556,2.28
adenosine 3'5' monophosphate,103,556,2.28
exhibits,739,4005,2.28
inventory,52,281,2.28
social cognitive theory,32,174,2.27
health care availability,70,380,2.27
health care service access,70,380,2.27
drug craving,164,893,2.27
locomotion,89,483,2.27
up-regulation,199,1080,2.27
healthcare service access,70,380,2.27
synapse,748,4068,2.27
drug screening,79,429,2.27
social learning theory,32,174,2.27
rats mammals,1063,5766,2.27
accessibility of health care,70,380,2.27
access to healthcare,70,380,2.27
comparative,99,539,2.27
steroids,35,190,2.27
access to health care,70,380,2.27
prevent drug use,83,451,2.27
prevent drug abuse,83,451,2.27
naloxone,225,1223,2.27
high blood pressure,68,371,2.26
normal cell,35,191,2.26
functional disability,47,257,2.26
patient self-report,509,2782,2.26
gs,48,262,2.26
core facility,37,202,2.26
g(s),48,262,2.26
elders,99,541,2.26
syndrome,131,716,2.26
molecular target,161,880,2.26
self-report,509,2782,2.26
meta-analysis,107,584,2.26
physical dependence,79,431,2.26
later life,99,541,2.26
small interfering rna,60,327,2.26
attenuated,573,3132,2.26
metropolitan,47,257,2.26
ethanol research,186,1013,2.26
alcohol research,186,1013,2.26
epilepsia,127,697,2.25
receptor activation,242,1325,2.25
early intervention,86,472,2.25
coding system,249,1363,2.25
self help organization,37,203,2.25
criminal justice,121,664,2.25
biological factors,59,324,2.25
epileptogenic,127,697,2.25
intervention design,189,1036,2.25
therapy design,189,1036,2.25
ethanol craving,112,614,2.25
epileptics,127,697,2.25
treatment design,189,1036,2.25
epileptic seizures,127,697,2.25
code,249,1363,2.25
alcohol craving,112,614,2.25
ventral tegmental area,426,2342,2.24
negotiation,166,914,2.24
negotiating,166,914,2.24
chicago,32,176,2.24
ventral tegmentum,426,2342,2.24
achievement attainment,93,511,2.24
trend,206,1132,2.24
reaction,484,2666,2.24
doubt,83,456,2.24
seizure disorder,127,700,2.24
self administration,958,5275,2.24
uncertainty,83,456,2.24
country,293,1613,2.24
mediation,166,914,2.24
mood disorders,192,1056,2.24
health services evaluation,121,668,2.23
amygdaloid body,556,3071,2.23
amygdaloid nucleus,556,3071,2.23
knock-out mice,242,1339,2.23
psychopathology,225,1244,2.23
health services research,121,668,2.23
data bases,261,1442,2.23
time use,62,343,2.23
knockout mice,242,1339,2.23
lectures,60,332,2.23
medical care research,121,668,2.23
amygdaloid structure,556,3071,2.23
amygdaloid nuclear complex,556,3071,2.23
intervention studies,134,741,2.23
services research,121,668,2.23
intervention research,134,741,2.23
synaptic plasticity,329,1821,2.23
neurobiology,905,5014,2.23
hiv1,67,371,2.23
hiv-i,67,371,2.23
friends,89,493,2.23
medication adherence,101,559,2.23
hiv-1,67,371,2.23
noise,50,277,2.23
medication compliance,101,559,2.23
subcellular process,164,911,2.22
knockout,244,1355,2.22
cell process,164,911,2.22
cell function,164,911,2.22
cellular process,164,911,2.22
cellular function,164,911,2.22
cellular physiology,164,911,2.22
primary care setting,82,455,2.22
oxides,32,178,2.22
knock-out,244,1355,2.22
cell physiology,164,911,2.22
sucrose,131,728,2.22
school of medicine,209,1162,2.22
midbrain structure,221,1230,2.22
instructional intervention,48,267,2.22
training intervention,48,267,2.22
doctor of philosophy,213,1186,2.22
questionnaires,229,1275,2.22
ph.d.,213,1186,2.22
investigation,874,4845,2.22
phd,213,1186,2.22
imaging modality,73,406,2.22
ethnic minority population,59,328,2.22
imaging method,73,406,2.22
conformation,107,595,2.22
instruction intervention,48,267,2.22
educational intervention,48,267,2.22
midbrain,221,1230,2.22
education for intervention,48,267,2.22
mid-brain,221,1230,2.22
anterior,238,1322,2.22
drug detection,72,402,2.21
neuroplasticity,237,1324,2.21
brief treatment,97,541,2.21
mediator,468,2607,2.21
neuronal plasticity,237,1324,2.21
self regulation,71,396,2.21
cns plasticity,237,1324,2.21
brief therapy,97,541,2.21
membrane proteins,51,284,2.21
insurance,52,290,2.21
behavioral control,172,959,2.21
health care policy,95,529,2.21
behavioral manipulation,172,959,2.21
behavior control,172,959,2.21
transcription regulation,70,393,2.2
indiana,47,263,2.2
biotechnology,31,174,2.2
life style,72,404,2.2
injecting drug user,90,504,2.2
alcohols,1375,7722,2.2
transcriptional regulation,70,393,2.2
adenosine,136,764,2.2
injection drug user,90,504,2.2
4-aminobutanoic acid,286,1614,2.19
enzymes,315,1776,2.19
4-aminobutyric acid,286,1614,2.19
electronics,73,411,2.19
cell line,216,1219,2.19
saline,149,841,2.19
saline solution,149,840,2.19
trial treatment,134,753,2.19
therapeutic estrogen,45,253,2.19
aminalone,286,1614,2.19
trial regimen,134,753,2.19
psychiatric care,43,242,2.19
psychiatric therapeutic procedure,43,242,2.19
gaba,286,1614,2.19
gene expression,641,3604,2.19
cognitive function,240,1352,2.19
psychiatric treatment,43,242,2.19
aminalon,286,1614,2.19
psychiatric therapy,43,242,2.19
psychosocial,327,1847,2.18
alcoholic beverage consumption,1149,6487,2.18
epidemiological,251,1417,2.18
biological models,208,1178,2.18
ligands,469,2651,2.18
at-risk drinking,48,271,2.18
plasma,442,2503,2.18
extinction,256,1448,2.18
achievement,93,526,2.18
diffusion,74,419,2.18
texas,73,413,2.18
risky drinking,48,271,2.18
5-hydroxytryptamine receptors,34,192,2.18
high risk drinking,48,271,2.18
research institute,102,578,2.18
5-ht receptors,34,192,2.18
oral administration,44,249,2.18
epilepsy,127,722,2.17
htlv-iii-lav infections,223,1268,2.17
alcohol cue,79,450,2.17
oregon,53,301,2.17
ethanol cue,79,450,2.17
blinded,32,182,2.17
k23 award,76,431,2.17
cannabinergic,57,324,2.17
prevention service,48,273,2.17
htlv-iii infections,223,1268,2.17
cannabinoidergic,57,324,2.17
synaptic,748,4251,2.17
text,88,503,2.16
neurophysiology - biologic function,58,331,2.16
price,60,343,2.16
glutamatergic,605,3459,2.16
functional outcomes,44,251,2.16
pricing,60,343,2.16
drug exposure,176,1003,2.16
movement,155,883,2.16
l-glutamate,605,3459,2.16
neural function,58,331,2.16
transgenic organisms,185,1058,2.16
ion channel,130,743,2.16
minnesota,53,302,2.16
ionic channels,130,743,2.16
blood,264,1504,2.16
basic science,273,1567,2.15
basic research,273,1567,2.15
genetic alteration,292,1673,2.15
pulmonary cancer,97,556,2.15
genetic change,292,1673,2.15
intention,75,431,2.15
genetic defect,292,1673,2.15
upregulation,199,1142,2.15
malignant tumor of the lung,97,556,2.15
malignant neoplasm of lung,97,556,2.15
genome mutation,292,1673,2.15
neural adaptation,268,1538,2.15
clinical treatment,134,770,2.15
censuses,40,229,2.15
pulmonary malignant neoplasm,97,556,2.15
lung cancer,97,556,2.15
indexing,350,2005,2.15
neuroadaptation,268,1538,2.15
ethanol effect,333,1913,2.15
alcohol effect,333,1913,2.15
human genetics,65,373,2.15
response to stimulus physiology,32,184,2.14
mutation,292,1679,2.14
stimulus/response,32,184,2.14
associative learning,134,773,2.14
armed forces personnel,66,380,2.14
military,66,380,2.14
research into practice,32,184,2.14
research to practice,32,184,2.14
washington,102,587,2.14
nature,613,3534,2.14
pavlovian conditioning,134,773,2.14
estrogens,45,259,2.14
instrumentation,38,219,2.14
adopted,206,1187,2.14
potassium ion channels,38,219,2.14
environmental factor,224,1292,2.14
environmental risk factor,224,1292,2.14
environmental risk,224,1292,2.14
resting potentials,30,174,2.13
primary care,259,1500,2.13
military personnel,66,382,2.13
neurocognitive,163,942,2.13
relapse,1329,7705,2.13
low income,86,497,2.13
infusion procedures,209,1212,2.13
gamma-aminobutyric acid,286,1654,2.13
role model,34,197,2.13
stimulus,716,4137,2.13
hypothalamus,212,1229,2.13
infusion,209,1212,2.13
fluorescence,107,620,2.13
transmembrane potentials,30,174,2.13
hcv,78,451,2.13
serum,318,1850,2.12
cues,775,4506,2.12
nerve degeneration,110,641,2.12
advertising,43,250,2.12
major depression,131,761,2.12
behavioral influence,83,483,2.12
behavior influence,83,483,2.12
intake,364,2115,2.12
neuronal degeneration,110,641,2.12
neurodegenerative,110,641,2.12
neurodegeneration,110,641,2.12
neuron degeneration,110,641,2.12
life,799,4648,2.12
contingency management,100,582,2.12
post-translational modifications,53,308,2.12
gonadal steroid hormones,37,215,2.12
sex steroid hormones,37,215,2.12
medical imaging,252,1467,2.12
gonadal steroids,37,215,2.12
quality assurance,31,180,2.12
transcription factor,223,1297,2.12
genome,169,983,2.12
tobacco consumption,382,2222,2.12
tobacco use,382,2222,2.12
sex steroid,37,215,2.12
memory process,53,310,2.11
psychotic illness,31,181,2.11
drug therapy,685,4007,2.11
5'-monophosphate,103,601,2.11
cyclic 3',103,601,2.11
blood pressure,79,461,2.11
body movement,155,904,2.11
attenuation,96,562,2.11
pharmacotherapy,685,4005,2.11
5'-(hydrogen phosphate),103,601,2.11
alzheimer type dementia,158,924,2.11
glutamate transporter,37,216,2.11
basal nuclei,113,659,2.11
synapses,748,4374,2.11
ligand binding protein,68,397,2.11
glutamates,605,3535,2.11
side,85,497,2.11
quantitative trait loci,74,432,2.11
psychopharmaceuticals,52,306,2.1
women's health,53,311,2.1
psychoactive agents,52,306,2.1
psychoactive drugs,52,306,2.1
motivational processes,33,194,2.1
sirna,60,352,2.1
psychoactive compound,52,306,2.1
cell viability,58,343,2.09
neuropeptides,234,1380,2.09
belief,132,779,2.09
charge,69,408,2.09
residual state,30,177,2.09
cell survival,58,343,2.09
mentored patient-oriented research career development award (k23),76,448,2.09
social,818,4819,2.09
k23 mechanism,76,448,2.09
hedonic,80,472,2.09
operation,144,849,2.09
dna molecular biology,80,471,2.09
mentored patient-oriented research career development award,76,448,2.09
k23 program,76,448,2.09
diffuse,40,236,2.09
analog,273,1615,2.08
cigarette smoker,97,576,2.08
action potentials,85,503,2.08
tobacco use cessation,81,481,2.08
tobacco,566,3363,2.08
develop software,35,208,2.08
developing computer software,35,208,2.08
software development,35,208,2.08
probability,222,1315,2.08
residual,30,178,2.08
health sciences,90,534,2.08
tobacco cessation,81,481,2.08
substantia grisea,50,297,2.08
mutagenesis,72,429,2.07
and referral to treatment,43,256,2.07
non-human primate,158,940,2.07
food intake,116,690,2.07
striatal,606,3604,2.07
nonhuman primate,158,940,2.07
risk perception,30,179,2.07
striate body,606,3604,2.07
deoxyribonucleic acid,216,1288,2.07
referral,43,256,2.07
corpus striatum structure,606,3604,2.07
sbirt,43,256,2.07
mesencephalon,221,1314,2.07
and treatment,43,256,2.07
rehabilitation,86,515,2.06
in vitro assay,43,257,2.06
promotor,178,1067,2.06
functional imaging,56,335,2.06
promoter,178,1067,2.06
physiologic imaging,56,335,2.06
cell migration,31,186,2.06
population based,72,432,2.06
cell death,80,478,2.06
histones,68,407,2.06
adolescent development,31,186,2.06
peptides,228,1367,2.06
reinforcement,409,2447,2.06
biological chemistry,69,415,2.05
prevention research,55,331,2.05
nuclear,73,439,2.05
immune function,45,271,2.05
total human and non-human gene mapping,38,229,2.05
membrane channels,130,782,2.05
neural degeneration,110,661,2.05
gene mapping genetics,38,229,2.05
hepatitis c virus,78,469,2.05
medical,973,5864,2.05
lifestyle,72,434,2.05
drinking,640,3854,2.05
viewpoint,43,260,2.04
commentary,43,260,2.04
editorial comment,43,260,2.04
published comment,43,260,2.04
comment,43,260,2.04
college student,85,515,2.04
research training,332,2003,2.04
methylation,73,441,2.04
coupling,129,779,2.04
motility,30,181,2.04
gray matter,50,302,2.04
adolescence,338,2054,2.03
12-20 years old,338,2054,2.03
curriculum,130,789,2.03
amygdala,556,3371,2.03
ingestion,44,267,2.03
next generation sequencing,48,292,2.03
pulse,71,432,2.03
physiologic pulse,71,432,2.03
vascular hypertensive disease,68,415,2.02
hypertensive disease,68,415,2.02
hyperpiesis,68,415,2.02
hyperpiesia,68,415,2.02
growth agents,32,195,2.02
drug metabolic detoxication,77,470,2.02
vascular hypertensive disorder,68,415,2.02
growth substances,32,195,2.02
drug metabolic detoxification,77,470,2.02
physical activity,53,324,2.02
drug relapse,148,903,2.02
food,298,1816,2.02
economics,265,1614,2.02
europe,37,226,2.02
boston,60,369,2.01
b-lymphocytes,30,184,2.01
striatum,606,3710,2.01
transmission process,544,3336,2.01
short hairpin rna,81,498,2.01
small hairpin rna,81,498,2.01
drinking behavior,191,1170,2.01
virus-hiv,523,3210,2.01
economic cost,74,453,2.01
lymphadenopathy-associated virus,523,3210,2.01
lav-htlv-iii,523,3210,2.01
human immunodeficiency viruses,523,3210,2.01
protein expression,134,822,2.01
post treatment,229,1402,2.01
transmission,544,3342,2.01
rattus,1063,6528,2.01
molecular interaction,652,4010,2.01
b-cells,30,184,2.01
shrna,81,498,2.01
imaging technics,105,644,2.01
aids virus,523,3210,2.01
b blood cells,30,184,2.01
l-lysine,31,190,2.01
brief intervention,183,1121,2.01
acquired immunodeficiency syndrome virus,523,3210,2.01
acquired immune deficiency syndrome virus,523,3210,2.01
common rat strains,1063,6528,2.01
methadone,339,2088,2.0
health care service availability,70,431,2.0
hiv,523,3232,2.0
histone modification,47,290,2.0
binding,652,4011,2.0
attitude,180,1110,2.0
reticuloendothelial system,221,1361,2.0
presynaptic,206,1269,2.0
nervous system degenerative diseases,97,599,2.0
imaging technology,33,204,2.0
subgroup,214,1319,2.0
treatment outcome,420,2588,2.0
computerized medical record,36,223,1.99
functional mri,358,2215,1.99
procedures,628,3891,1.99
biochemical,431,2668,1.99
null mouse,242,1502,1.99
physiologic psychology,50,310,1.99
trial comparing,81,501,1.99
physiological psychology,50,310,1.99
target populations,67,415,1.99
immediate-early genes,49,304,1.99
out of work,46,287,1.98
synaptic transmission,209,1305,1.98
joblessness,46,287,1.98
unemployed,46,287,1.98
dna,216,1345,1.98
cellular biology,64,398,1.98
new york,85,530,1.98
jobs,59,367,1.98
group intervention,45,281,1.98
restoration,53,330,1.98
transgenic,185,1151,1.98
cardiovascular,139,866,1.98
youth substance use,81,504,1.98
adolescent substance use,81,504,1.98
unemployment,46,287,1.98
jobless,46,287,1.98
sobriety,50,313,1.97
da neuron,353,2213,1.97
viral burden,59,369,1.97
viral load result,59,369,1.97
sober,50,313,1.97
viral load,59,369,1.97
dopamine neuron,353,2213,1.97
dopaminergic neuron,353,2213,1.97
family member,98,613,1.97
alcohol intoxication,59,370,1.97
grant proposals,207,1297,1.97
racial group,172,1075,1.97
lysine,31,194,1.97
electronic,69,432,1.97
property,1020,6397,1.97
food or food product,120,752,1.97
sex hormones,37,232,1.97
ethanol intoxication,59,370,1.97
drunkenness,59,370,1.97
etoh intoxication,59,370,1.97
compulsive behavior,46,290,1.96
hydrogen oxide,95,598,1.96
reinforcement schedule,47,295,1.96
heart diseases,71,447,1.96
cardiac disorders,71,447,1.96
cardiac diseases,71,447,1.96
surface,152,955,1.96
balance function,239,1515,1.95
trait,256,1619,1.95
randomized trial,176,1114,1.95
water,95,600,1.95
heart disorder,71,448,1.95
alcoholic intoxication,59,373,1.95
equilibrium,239,1515,1.95
posttranslational modifications,53,336,1.95
ethyl alcohol,339,2148,1.95
pharmacological treatment,210,1329,1.95
oxidative stress,63,398,1.95
basal ganglia,113,716,1.95
growth factor,32,203,1.94
balance,239,1519,1.94
ethanol dependence,104,661,1.94
cingulate cortex,118,750,1.94
corpus striatum,606,3847,1.94
choice behavior,50,318,1.94
university student,85,539,1.94
ethanol addiction,104,661,1.94
ethanol dependency,104,661,1.94
electronic medical record,36,229,1.94
craving,731,4640,1.94
receptor protein,1056,6729,1.94
longitudinal studies,217,1389,1.93
men,300,1913,1.93
supervision,118,754,1.93
abstinence,866,5540,1.93
proteins,812,5193,1.93
long-term study,217,1389,1.93
pharmacokinetics,336,2146,1.93
social support network,154,984,1.93
signal pathway,330,2114,1.93
primates mammals,84,536,1.93
intracranial central nervous system disorders,147,938,1.93
morphine,455,2911,1.93
interest,994,6359,1.93
comparative efficacy,55,352,1.93
compare efficacy,55,352,1.93
encephalon diseases,147,938,1.93
brain diseases,147,938,1.93
intracranial cns disorders,147,938,1.93
research proposals,123,785,1.93
protein modification,53,339,1.93
opiate peptides,60,385,1.92
neurosciences research,82,528,1.92
cytoplasmic membrane,113,727,1.92
plasma membrane,113,727,1.92
plasmalemma,113,727,1.92
brain disorders,147,942,1.92
opioid peptide,60,385,1.92
occupations,59,379,1.92
knock-in,48,309,1.92
desensitization,86,553,1.92
protein complex,43,276,1.92
binding proteins,68,437,1.92
endogenous cannabinoids,112,721,1.92
aids prevention,106,682,1.92
hiv prevention,106,682,1.92
hiv/aids prevention,106,682,1.92
manuals,152,975,1.92
pennsylvania,58,374,1.91
pharmacophore,40,258,1.91
world health organization,40,258,1.91
behavioral research,45,291,1.91
corticotropin releasing hormone,100,645,1.91
arousal,120,773,1.91
corticotropin-releasing hormone-41,100,645,1.91
corticotropin-releasing factor-41,100,645,1.91
corticotropin-releasing factor,100,645,1.91
corticoliberin,100,645,1.91
crf-41,100,645,1.91
acth-releasing factor,100,645,1.91
protein binding,68,439,1.91
rna,208,1345,1.91
social network,86,554,1.91
alzheimer sclerosis,158,1027,1.9
alzheimer syndrome,158,1027,1.9
alzheimers dementia,158,1027,1.9
primary senile degenerative dementia,158,1027,1.9
primary degenerative dementia,158,1027,1.9
nucleus accumbens,811,5257,1.9
cell biology,64,415,1.9
jail,45,292,1.9
employment,101,656,1.9
modification,332,2150,1.9
hippocampal,338,2193,1.9
cornu ammonis,338,2191,1.9
ammon horn,338,2191,1.9
senile dementia of the alzheimer type,158,1027,1.9
adrenals,31,202,1.89
hiv infections,223,1452,1.89
cities,98,638,1.89
vector,61,399,1.89
alzheimer's,158,1030,1.89
cost effectiveness,155,1013,1.89
impulsivity,251,1638,1.89
withdrawal syndrome,40,261,1.89
substance withdrawal syndrome,40,261,1.89
suprarenal gland,31,202,1.89
drosophila genus,56,367,1.88
individual differences,265,1743,1.88
allelic variant,170,1114,1.88
gene variant,170,1114,1.88
western immunoblotting,113,743,1.88
motivational interview,117,766,1.88
protein blotting,113,743,1.88
genetic markers,45,296,1.88
series,525,3449,1.88
motivational enhancement therapy,117,766,1.88
clinical practice guideline,37,243,1.88
acids,34,224,1.87
alcohol reward,52,343,1.87
psychology,109,719,1.87
micro rna,68,449,1.87
ethanol reward,52,343,1.87
outpatients,254,1672,1.87
weight increase,31,204,1.87
body weight gain,31,204,1.87
national research service awards,31,204,1.87
body weight increase,31,204,1.87
travel,95,628,1.87
mirna,68,449,1.87
substances of abuse,41,270,1.87
wt gain,31,204,1.87
substance of abuse,41,270,1.87
virginia,34,224,1.87
carbon monoxide,40,264,1.87
nh2-terminal,31,204,1.87
nrsa,31,204,1.87
n-terminal,31,204,1.87
out-patients,254,1672,1.87
corpulence,175,1159,1.86
magnetic resonance imaging,250,1655,1.86
benzodiazepines,88,584,1.86
journals,107,711,1.86
adiposity,175,1159,1.86
magazine,107,710,1.86
treatment duration,77,511,1.86
progenitor cells,52,344,1.86
active follow-up,650,4307,1.86
treatment days,77,511,1.86
expectation,134,887,1.86
placebo control,116,768,1.86
follow-up,650,4307,1.86
treatment period,77,511,1.86
new york city,32,212,1.86
density,221,1465,1.86
stem cells,52,345,1.86
health instruction,36,239,1.86
health tutoring,36,239,1.86
micrornas,68,450,1.86
aftercare,229,1521,1.86
after care,229,1521,1.86
after-treatment,229,1521,1.86
desoxyephedrine,253,1686,1.85
n-methylamphetamine,253,1686,1.85
neurogenesis,47,314,1.85
seminal,40,266,1.85
age dependent,57,381,1.85
k channel,38,254,1.85
injections,400,2667,1.85
metabotropic glutamate receptors,45,300,1.85
voltage,79,528,1.85
methylamphetamine,253,1686,1.85
deoxyephedrine,253,1686,1.85
crystal meth,253,1686,1.85
postsynaptic,195,1297,1.85
neuropathology,56,373,1.85
cardiac,56,375,1.84
respiratory aspiration,57,382,1.84
anatomical sciences,138,925,1.84
respiratory inspiration,57,382,1.84
weight gain,31,208,1.84
treatment schedule,107,716,1.84
treatment regimen,107,716,1.84
alzheimer's disease,158,1058,1.84
bronchial asthma,34,228,1.84
asthma,34,228,1.84
mrna,217,1451,1.84
manic-depressive psychosis,58,388,1.84
bipolar affective psychosis,58,388,1.84
anatomic,138,926,1.84
human tissue,47,317,1.83
dextrose,44,296,1.83
visual,100,673,1.83
air,45,304,1.83
heroin,368,2481,1.83
varenicline,81,546,1.83
messenger rna,217,1465,1.83
antianxiety agent,62,418,1.83
noradrenaline,108,728,1.83
alcohol response,149,1006,1.83
laboratories,958,6453,1.83
levonorepinephrine,108,728,1.83
ethanol response,149,1006,1.83
levarterenol,108,728,1.83
response to alcohol,149,1006,1.83
response to ethanol,149,1006,1.83
photoradiation,385,2592,1.83
marihuana,173,1175,1.82
preventive intervention,189,1280,1.82
preventional intervention strategy,189,1280,1.82
c.elegans,40,271,1.82
readiness,90,611,1.82
hepatitus c,70,475,1.82
alcohol reinforcement,36,244,1.82
social functioning,36,244,1.82
preparedness,90,611,1.82
maintenance,512,3463,1.82
sorting,48,326,1.82
ethanol reinforcement,36,244,1.82
human immunodeficiency virus 1,67,453,1.82
mesolimbic system,86,586,1.81
adolescent youth,521,3552,1.81
mesolimbic dopamine system,86,586,1.81
behavior intervention,419,2854,1.81
juvenile,521,3552,1.81
longterm effects,98,668,1.81
lung disorder,41,280,1.81
pulmonary disorder,41,280,1.81
pulmonary diseases,41,280,1.81
juvenile human,521,3552,1.81
neurologic body system,167,1138,1.81
biochemistry,69,471,1.81
c elegans,40,272,1.81
neurologic organ system,167,1138,1.81
behavioral intervention,419,2854,1.81
marijuana,173,1178,1.81
behavioral conditioning therapy,419,2854,1.81
conditioning therapy,419,2854,1.81
behavioral treatment,419,2854,1.81
behavioral therapy,419,2854,1.81
drug reward,132,898,1.81
behavioral modification,419,2854,1.81
blood alcohol level,36,245,1.81
blood alcohol concentration,36,245,1.81
blood alcohol level measurement,36,245,1.81
blood alcohol content,36,245,1.81
behavior treatment,419,2854,1.81
cognitive neuroscience,46,313,1.81
behavior conditioning therapy,419,2854,1.81
early adolescence,39,266,1.81
clinical trials network,131,895,1.81
degenerative neurologic disorders,97,663,1.8
functional magnetic resonance imaging,358,2458,1.8
neurodegenerative diseases,97,663,1.8
neurologic degenerative conditions,97,663,1.8
neurodegenerative disorders,97,663,1.8
membrane potentials,30,206,1.8
neurodegenerative illness,97,663,1.8
deprivation,53,364,1.8
imaging procedures,105,721,1.8
obesity,175,1201,1.8
followup studies,34,233,1.8
follow-up studies,34,233,1.8
glucose,44,301,1.8
antioxidants,31,212,1.8
imaging techniques,105,721,1.8
controlled study,31,212,1.8
students,245,1675,1.8
nervous system function,39,269,1.79
eating disorders,50,344,1.79
eating,116,801,1.79
patient cooperation,38,262,1.79
patient adherence,38,262,1.79
patient compliance,38,262,1.79
letters,91,627,1.79
psychiatrist,53,366,1.79
lung diseases,41,282,1.79
dopamine d1 receptor,89,613,1.79
drug use disorder,76,523,1.79
d1 receptor,89,613,1.79
drops,77,531,1.79
transphosphorylases,136,937,1.79
neurological function,39,269,1.79
neurologic function,39,269,1.79
phosphotransferases,136,938,1.79
kinases,136,937,1.79
corticotropin-releasing hormone,100,689,1.79
nervous system physiology,39,269,1.79
cognitive therapy,171,1178,1.79
light,385,2664,1.78
conscious,35,243,1.78
dendrite spine,87,602,1.78
societies,426,2952,1.78
gold,66,457,1.78
computerized,66,457,1.78
names,88,610,1.78
dendritic spines,87,602,1.78
achievement mainstream education,34,235,1.78
prescription opioid abuse,48,333,1.78
cognitive deficits,125,866,1.78
cholinergic,98,679,1.78
predisposing factor,30,208,1.78
psychophysiological,50,349,1.77
adrenal glands,31,216,1.77
signaling molecule,67,468,1.77
behavior measurement,122,849,1.77
intervention program,60,419,1.77
behavioral measure,122,849,1.77
recurrence prevention,144,1005,1.77
euphoria,46,320,1.77
motor,195,1357,1.77
d-glucose,44,306,1.77
psycho-physiological,50,349,1.77
disease recurrence prevention,144,1005,1.77
physiopsychology,50,349,1.77
long-term synaptic depression,46,320,1.77
equation,62,433,1.77
behavioral measurement,122,849,1.77
body weight,36,252,1.76
cognition,342,2397,1.76
learning extinction,33,231,1.76
instruction,111,777,1.76
double-masked study,187,1307,1.76
double-blind study,187,1307,1.76
double-blind method,187,1307,1.76
instrument,106,743,1.76
tracer,65,455,1.76
electrical stimulation,45,316,1.76
defect,87,608,1.76
double-blinded,187,1307,1.76
double-masked method,187,1307,1.76
wages,32,225,1.75
bdnf,70,494,1.75
lesion,137,963,1.75
endocannabinoids,112,789,1.75
urine,216,1518,1.75
disorder management,39,275,1.75
salaries,32,225,1.75
negative mood,33,232,1.75
moods,222,1562,1.75
network-based,30,211,1.75
disease management,39,275,1.75
social context,86,607,1.75
social environment,86,607,1.75
social climate,86,607,1.75
brain-derived neurotrophic factor,70,494,1.75
molecular marker,32,225,1.75
occupational,39,275,1.75
burden of disease,63,446,1.74
quit line,37,263,1.74
cigarette smoking,250,1771,1.74
naltrexone,236,1675,1.74
length,137,972,1.74
burden of illness,63,446,1.74
quitline,37,263,1.74
tobacco abstinence,35,248,1.74
circulation,33,234,1.74
adolescence (12-20),338,2393,1.74
feeding,111,789,1.74
cell membrane,113,799,1.74
chromosome mapping,38,269,1.74
gene localization,38,269,1.74
disease burden,63,446,1.74
sum,71,503,1.74
embryo,42,298,1.74
embryonic,42,297,1.74
conflict (psychology),108,764,1.74
consciousness,35,250,1.73
methylcarbinol,339,2423,1.73
baltimore,34,242,1.73
conflict,108,768,1.73
cannabinoids,141,1003,1.73
anxiety disorders,141,1006,1.73
self-administered,358,2556,1.73
absolute ethanol,339,2423,1.73
etoh,339,2423,1.73
theoretic models,42,299,1.73
grain alcohol,339,2423,1.73
electrodes,60,428,1.73
problem solving,49,349,1.73
florida,43,307,1.73
control groups,175,1252,1.72
dependovirus,34,244,1.72
voice,38,273,1.72
dynorphins,81,581,1.72
therapeutic agents,87,623,1.72
adeno-associated viruses,34,244,1.72
ingestive behavior,31,222,1.72
drug user,131,941,1.72
psychological reinforcement,409,2927,1.72
antibodies,121,875,1.71
anti-retroviral agents,46,332,1.71
hormonal,57,410,1.71
san francisco,36,259,1.71
gustation,52,376,1.71
anti-retroviral,46,332,1.71
preventive,52,374,1.71
adeno associated virus group,34,245,1.71
taste perception,52,376,1.71
client,124,894,1.71
expectancy,68,494,1.7
synapse formation,42,305,1.7
cognitive behavior intervention,171,1242,1.7
cognitive behavioral therapy,171,1242,1.7
cognitive behavior modification,171,1242,1.7
meetings,497,3616,1.7
cognitive behavioral intervention,171,1242,1.7
cognitive behavioral modification,171,1242,1.7
nicotine replacement therapy,113,820,1.7
prevention intervention,189,1377,1.69
extracellular,225,1645,1.69
severe mental illness,30,219,1.69
serious mental illness,30,219,1.69
drug delivery,87,634,1.69
adenylyl cyclase,37,270,1.69
biologic assays,561,4103,1.69
5 cyclic amp synthetase,37,270,1.69
cigarette,284,2078,1.69
adenyl cyclase,37,270,1.69
cognitive behavior therapy,171,1259,1.68
united states substance abuse and mental health services administration,75,549,1.68
comparative effectiveness,56,411,1.68
mainstreaming,34,250,1.68
educational mainstreaming,34,250,1.68
schedule,208,1523,1.68
mutate,62,454,1.68
neural plasticity,237,1743,1.68
substance abuse and mental health services administration,75,549,1.68
cyclic amp,103,759,1.67
feeding behaviors,31,231,1.66
weight reduction,30,223,1.66
molecular biology,80,595,1.66
endocrine gland secretion,96,712,1.66
feeding-related behaviors,31,231,1.66
n-methyl-d-aspartate,93,693,1.66
n methyl d aspartate,93,693,1.66
nmda,93,693,1.66
amino acids,77,572,1.66
n methyl d aspartic acid,93,693,1.66
patient oriented study,56,417,1.66
outcome measure,174,1291,1.66
combining site,112,832,1.66
hippocampus,338,2511,1.66
body weight decreased,30,223,1.66
body weight loss,30,223,1.66
reactive site,112,832,1.66
coping,150,1114,1.66
wt-loss,30,223,1.66
high school,73,543,1.66
fruit fly,56,417,1.66
therapeutic hormone,96,712,1.66
health care service utilization,90,673,1.65
methamphetamine,253,1895,1.65
neuroanatomy,79,592,1.65
exposed to cocaine,146,1091,1.65
dendrites,67,502,1.65
natural history,30,224,1.65
exposure to cocaine,146,1091,1.65
disadvantaged,59,440,1.65
homologue,39,291,1.65
cocaine exposure,146,1091,1.65
reconstitute,31,232,1.65
genehomolog,39,291,1.65
cocaine-exposed,146,1091,1.65
nicotine dependence,419,3141,1.65
homologous gene,39,291,1.65
forebrain,80,599,1.65
fore-brain,80,599,1.65
homolog,39,291,1.65
reconstitution,31,232,1.65
hormones,96,717,1.65
drug controls,43,324,1.64
los angeles,30,225,1.64
binding sites,112,842,1.64
drosophila,64,481,1.64
protein protein interaction,51,383,1.64
agonist,582,4371,1.64
circadian,45,338,1.64
caenorhabditis elegans,40,300,1.64
combination therapy,95,715,1.64
hepatic,53,399,1.64
breathing,57,429,1.64
behavior modification,419,3145,1.64
ventral striatum,150,1128,1.64
tyrosine 3-monooxygenase,34,257,1.63
flavoring agents,30,227,1.63
nicotine withdrawal,101,762,1.63
mouse strains,41,310,1.63
stream,33,249,1.63
manic depressive disorder,58,438,1.63
flavoring,30,227,1.63
root,42,318,1.63
plant roots,42,318,1.63
genetic screening,41,310,1.63
tyrosine hydroxylase,34,257,1.63
manic depressive illness,58,438,1.63
bipolar affective disorder,58,438,1.63
metabolic drug detoxications,77,583,1.63
metabolism of toxic agents,77,583,1.63
ampa receptors,77,583,1.63
bipolar disorder,58,438,1.63
neuropsychiatry,138,1050,1.62
neuropsychiatric,138,1050,1.62
early therapy,40,305,1.62
national institute of mental health,87,661,1.62
weight loss,30,229,1.62
costs and benefits,37,281,1.62
aminoacid,77,587,1.62
tobacco dependence,160,1228,1.61
blood - brain barrier anatomy,84,643,1.61
tobacco smoke,47,361,1.61
2-arachidonylglycerol,30,230,1.61
blood-brain barrier,84,643,1.61
hemato-encephalic barrier,84,643,1.61
endophenotype,57,436,1.61
2-arachidonyl-glycerol,30,230,1.61
2-arachidonoylglycerol,30,230,1.61
2-arachidonoyl-glycerol,30,230,1.61
scanning,182,1394,1.61
genetic analyses,81,619,1.61
rhesus monkey,63,482,1.61
high speed liquid chromatography,30,230,1.61
genetic analysis,81,619,1.61
rhesus macaque,63,482,1.61
high pressure liquid chromatography,30,230,1.61
cocaine use,213,1628,1.61
drug dependence,964,7441,1.6
compliance behavior,34,262,1.6
acamprostate,33,255,1.6
n-acetylhomotaurine,33,255,1.6
counselor,71,546,1.6
excitatory synapse,52,400,1.6
professional counselor,71,546,1.6
effectiveness of interventions,63,486,1.6
brain damage,60,464,1.59
brain injuries,60,464,1.59
vascular,49,379,1.59
acquired brain injury,60,464,1.59
long-term effects,98,760,1.59
discounting,83,644,1.59
hydroxytyramine,719,5592,1.59
computer aided,33,258,1.58
candidate disease gene,146,1139,1.58
computer assisted,33,258,1.58
western blotting,113,883,1.58
candidate gene,146,1139,1.58
pain threshold,35,274,1.58
hiv seropositivity,42,330,1.57
htlv-iii seropositivity,42,330,1.57
htlv-iii seroconversion,42,330,1.57
nerve transmitter substances,335,2634,1.57
anti-hiv positivity,42,330,1.57
hiv positive,42,330,1.57
hiv positivity,42,330,1.57
hiv seroconversion,42,330,1.57
psychotropic drugs,52,412,1.56
chemical structure function,93,735,1.56
technology transfer,40,317,1.56
mutant,219,1730,1.56
neurosecretory systems,54,428,1.56
preference,401,3173,1.56
cannabinoid receptor,80,633,1.56
neuroendocrine,54,428,1.56
isoforms,82,648,1.56
acamprosate,33,261,1.56
parenting behavior,65,518,1.55
educational process of instructing,119,946,1.55
health behavior,89,707,1.55
psychometrics,65,518,1.55
endocrine,40,319,1.55
professor,91,724,1.55
therapy cooperation,33,262,1.55
acquired immune deficiency,105,840,1.54
acquired immunodeficiency syndrome,105,840,1.54
teaching,119,953,1.54
recycling,34,272,1.54
addictive behavior,189,1509,1.54
ions,32,256,1.54
twin multiple birth,61,489,1.54
spectroscopy,33,264,1.54
parenting,65,521,1.54
treatment trial,31,249,1.54
brain imaging,148,1185,1.54
schools,195,1559,1.54
aeroseb-hc,64,516,1.53
hytone,64,516,1.53
proctocort,64,516,1.53
cetacort,64,516,1.53
clinical research,780,6288,1.53
hydrocortisone,64,516,1.53
eldecort,64,516,1.53
dermacort,64,516,1.53
cortril,64,516,1.53
cortispray,64,516,1.53
early treatment,40,323,1.53
potassium channel,40,323,1.53
cortenema,64,516,1.53
hydrocortone,64,516,1.53
cortef,64,516,1.53
nutracort,64,516,1.53
cort-dome,64,516,1.53
affinity,230,1859,1.53
nonsmoker,69,561,1.52
psychostimulant,185,1502,1.52
brain visualization,148,1200,1.52
protein isoforms,82,665,1.52
non-smoker,69,561,1.52
behavior therapy,419,3406,1.52
taste,52,421,1.52
prosencephalon,80,650,1.52
prisons,46,374,1.52
splicing,38,308,1.52
acquired immune deficiency syndrome,105,852,1.52
drd2 gene,47,383,1.51
neural cell body,53,434,1.51
neuronal cell body,53,434,1.51
treatment center,51,417,1.51
theoretical model,42,342,1.51
non-a,140,1146,1.51
non a,70,573,1.51
drd2,47,383,1.51
d2dr,47,383,1.51
d2dr gene,47,383,1.51
d2r,47,383,1.51
hepatitis non a non b,70,573,1.51
parenterally-transmitted,70,573,1.51
non-b,70,573,1.51
hepatitis c virus infection,70,573,1.51
hcv infection,70,573,1.51
d2r gene,47,383,1.51
dopamine receptor d2 gene,47,383,1.51
d(2) dopamine receptor gene,47,383,1.51
non b hepatitis,70,573,1.51
synaptogenesis,42,342,1.51
socioenvironment,86,709,1.5
drugs abused,550,4535,1.5
treatment planning,32,263,1.5
drug of abuse,550,4535,1.5
abused drugs,550,4535,1.5
drugs of abuse,550,4535,1.5
response time,42,345,1.5
reuptake,55,451,1.5
on-line systems,106,870,1.5
online systems,106,870,1.5
response rt,42,345,1.5
web based,106,870,1.5
reaction time,42,345,1.5
twins,61,500,1.5
protein phosphorylation,157,1298,1.49
smoking status,33,273,1.49
twin studies,32,265,1.49
psychoses,44,364,1.49
aids test,39,322,1.49
drd2 receptor,128,1059,1.49
aids/hiv test,39,322,1.49
hiv test,39,322,1.49
primary parkinsonism,171,1412,1.49
comparison group,47,390,1.49
parkinson,171,1412,1.49
paralysis agitans,171,1412,1.49
diet,67,554,1.49
human immunodeficiency virus test,39,322,1.49
dopamine d2 receptor,128,1059,1.49
d2 receptor,128,1059,1.49
skills training,38,315,1.49
parkinson disease,171,1412,1.49
inspiration,57,476,1.48
genetic variation,113,939,1.48
smoking prevalence,60,501,1.48
genetic diversity,113,939,1.48
ethanol,339,2824,1.48
method development,50,417,1.48
soma,53,443,1.48
substantia alba,58,486,1.47
cease smoking,355,2984,1.47
n-methylaspartate receptors,98,820,1.47
stop smoking,355,2984,1.47
online computer,106,887,1.47
mind,38,318,1.47
potentiation,79,661,1.47
nicotine replacement,113,950,1.47
chemosensitization,79,661,1.47
shortterm memory,88,736,1.47
immediate memory,88,736,1.47
chemosensitization/potentiation,79,661,1.47
short-term memory,88,736,1.47
quit smoking,355,2984,1.47
behavioral disorder,48,403,1.47
receptor function,162,1360,1.47
breeding,60,502,1.47
drug delivery systems,87,730,1.47
counseling,235,1973,1.47
magnetic resonance spectroscopy,35,295,1.46
neurotransmitters,335,2830,1.46
primates,84,712,1.46
mr spectroscopy,35,295,1.46
hepatitis,89,754,1.46
problem alcohol use,383,3257,1.45
genetic association,45,382,1.45
teenagers,65,552,1.45
programmed cell death,51,435,1.45
teen,65,552,1.45
knock-in mouse,41,348,1.45
sensory cell afferent neuron,37,315,1.45
alcohol sensitivity,56,477,1.45
ethanol sensitivity,56,477,1.45
teen years,65,552,1.45
white matter,58,494,1.45
left,133,1129,1.45
cerebellum,38,324,1.45
sensitivity to ethanol,56,477,1.45
sensitivity to alcohol,56,477,1.45
fire - disasters,37,318,1.44
therapeutically effective,167,1431,1.44
cdc,92,786,1.44
kinetics,100,858,1.44
camp-dependent protein kinases,43,368,1.44
prospective studies,50,427,1.44
nicotine addiction,419,3587,1.44
fires,37,318,1.44
pka,43,368,1.44
nyctohemeral rhythm,37,316,1.44
twenty-four hour rhythm,37,316,1.44
circadian process,37,316,1.44
daily biorhythm,37,316,1.44
cyclic amp-dependent protein kinases,43,368,1.44
adenosine cyclic monophosphate-dependent protein kinases,43,368,1.44
tobacco addiction,160,1372,1.44
computers,93,803,1.43
ribosomal protein synthesis,30,259,1.43
ribosomal protein biosynthesis,30,259,1.43
ribosomal peptide biosynthesis,30,259,1.43
sexually transmitted infection,46,399,1.42
substantia nigra structure,62,540,1.42
opioid receptor,326,2832,1.42
positron emission tomography medical imaging,99,858,1.42
principal investigator,194,1684,1.42
inherited,33,286,1.42
habits,89,775,1.42
venereal infections,46,399,1.42
venereal disorders,46,399,1.42
venereal diseases,46,399,1.42
sexually transmitted disorder,46,399,1.42
trafficking,143,1245,1.42
minor,47,407,1.42
incentives,159,1391,1.41
predominantly hyperactive-impulsive type hyperactivity disorder,114,1000,1.41
health education,36,314,1.41
predominantly hyperactive-impulsive type attention-deficit disorder,114,1000,1.41
psychomotor reaction time,42,367,1.41
racial stocks,107,933,1.41
hippophaine,146,1285,1.4
enteramine,146,1285,1.4
5ht,146,1285,1.4
5-hydroxytryptamine,146,1285,1.4
5-ht,146,1285,1.4
hepatitis c,70,615,1.4
violent behavior,74,651,1.4
neural transmission,209,1840,1.4
psyche structure,71,624,1.4
tobacco smoking,69,610,1.4
chemical dependence,964,8503,1.4
substance dependence,167,1467,1.4
drug dependency,964,8503,1.4
inherited predisposition,71,630,1.39
genetic etiology,71,630,1.39
inherited susceptibility,71,630,1.39
genetic mechanism of disease,71,630,1.39
genetic predisposition,71,630,1.39
mathematical model,49,435,1.39
genetic predisposition to disease,71,630,1.39
n-methylaspartate,93,827,1.39
genetic vulnerability,71,630,1.39
treatment effect,117,1041,1.39
alcohol addiction,583,5207,1.38
huntington chorea,34,303,1.38
huntington's disease,34,304,1.38
single base polymorphism,63,564,1.38
alcohol dependency,583,5207,1.38
linkage mapping,38,339,1.38
huntington disease,34,303,1.38
laboratory study,76,678,1.38
degenerative neurologic diseases,67,599,1.38
huntington's,34,303,1.38
huntingtons disease,34,303,1.38
neurohumor receptors,34,303,1.38
genotype,236,2111,1.38
alcohol dependence,583,5207,1.38
smoker,397,3544,1.38
fear conditioning,45,404,1.37
detoxification,77,694,1.37
conditioned fear,45,404,1.37
sexually transmitted diseases,46,413,1.37
effectiveness trial,45,409,1.36
rna splicing,38,344,1.36
nih rfa,54,488,1.36
cerebral,43,390,1.36
nutrient intake activity,31,281,1.36
request for applications,54,488,1.36
organism,84,765,1.35
living system,84,765,1.35
adverse effects,285,2595,1.35
cerebrum,43,392,1.35
atp-protein phosphotransferase,33,304,1.34
dependence,812,7475,1.34
phosphorylase b kinase kinase,33,304,1.34
hydroxyalkyl protein kinase,33,304,1.34
glycogen synthase a kinase,33,304,1.34
non-b hepatitis,70,645,1.34
gene mapping,38,349,1.34
population study,31,285,1.34
diagnostic and statistical manual of mental disorders,104,957,1.34
housing,84,781,1.33
hiv/aids,122,1134,1.33
circadian rhythms,37,342,1.33
apoptosis pathway,51,473,1.33
laboratory animals,31,287,1.33
knowledge base,52,481,1.33
aids/hiv,122,1134,1.33
recombinants,53,491,1.33
drug use prevention,83,771,1.33
drug addiction prevention,83,771,1.33
operant conditioning,52,481,1.33
behavior disorders,48,449,1.32
dopamine,719,6718,1.32
radioligand,45,425,1.31
heart,57,538,1.31
working memory,88,829,1.31
treatment program,234,2210,1.31
neuron toxicity,44,415,1.31
neuronal toxicity,44,415,1.31
posttraumatic stress disorders,121,1142,1.31
in situ hybridization,102,958,1.31
smoking,498,4691,1.31
hplc,30,282,1.31
neurotoxicity,44,415,1.31
drug interactions,76,723,1.3
task performances,42,397,1.3
alcohol abuse,383,3633,1.3
alcohol problem,383,3633,1.3
ethanol abuse,383,3633,1.3
hazardous alcohol use,383,3633,1.3
problem drinking,383,3633,1.3
european,50,477,1.29
cortisol,64,610,1.29
sham treatment,235,2255,1.29
sham therapy,235,2255,1.29
norepinephrine,108,1034,1.29
violent,74,706,1.29
recidivism,42,402,1.29
hand,62,595,1.29
violence,74,709,1.29
frontal cortex,80,766,1.29
psychophysiology,50,481,1.28
cotinine,53,509,1.28
scotine,53,509,1.28
frontal lobe,80,770,1.28
human data,43,417,1.27
apoptosis,51,497,1.27
nmda receptor-ionophore complex,98,954,1.27
n-methyl-d-aspartate receptors,98,954,1.27
rad.-pet,99,961,1.27
positron-emission tomography,99,961,1.27
heavy drinker,49,477,1.27
alcoholic beverage heavy drinker,49,477,1.27
smoking cessation,355,3447,1.27
positron emission tomography scan,99,961,1.27
pett,99,961,1.27
petscan,99,961,1.27
cocaine users,53,513,1.27
pet imaging,99,961,1.27
pet scan,99,961,1.27
acetylcholine,75,733,1.26
acquired immunologic deficiency syndrome,74,722,1.26
molecular genetics,84,824,1.26
pleasure,41,400,1.26
afro american,112,1106,1.25
afroamerican,112,1106,1.25
environment effect on gene,38,374,1.25
aids,104,1026,1.25
nicotinic acetylcholine receptors,128,1267,1.25
phosphorylation,157,1553,1.25
receptor expression,168,1663,1.25
hiv risk,66,653,1.25
alcohol related problem,51,503,1.25
radiolabel,37,364,1.25
brain behavior,45,446,1.24
smoking relapse,38,377,1.24
heroin addiction,37,367,1.24
heroin dependence,37,367,1.24
abuse of substances,474,4706,1.24
substance abuse problem,474,4706,1.24
prevention program,84,835,1.24
placebos,235,2335,1.24
diffusion weighted mri,37,372,1.23
substance addiction,167,1671,1.23
diffusion tensor imaging,37,372,1.23
substantia nigra,62,620,1.23
budgets,51,511,1.23
diffusion magnetic resonance imaging,37,372,1.23
corticosterone,32,322,1.23
diffusion mri,37,372,1.23
dopamine system,106,1074,1.22
long-term potentiation,48,486,1.22
suggestion,30,303,1.22
cocaine addiction,235,2374,1.22
monkeys,89,902,1.22
smoke,230,2325,1.22
stimulant abuse,53,540,1.21
illicit drugs,150,1535,1.21
psychostimulant abuse,53,540,1.21
weight,66,670,1.21
aggressive behavior,43,439,1.21
web,85,876,1.2
neuropsychology,64,659,1.2
world wide web,85,876,1.2
chemical synthesis,33,338,1.2
ad/hd,114,1173,1.2
smoking behavior,105,1082,1.2
adhd,114,1173,1.2
attention deficit hyperactivity disorder,114,1173,1.2
psychotherapy,79,810,1.2
www,85,876,1.2
antiretroviral agents,32,332,1.19
antiretroviral,32,332,1.19
teacher,36,374,1.19
neuroregulator receptors,34,356,1.18
neuromediator receptors,34,356,1.18
enkephalins,48,502,1.18
gene transfer,31,325,1.18
mutant strains mice,45,471,1.18
substance abuse,474,4960,1.18
neurochemical,209,2205,1.17
genetic mapping,38,401,1.17
aged 65 and over,33,347,1.17
crime,58,611,1.17
nmda receptors,98,1036,1.17
years of life lost to disability,42,446,1.16
behavioral problem,49,522,1.16
problem behavior,49,522,1.16
depressed mood,52,551,1.16
sadness,52,551,1.16
dementia,57,605,1.16
years of life lost to disease,42,446,1.16
nicotinic receptors,128,1358,1.16
self stimulation,39,417,1.15
chronic painful condition,99,1061,1.15
protein synthesis,30,323,1.15
serotonin receptor,34,369,1.14
protein kinase,35,378,1.14
neurotoxic,35,378,1.14
20-dione,82,887,1.14
single nucleotide polymorphism,63,682,1.14
alcohol and other drug,46,499,1.14
protein kinase a,43,468,1.13
in silico,68,740,1.13
meth dependence,48,529,1.12
methamphetamine addiction,48,529,1.12
meth addiction,48,529,1.12
methamphetamine dependence,48,529,1.12
antidepressant drugs,57,635,1.11
dataset,209,2313,1.11
nicotine patch,33,368,1.11
antidepressive agents,57,635,1.11
nicotine skin patch,33,368,1.11
antidepressant agent,57,632,1.11
conditioning,100,1111,1.11
cocaine abuse,83,924,1.11
monoamine,52,583,1.1
psychotic disorders,31,349,1.1
endocytosis,31,348,1.1
biologic availability,37,413,1.1
risky behavior,172,1939,1.09
at risk behavior,172,1939,1.09
risk behaviors,172,1939,1.09
acquired immuno-deficiency syndrome,74,840,1.09
depressed,52,586,1.09
randomized controlled trials,158,1806,1.08
nicotine,490,5585,1.08
internet,85,980,1.07
neuroendocrine system,54,623,1.07
research infrastructure,117,1349,1.07
model organism,440,5134,1.06
genetic determinants of behavior,41,481,1.05
behavior genetics,41,481,1.05
therapy compliance,54,633,1.05
locomotor activity,62,729,1.05
motor activity,62,729,1.05
stimulant dependence,56,661,1.04
stimulant addiction,56,661,1.04
psychostimulant dependence,56,661,1.04
psychostimulant addiction,56,661,1.04
genetic susceptibility,71,848,1.03
impulsive behavior,39,465,1.03
behavior test,168,2025,1.02
abuse of drugs,512,6217,1.02
abuses drugs,512,6217,1.02
aggression,43,522,1.02
accounting,198,2433,1.0
mouse mutant,45,553,1.0
methamphetamine abuse,31,385,0.99
microinjections,52,646,0.99
gene environment interaction,38,476,0.98
allelomorphs,87,1109,0.97
protein biosynthesis,30,380,0.97
adenylate cyclase,37,470,0.97
antidepressants,57,730,0.96
drug abuse prevention,83,1061,0.96
randomized clinical trials,80,1028,0.96
dopamine receptor,158,2052,0.95
macaca mulatta,63,820,0.95
placebo controlled study,30,394,0.94
information processing,34,444,0.94
transfection,31,408,0.94
cell surface,34,448,0.94
predoc,31,408,0.94
drug addiction,964,12764,0.93
downregulation,50,661,0.93
primary health care,113,1500,0.93
primary healthcare,113,1500,0.93
serotonin,147,1948,0.93
phenopromin,102,1365,0.92
dl-amphetamine,102,1365,0.92
receptor gene,40,538,0.92
phenamine,102,1365,0.92
desoxynorephedrin,102,1365,0.92
extinction (psychology),104,1448,0.89
glutamate receptor,88,1221,0.89
dosage,87,1228,0.87
sequence-specific posttranscriptional gene silencing,44,622,0.87
rnai,44,622,0.87
rna silencing,44,622,0.87
post-transcriptional gene silencing,44,622,0.87
posttranscriptional gene silencing,44,622,0.87
volunteer,38,545,0.86
rna interference,44,630,0.86
buproprion,30,429,0.86
amfebutamone,30,429,0.86
sexual activity,33,472,0.86
sexual behavior,33,472,0.86
sex activity,33,472,0.86
hereditary,33,477,0.85
self-control as a personality trait,34,500,0.84
methylphenidate,31,457,0.84
narcotics,53,775,0.84
self control,34,500,0.84
reading,33,493,0.83
epileptiform,47,697,0.83
neurochemistry,209,3096,0.83
alcoholic,117,1763,0.82
boozer,117,1756,0.82
dependent drinker,117,1756,0.82
problem drinker,117,1756,0.82
behavioral extinction,104,1556,0.82
dat dopamine transporter,65,984,0.81
neurotransmitter receptor,34,517,0.81
drug abuse,512,7830,0.81
cocaine,715,10881,0.81
gene targeting,62,955,0.8
pharmacogenetics,52,815,0.79
amphetamines,102,1589,0.79
urine urinary system,75,1173,0.79
mediator of activation protein,164,2607,0.78
mediator of activation,164,2607,0.78
thinking,117,1858,0.78
genetic polymorphism,70,1109,0.78
pregn-4-ene-3,41,662,0.76
alcoholism,201,3266,0.76
black populations,67,1106,0.75
substance abuse treatment,65,1090,0.74
substance abuse therapy,65,1090,0.74
hippocampus (brain),132,2191,0.74
microdialysis,77,1297,0.73
dementia of the alzheimer type,61,1027,0.73
alzheimers disease,61,1027,0.73
institutes,91,1531,0.73
alzheimer,61,1027,0.73
ethanol-dependent,39,661,0.73
men's,114,1913,0.73
alzheimer disease,61,1027,0.73
bupropion,30,512,0.72
health care service,35,607,0.71
hispanics,35,629,0.69
hispanic populations,35,629,0.69
reinforcer,124,2251,0.68
outcomes research,44,807,0.67
disorder later incidence prevention,54,1005,0.66
behavioral genetics,41,765,0.66
disorder recurrence prevention,54,1005,0.66
drug metabolism,50,964,0.64
screening procedure,47,902,0.64
sex behavior,33,647,0.63
quelling,32,622,0.63
nervous system structure,57,1138,0.62
risk-taking,36,717,0.62
brain mapping,35,708,0.61
dopamine transporter,65,1339,0.6
patient oriented research,56,1153,0.6
gender difference,59,1246,0.58
personality,32,679,0.58
alcohol-dependent,231,5207,0.55
high performance liquid chromatography,30,696,0.53
alcoholism therapy,38,891,0.53
alcohol dependence therapy,38,891,0.53
alcohol addiction therapy,38,891,0.53
parkinsons disease,58,1412,0.51
teenage,65,1582,0.51
mammals,88,2142,0.51
hiv/aids problem,47,1134,0.51
aids/hiv problem,47,1134,0.51
parkinson's disease,58,1464,0.49
radiotracer,37,945,0.48
drug withdrawal,79,2084,0.47
receptor binding,53,1409,0.46
attention deficit hyperactive disorder,42,1173,0.44
alcoholism treatment,38,1127,0.42
databanks,33,1130,0.36
data banks,33,1130,0.36
data repository,33,1130,0.36
neuropharmacology,55,1936,0.35
clinical investigation,56,2061,0.34
research study,167,6773,0.3
human subject,103,4943,0.26
